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Abstract
Cells sense and respond to their environment by maintaining appropriate activity
levels and localizations of key signaling proteins. In eukaryotic cells, cell size is
increasingly appreciated as being coordinated by the Target of Rapamycin (TOR)
Pathway. TOR is a serine/threonine kinase that resides in two distinct protein
complexes which in mammals are referred to as mTORC1 and mTORC2. While
significant emphasis has been placed on defining which pathways TOR controls and on
how TOR activity is set, less is known about where TOR is positioned or positions its
effectors to control growth. In the work described here, we identify and characterize
three distinct aspects of the localization of mTORC1 signaling: the redistribution of the
mTORC1 effectors, lipin 1 and SREBP, in controlling sterol- and lipogenesis; mTORC1-
mediated regulation of actin-myosin contractility during cytokinesis; the regulation of
mTORC1 localization in response to amino acids. Through these studies, we provide
not only insights into the topology of cell growth, but also reveal how derangements of
these localizations might contribute to conditions such as cancer and metabolic disease.
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Chapter 1
1. Introduction to cell growth
Growing cells have the challenge of building the molecules that will comprise
them at both the right time and place. The issue of synthesizing the right molecules at
the right time and the right place are relevant to seemingly all aspects of a cell's
existence: its replication, differentiation, migration, and defense against various insults.
One way a cell ensures that a given synthetic pathway occurs at the right time is by
synchronizing the levels of the input and output of that pathway. This can be
accomplished by coordinating the uptake of a given precursor with the synthesis of its
product. It is also challenging to determine the 'right place' for cell growth because
molecules can diffuse or, on the other hand, are restricted in space. Compared with
eukaryotes, prokaryotes simplify many of these production decisions by being less
compartmentalized, e.g., unlike eukaryotes, they lack internal membranes that surround
their transcriptional as well as major ATP-producing machinery. That eukaryotes have
these membranes suggests that they have likely evolved mechanisms to coordinate
their growth across their compartments. Once such key coordinator we discuss the
importance of below is the TOR signaling pathway.
II. The TOR pathway
A. The origins of the Target Of Rapamycin (TOR) pathway
The history of TOR signaling originates with the isolation of rapamycin from the
bacteria Streptomyces hygroscopicus taken from soil samples in Easter Island (Rapa
nui) in the 1970s and subsequent attempts to understand the molecular mechanism
behind its antifungal (1) and anti-tumor properties (2). The discovery that rapamycin is
also a potent immunosuppressant with low toxicity (3) accelerated investigation of this
molecule. The budding yeast, Saccharomyces cerevisiae, was a key tool for unlocking
the first major mystery of how rapamycin works. To identify intracellular targets of
rapamycin, two groups conducted mutagenesis screens for mutations that conferred
resistance to the G1 arrest caused by rapamycin (4, 5). Both groups identified mutations
in FPR1, the homologue for the mammalian FKBP12, though the observation that loss
of FPR1 had no obvious consequences made it not likely to be the sole target of
rapamycin. The other two classes of mutations were dominant gain-of-function defects
in two similar genes, which were named the target of rapamycin (TOR1 and TOR2).
Although this work established a solid rationale for the TOR proteins as the direct
targets of rapamycin, that idea wasn't elucidated until a few years later. In independent
approaches to isolate proteins which interact with the FKBP12-rapamycin complex,
several groups identified a large protein with homology to the yeast TORs (6-9). This
protein was given several names upon its discovery, including FRAP, RAFT1, and
RAPT1, but is now referred to simply as mammalian TOR, or mTOR. The high degree
of sequence similarity between the mammalian and yeast homologues provided an
early indication that many of features of TOR signaling were preserved between these
highly diverged species.
Despite its catalytic site having strong sequence similarity to the better known at
the time lipid kinase, phosphatidylinositide 3-kinase (P13K), it was soon realized that
TOR is a protein kinase. This was first suggested by experiments which showed that
mTOR autophosphorylates in a rapamycin-sensitive manner (10, 11). Comparison of
the genomes of divergent species further revealed that TOR belongs to a family of
P13K-related, protein kinases (PIKK) that includes ATM, ATR, DNA-PK and SMG1 (12).
The similarity between the PIKKs is concentrated in their C-terminal kinase domains,
which is similar to the kinase domain of P13K and gives this family its name.
B. Components of the TOR complexes, TORC1 and TORC2
In large part to rapamycin, our understanding of TOR signaling has progressed
quickly since the discovery of the TOR genes over almost two decades ago. Since then,
one of the most revealing features of TOR signaling is that has separable functions
which are attributable to two physically distinct complexes, called TORC1 and TORC2
(mTORC1 and mTORC2 in mammalian cells). The early genetic studies of TOR
function hinted at this complexity. Loss of TOR1 severely hindered cell growth, but it
failed to recapitulate the G1 arrest caused by rapamycin treatment (13). By contrast,
TOR2 was found to be an essential gene and its deletion caused a random cell cycle
arrest (13). Curiously, the combined deletion of TOR1 and TOR2 caused a G1 arrest
that was similar to rapamycin treatment (13). Later work showing that rapamycin-
resistant alleles of TOR1 could support normal growth in the presence of rapamycin
suggested that the essential function of TOR2 was rapamycin-insensitive (14). While
these studies of TOR2 gave us early hints of rapamycin-insensitive functionality in TOR
signaling, it was the biochemical purification of TORC1 - and TORC2-specific binding
partners that provided the key evidence to support this claim (15, 16). Fittingly, only one
complex, TORC1, was shown to bind the rapamycin-FKBP12 complex, and these two
complexes are now often referred to as the rapamycin-sensitive and rapamycin-
insensitive pathways (15, 16).
mTORC1 has four components in addition to mTOR (Fig. 1): regulatory
associated protein of mTOR (raptor); mammalian lethal with Sec13 protein 8 (mLST8,
also known as GPL); proline-rich AKT substrate 40 kDa (PRAS40); and DEP-domain-
containing 6 mTOR interacting protein (DEPTOR, also known as DEPDC6). The
functional role for each of these proteins within mTORC1 is being actively researched.
Raptor is crucial for mTORC1 assembly and is thought to recruit mTORC1 substrates
such as the translational regulators, S6 kinase 1 (S6K1) and the eIF4E-binding protein 1
(4E-BP1) (17-19). The role of mLST8 in mTORC1 remains unclear, for deletion of the
gene has no affect on mTORC1 activity in vivo (20, 21). PRAS40 and DEPTOR both
inhibit mTORC1 kinase activity, though their modes of inhibition likely differ (22-25)
(Chapter 3).
Regarding the conservation of TORC1 components, in some species of yeast
including S. cerevisiae, TORC1 contains two TOR proteins, TOR1 and TOR2, whereas
most other eukaryotes contain only one TOR protein (26). Homologs of raptor, mTOR,
and mLST8 are present in all eukaryotes. PRAS40 and DEPTOR homologs are found
as early in evolution as Arthropoda and Chordata, respectively (26)(Chapter 3). On the
other hand, in yeast, TORC1 contains TC089 which does not appear to be conserved
in higher eukaryotes.
mTORC2 shares several proteins with mTORC1 such as mTOR, mLST8 and
DEPTOR (Fig. 1). However, mTORC2 also contains several unique components:
rapamycin insensitive companion of mTOR (rictor), stress-activated protein kinase
interacting protein (SIN1), and protein observed with Rictor-1 (Protor-1), which is also
known as PRR5 or PRRL5. Rictor, SIN1, mLST8 stabilize each other and are required
for mTORC2 to phoshorylate the substrate, Akt/PKB (21, 27, 28). To date, there has
been no unified mTORC2 function ascribed to Protor-1/PRR5/PRR5L other than its
interaction with mTORC2 components (29-31). Similar to its effects on mTORC1,
DEPTOR serves as an inhibitor of mTORC2 (Chapter 3). All mTORC2 components with
the exception of DEPTOR have clear homologs in yeast (26).
The research results described in this thesis primarily focus on mTORC1 biology,
therefore the remainder of the introduction will focus on the signaling upstream and
downstream of mTORC1, as well as its role in growth, metabolism and disease.
C. TORC1 prologue
The defining member of the TORC1 complex is referred to as raptor in mammals
and kog1 or mip1 in yeast. The first reference to the function of this gene was in S.
pombe, were it was characterized in a screen for high-copy suppressors of ectopic
meiosis caused by expression of the meiotic regulator mei2 (32). Mei2p normally
induces meiosis only in response to starvation conditions, and loss of Mipi p interfered
with this process. However, it was not until the identification of the human homologue,
raptor, by immunoprecipitation and mass-spectrometry that this protein was associated
with TOR signaling (17, 18). Soon after, the raptor homolog kog1p was found to
associate with both TOR1 and TOR2, thus defining TORC1 in budding yeast (15). In
cells, raptor has a clear positive role in mTORC1 activity, and depletion of it by RNAi
leads to inhibition of downstream targets, S6K1 and 4E-BP1, similar to rapamycin
treatment (17, 18). Interestingly, TORC1 is known to have activity towards S6K1 in vitro
even in the absence of raptor (33). Although potentially an artifact, this observation
suggests that raptor might activate mTOR in cells through a mechanism that doesn't
directly alter its kinase activity, such as localization or substrate recognition. On the
subject of substrate binding, several groups have suggested that a conserved, short
TOR-signaling (TOS) motif which appears in many TORC1 substrates is key for their
recognition by raptor (19, 34).
mTORC1 also contains three other components: mLST8/GPL and DEPTOR,
which bind directly to rnTOR, and PRAS40, which binds raptor. mLST8/GpL was first
identified as a TORC1 component in budding yeast (15) and shortly after in mammalian
cells (20). Although there is some debate concerning the function of mLST8 in
mammalian cells, in yeast, LST8 has been shown to negatively regulate amino acid
biosynthesis and uptake, phenocopying some of the effects of rapamycin (35).
PRAS40 and DEPTOR are the most recently described mTORC1 components.
PRAS40 was recently identified as a raptor-binding protein and a negative regulator of
the pathway (22, 23). Its homolog in the fruit fly, Drosophila melanogaster, Lobe, has
long been known to regulate developmental processes (36), but if and how those
phenotypes might connect with TORC1 signaling has only been recently begun to be
assessed (37). A more detailed discussion of the functions of DEPTOR and the
signaling downstream of TORC1 follows in later sections.
D. On the activation of TORCI
TORC1 is controlled by a constellation of signals that reflect the overall metabolic
state of the cell. Most famously, TORC1 is thought to act as an intracellular sensor of
nitrogen availability. However, numerous inputs including glucose sufficiency, oxygen
availability, energy status, membrane composition, and in metazoans, growth factors
such as insulin, have been shown be potently regulate TORC1 output (38).
Impressively, all of these inputs likely converge upon the heterodimer Tuberous
Sclerosis Complex (consisting of TSC1, also known as hamartin; and TSC2, also known
as tuberin) and the small GTPase Rheb (Ras homolog enriched in brain).
Rheb was first associated with cell growth in S. pombe, where its loss causes a
growth arrest with a terminal phenotype similar to that caused by nitrogen starvation
(39). However, it was studies in Drosophila melanogaster and mammalian cells which
directly connected Rheb and TSC1/2 genes to the TOR pathway (40-44). How Rheb
and TSC1/2 act on TORC1 has recently begun to be elucidated. The TSC1/2
heterodimer catalyzes the conversion of Rheb-GTP to Rheb-GDP Rheb, and in its GTP-
bound state, Rheb directly binds and activates mTORC1 (23, 45, 46). Only the TSC2
protein contains a GAP domain, but its activity toward mTORC1 is dependent on its
association with TSC1, perhaps by localizing TSC2 to endomembranes where Rheb
resides (47-50).
Kinases stimulated by upstream signals such as insulin or glucose regulate
mTORC1 by phosphorylating a collection of sites on TSC2 and/or raptor (51-55). The
effects of these phosphorylations have been shown or are presumed to change of the
activities of the TSC1/2 or mTORC1 complexes, respectively thereby regulating S6K
and 4E-BP1 phosphorylation. One of the kinases that acts on TSC2 is the P13K-
regulated kinase, Akt, which phosphorylates TSC2 in response to insulin (51, 52). This
phosphorylation is thought to provide a critical piece of the mechanism by which this
growth factor stimulates mTORC1. More recently, this mechanism has been elucidated
further by Cai et al. who show that TSC2 phosphorylation by Akt maintains the GTP-
bound state of Rheb by dissociating TSC2 from membranes where Rheb resides (50).
AMPK, which is activated by rising intracellular AMP in response to glucose deprivation
or energetic stress, also phosphorylates TSC2 and raptor and regulates mTORC1
activity (54, 55). Under what circumstances this kinase acts on either or both of these
mTORC1 pathway components is not yet well understood.
Lastly, the Drosophila hypoxia-induced proteins, Scylla and Charybdis, as well as
the Scylla mammalian homolog Reddl/RTP801 are also thought to act on the TSC1/2
complex to inhibit TORC1 (56) (57). Recently it has been posited that Redd1 might
inhibit mTORCI by controlling the release of TSC2 from its growth-factor-induced
association with 14-3-3 proteins (58, 59).
Despite many attempts to connect amino acids to TORCI through any of the
aforementioned upstream regulators, the view on this longstanding question remains
murky. For instance, some groups had proposed that loss of TSC1 and TSC2 rendered
TORC1 signaling resistant to amino acid deprivation (41). However, it is now widely
believed that, although loss of TSC1/2 hyperactivates TORC1 signaling and can
overcome the effects of growth factor withdrawal, it cannot overcome the effects of
amino acid deprivation (60) (61). Other groups have shown that overexpression of Rheb
can overcome the effects of amino acid starvation on mTORC1 signaling in cultured
cells and that overexpression in drosophila embryonic tissue causes overgrowth
regardless of amino acid availability (43). However, these results are complicated by the
likelihood that ectopic overexpression of Rheb might not reflect a physiological state
comparable to the manipulation of intracellular amino acid levels. Moreover, it is worth
noting that TORC1 signaling is strongly regulated by amino acids in S. cerevisiae
despite the lack of TSC1/2 homologs and that the loss of Rheb in this species does not
cause as significant a growth defect as it does in most other organisms (62). These
results suggest that if the sensory mechanism were to be conserved, it likely involves
additional or distinct pathways from the TSC/Rheb axis.
One attractive candidate amino acid-regulated pathway that is conserved in S.
cerevisiae is the vacuolar membrane-associated protein complex (EGO), composed of
EGO1, EGO3 and the GTPases Gtrl and Gtr2 (63, 64). This complex has been shown
to be required for the resumption of growth following a rapamycin-induced G1 arrest
(63) and to have synthetic interactions with a TOR1 mutation (64). Moreover,
comparable to the effects of amino acid starvation, Gtrl and Gtr2 are known to regulate
the sorting of the general amino acid permease Gapi p (65, 66). Dubouloz et al.
suggested that the EGO proteins might act upstream of TORC1 in amino acid sensing
because diverse readouts which are negatively controlled by TORC1, e.g., glycogen
accumulation, phosphorylation of elF2a on Ser 51, and macroautophagy, depend on the
presence of Egol, Gtr2, and Ego3 during recovery from rapamycin treatment for
resetting to their initial status. In further support of this idea, overproduction of Gtr2 or
Ego3 enhances rapamycin resistance (63) and an engineered molecule that was found
to bind Ego3 directly in cells could overcome the effects of rapamycin, possibly by
causing a gain of function of Ego3 (67).
Ill. TORC1 controls growth-associated processes
A. TORCI, protein synthesis, and ribosome biogenesis
Studies in mammalian cells on the cell cycle inhibitory effects of rapamycin first
suggested the signaling cascade that is perhaps most commonly associated with TOR,
i.e., the regulation of protein synthesis through p70 S6 kinase (a 70kDa protein also
known as S6K). S6K received its name fittingly after being found to be a major kinase of
the ribosomal protein, S6 (68). S6, is a protein of the 40s ribosomal subunit long known
to be phosphorylated upon stimulation of cells with mitogens (e.g., growth promoting
stimuli that are present in serum including insulin, EGF, IL-2, erythropoietin) (69). mTOR
came into the protein synthesis picture when rapamycin was shown to prevent the
phosphorylation and activation of S6K (70-74). In addition to growth factors, depletion of
amino acids from cells profoundly inhibits protein synthesis (75). Therefore, it was an
exciting discovery that rapamycin also abolished amino acid stimulation of S6K
phosphorylation and activation (76).
As with short term fasting in animals (where growth factors such as insulin
become depleted from the blood) (77), amino acid withdrawal from cells is characterized
by a loss of polysomes and an increase in monomeric ribosomes (78, 79). These
findings both point to growth factors and nutrients controlling translation at its initiation.
The rapamycin-sensitive S6K pathway is thought to participate in regulating translation
initiation by controlling the translational efficiency of a specific subset of transcripts,
namely elongation factor and ribosomal protein mRNAs which possess an unusual
pyrimidine-rich sequence at their 5' end, referred to as a 5' TOP (terminal
oligopyrimidine) (80-82). In addition to its role in 5' TOP-mediated translation, mTORC1-
S6K signaling has also recently been shown to control translation by regulating pre-
mRNA splicing (83).
mTORC1 regulates S6K by directly phosphorylating it on a highly conserved
residue, threonine 389, that is essential for its activity (84, 85). Recently, Sch9 was
shown to be a direct substrate of TORC1 and thus likely represents the yeast S6K
homolog (86). Regarding the localization of Sch9, it has been shown to be enriched at
the vacuole (87, 88), which interestingly, is a cellular compartment in eukaryotic cells
that serves as the major storage vesicle of amino acids (89). However, how Sch9
localizes to this compartment is still not well understood.
Entry of yeast cells into the GO or stationary phase in cells lacking TOR function
is accompanied by loss of cell proliferation including a reduction in translation initiation.
That loss of TOR function is suppressed by altering the translational control of the G1
cyclin, CLN3, suggested that TOR likely controls G1 progression by regulating
translation initiation (90). Subsequent investigation into the effects of TOR on CLN3
centered on the translation initiation factor, eIF4E. The justification for this is because
CDC33 (eIF4E) and TOR mutants are known to have remarkably similar phenotypes,
including a G1-specific function as well as an essential function that is not G1 specific
(90). Also, in mammalian cells, similar to that found with S6K, rapamycin was shown to
block the serum-stimulated phosphorylation of a key repressor of eIF4E-mediated
translation, eIF4E-binding protein 1 (4E-BP1/PHAS-1) (91, 92). The phosphorylation of
4E-BP1 controls cap-dependent translation of mRNAs with extensive secondary
structure including the G1-regulating, CLN3 homolog, cyclin D1 (93-95). Initiation factor
4F complexes with these mRNAs through the interaction of its elF-4G subunit with elF-
4E, which is the cap-binding protein that recognizes the N7-methyl-GpppN structure of
the 5' end of all nonorganellar mRNAs. In quiescent cells, 4E-BP1 competes with elF-
4G for binding to elF-4E and represses translation by displacing the initiation factor 4F
from the mRNA. Growth stimuli activate phosphorylation of 4E-BP1, which decreases its
affinity for elF-4E and releases the block on cap-dependent translation (95).
Interestingly, regulation of 4E-BP1 phosphorylation by serum starvation or rapamycin
treatment has been shown to redistribution of eIF4E from the cytoplasm to the nucleus
(96). However, the significance of this regulation in translational control has not yet
been investigated.
Regarding the mechanism of 4E-BP1 phosphorylation, mTORC1 has been
shown to direct phosphorylate 4E-BP1 on multiple residues, including threonines 37 and
46 (T37/T46) (84, 97). The significance of mTORC1 in regulating translation via 4E-BP1
is highlighted by the finding that the T37/T46 residues are critical for its association with
eIF4E (98). Interestingly, mTORC1 kinase activity towards 4E-BP1 has been shown to
be aided by its increased binding to raptor in mTORC1 (99). Because S6K has not been
demonstrated to interact with mTORC1 in a similar manner, it remains to be determined
whether or not this finding will apply to other mTORC1 substrates.
In addition to controlling translation initiation, TORC1 is known to regulate
ribosome biogenesis (100), which refers to the transcription of ribosomal protein and
rRNA genes. TORC1 regulates the expression of these genes by controlling the
nuclear-cytoplasmic translocation of multiple transcriptional regulators, including Sfp1
and CRF1, which in the absence of TORC1 function, are recruited or prevented from
interacting with, respectively, the promoters of ribosomal and/or rRNA genes (101, 102).
TORC1 controls CRF1 indirectly by repressing the activity of the PKA target, YAK1,
whose phosphorylation of CRF1 promotes its nuclear accumulation (102). The
mechanism of Sfp1 translocation was recently explored by Lempianinen et al. (103). In
contrast to CRF1, Sfp1 localization is regulated by its direct interact with TORCI in a
manner dependent on TORC1 -catalyzed phosphorylation (103).
Because of their functional similarities, the protooncogene, c-myc, is thought to
be the homolog of Sfp1 in multicellular eukaryotes (104). Notably, c-myc has previously
been functionally linked to mTORC1 signaling and its overexpression increases cell size
and increased ribosomal and nucleolar gene expression similar to that of Sfpl
overexpresion (88, 105, 106).
B. TORCI and autophagy
Considering the prevalence of feedback loops in biological systems, it is intuitive
to think that because TORC1 promotes protein synthesis it would also inhibit protein
degradation. Indeed, when TORC1 activity is reduced in cells, organelles and proteins
are degraded en masse via a catabolic processed termed autophagy (107). Autophagy
involves the de novo synthesis of membrane bound vesicles, termed autophagosomes,
which sequester intra-cellular components and deliver them to the vacuole/lysosomes
via membrane fusion. Vacuole/lysosomal degradation of these components liberate
biological material to sustain macromolecule biosynthesis and energy production. The
inhibition of TORC1 by inactivation of TORC1 components, amino acid deprivation, or
rapamycin treatment triggers autophagy, whereas stimulation of TORC1 prevents this
process (108). Analogous to the mechanism of TORC1 -mediated 4E-BP1
phosphorylation and activation of translation, TORC1 represses autophagy by binding
and/or directly phosphorylating multiple components of a protein complex that initiates
autophagosome formation, unc-51-like kinase 1 (ULK1, Atg1/Apg1 in yeast),
autophagy-related gene 13 (ATG13, Atg13/Apg13 in yeast), and focal adhesion kinase
[FAK] family-interacting protein of 200 kDa (FIP200, Atg17/Apg17 in yeast) (109-114).
C. TORC1 regulates sterol-lipogenesis
In one of the first studies into the antifungal properties of rapamycin in C.
albicans, it was noted that this agent prevented the synthesis of lipids from the carbon-
containing precursor, acetate (1). Another early work pertaining to the role of TORC1 in
lipogenesis found that during amino acid starvation of fruit fly larvae, lipids mobilized
from adipose cells of the larval fat body became visible as lipid vesicle aggregates and
that this effect was indistinguishable from that caused by loss of the Drosophila TOR
homolog, dTOR (115). Despite these interesting findings, a thorough demonstration of
the involvement of TORC1 in lipid synthesis has only more recently been made. It was
shown in mammalian cells that Akt-dependent lipogenesis requires positive input from
mTORC1 to control de novo lipid synthesis as well as the levels of sterol regulatory
element binding protein 1 (SREBP1) (116). SREBP1 is a member of a transcription
factor family that plays a critical role in promoting fatty acid and cholesterol biosynthetic
gene expression (117). Further stating a case for SREBP functioning as a conserved
growth regulator, Porstmann et al. found that silencing of the Drosophila homolog of
SREBP, dSREBP1, results in reduced cell and organ size in a manner refractory to
dPl3K-induced growth (116).
Conversion of mouse 3T3-LI preadipocytes (fibroblasts) to fully developed
adipocytes under the influence of dexamethasone, 1 -methyl-3-isobutyl xanthine, and
insulin has been an invaluable approach to investigate differentiation-related changes in
lipid metabolism (118, 119). In this system, inhibition of either mTORC1 by rapamycin or
amino acid deprivation inhibits 3T3-LI preadipocyte differentiation by suppressing the
expression and transactivation activity of peroxisome proliferator activated receptor-
gamma (PPARy)- a master regulator of adipogenesis (120, 121). Additionally,
rapamycin has been shown to reduce the phosphorylation of lipin-1 (122), a
phosphatidic acid (PA) phosphatase that is key for preadipocyte differentiation, likely
due to its coactivation of many transcription factors linked to lipid metabolism, including
PPARy, peroxisome proliferator-activated receptor-alpha (PPARoc), and peroxisome
proliferative activated receptor gamma coactivator-alpha (PGCIc) (123). Consistent
with lipin 1 having a conserved key role in sterol and lipid homeostasis, mutation of its
S. cerevisiae homolog, Pah1, have been shown to strongly perturb intracellular neutral
lipid and phospholipid levels in stationary and active growing cells (124).
The ability of yeast to sense the availability of inositol and to adjust the
expression of genes required for lipid biosynthesis, in particular the INOI gene, has
been studied as a model for the integration of transcriptional signaling pathways. The
INOI gene encodes inositol-1 -phosphate synthase, which converts glucose-6-
phosphate to inositol-1-phosphate for its subsequent use in phospholipid synthesis
(125, 126). Consistent with a role for TORC1 in promoting phospholipid synthesis,
rapamycin represses INO1 expression (127). Also, deletion of the S. cerevisiae lipin 1
homolog, Pahl/smp2, or the phosphatase complex which is known to dephosphorylates
Pahl/smp2, Neml/Spo7, promotes INO1 expression (124, 128). That deletion of either
Nem1 or Spo7 confers rapamycin sensitivity suggest that TORC1 might have a
conserved role in regulating lipin 1/Pah1 phosphorylation (129). However, whether lipin-
1/Pah1 are direct substrates of mTORC1/TORC1 and whether lipin-l/Pahl might
regulate the aforementioned lipid-regulating transcriptional regulators in a manner
dependent on mTORC1/TORC1 is still unclear.
D. TORCI and the cytoskeleton
Tori p and Tor2p, both present in TORC1, are kinase homologs which have
structurally and functionally similar, but not identical functions (130). One critical Tor2p-
unique activity is known to be signaling to components required for proper remodeling of
actin and the integrity of the cell wall (131-134). These components include the Rhoip
GTPase and its associated regulatory partners Rom2p and Sac7p, which function in
part by regulating protein kinase C (Pkcl p), an upstream activator of the mitogen-
activated protein kinase (MAPK) Slt2p/Mpkl p. Because the Tor2p-dependent actin and
cell wall phenotypes found in this early work were rapamycin-insensitive, much of the
attention on the Tor2p-Rhol p-actin cascade subsequently focused on TORC2 (135,
136). However, more recently, the role of TORC1 in regulating cell structure has begun
to receive some attention. Using a combined proteomic and genomic approach, it was
found that a large number of yeast genes involved in actin polarization possessed
altered sensitivities to inhibition of the TORC1 components, TOR1 and TC089 (137).
Also as rapamycin treatment and inhibition of the TORC1 -controlled, Tap42p/Sit4p
phosphatase system were recently shown to alter actin polarization and cell wall
integrity, in contrast to previous reports, the role of the TORC1 in controlling the
cytoskeleton remains controversial (138, 139).
There is also evidence in mammalian cells that TORC1-relevant inputs, such as
amino acids, rapamycin, and raptor regulate various aspects of actin organization (140-
142). As with yeast, a common effector in these processes is thought to be the Rho
pathway. However, the involvement of Rho in mediating these mTORC1-dependent
effects has yet to be functionally tested.
Mitosis and cytokinesis rely heavily on cytoskeletal rearrangements to coordinate
cleavage of the cytoplasm of a dividing cell (143, 144). While the role of TORC2 in
completing the cell cycle has begun to be directly addressed (145), this information on
TORC1 is still largely through inference. The inhibition of translation observed during
mitosis results from a global decrease in cap-dependent translation, however the cap-
independent translation of some mRNAs are upregulated (146, 147). Wilker et al.
showed that a defective switch in this mechanism results in reduced mitotic-specific
expression of the endogenous internal ribosomal entry site (IRES)-dependent form of
the cyclin-dependent kinase Cdk1 1 (p58 PITSLRE) (148). PITLSRE is known to
regulate the cytoskeleton by promoting centrosome maturation and bipolar spindle
formation (149, 150). That TORC1 might be important in these PITLSRE-dependent
cytoskeletal events was suggested by the finding that impairing PITLSRE translation
during mitosis lead to impaired cytokinesis and the accumulation of binucleate cells,
both of which can be rescued using rapamycin (148). Additional observations of a
putative important role for TORC1 in regulating centrosomes and the mitotic spindle
have likewise been made only recently (151, 152).
E. TORC1 and mitochondria
Given that the bulk of cellular ATP synthesis occurs in the mitochondria, and that
anabolic processes require significant energy consumption, the notion that mTORC1
regulates mitochondrial metabolism is not surprising. Inhibition of mTORC1 by
rapamycin lowers mitochondrial membrane potential, oxygen consumption and cellular
ATP levels, and profoundly alters the mitochondrial phosphoproteome (153).
Conversely, hyper-activation of mTORC1 results in increased expression of PGC-10c,
which is known to promote increased mitochondrial abundance (as measured by
mitochondrial DNA copy number), as well as the expression of many genes encoding
proteins involved in oxidative metabolism (154). Additionally, conditional deletion of
raptor in the skeletal muscle of mice reduces the expression of genes involved in
mitochondrial biogenesis (155).
While PGC-1 cc lacks an obvious homolog in yeast, it is clear that TOR pathway
is a conserved important determinant of mitochondrial function. In S. cerevisiae,
regulators of TORC1 signaling (i.e., TOR1/2, LST8, rapamycin) control the transcription
of specific tricarboxylic acid (TCA) and glyoxylate cycle genes through a circuit referred
to as the retrograde (RTG) pathway (156). As early reactions of the tricarboxylic acid
cycle, retrograde gene products (encoded by the CIT2, ACQI, IDH1/2, and DLD3
genes) are particularly involved in regulating the balance of carbon and nitrogen
utilization by cells. TOR and nutrient based signals are thought to interface with the
RTG system by controlling the phosphorylation and/or nuclear-cytoplasmic distribution
of multiple RTG gene transcriptional regulators: RTG1, RTG2, RTG3, and Mksl (156).
For example, rapamycin treatment of cells grown under rich nutrient conditions causes
Rtgl p and Rtg3p proteins to translocate from the cytoplasm into the nucleus and
activate their target genes (157, 158). Several proteins have been identified that are
important for these TORC1 -regulated nucleocytoplasmic trafficking events, including
two cytoplasmic proteins, Rtg2p (157-159) and Mkslp (158, 160, 161). Dynamic
interactions between Rtg2p and Mksl p that involve TORC1 -mediated, Mksl
phosphorylation-dependent interactions with Bmh1p and Bmh2p, the latter being the
yeast homologues of mammalian 14-3-3 proteins, play critical roles in regulating the
localization and activity of the Rtg1p- Rtg3p complex (162, 163).
Because the glyoxylate cycle, which is an anabolic pathway that allows yeast,
plants, and several microorganisms to use fats for carbohydrate synthesis, is thought to
be absent in most animals (164), the conserved relevance of RTG pathway to TORC1
signaling has remained ambiguous. Regardless, that genetic screens continue to detect
many of these RTG enzymes as synthetic interactors with TORC1 signaling
components suggests that continued dissection of the relationship between these
systems is warranted (165).
F. TORC1 and protein sorting
The delivery to the plasma membrane of the general amino acid permease,
Gapi p, of Saccharomyces cerevisiae is regulated by the quality of the nitrogen source
in the growth medium. Gapi p sorting is thought to occur at either the endosome or
trans-Golgi compartments (166, 167) and one major class of mutations that influences
Gapip sorting is known to be in ubiquitination genes (168, 169). Because
polyubiquitination of Gapip is a signal for its sorting to the vacuole, mutation of genes
required for Gapip polyubiquitination (e.g., bull bu/2, rsp5, or doa4) causes Gapip to
be sorted to the plasma membrane more efficiently. While rapamycin curiously does not
regulate GAP1 p sorting, mutations in the TORC1 pathway components, Lst8 and the
EGO complex do, though in the case of the EGO complex there are clearly strain-
specific effects (66, 166, 170). Gln3 is also sorted in an TORC1- and ubiquitin-
dependent manner. This regulation occurs through a phosphorylation cascade involving
TOR, SIT4, Npr1, and Rsp5 whose details are still under investigation (171-173) (174).
TORC1 also appears to regulate microtubule-dependent protein trafficking. TSC2
deficient mouse cells alters the distribution of several proteins whose microtubule-based
trafficking has been well-studied, VSV-g, caveolin, and GLUT4 (175-177). Though it is
thought that mTORC1 controls this trafficking through the microtubule associated
protein, CLIP-1 70/Restin, and that in yeast TORC1 controls the CLIP-1 70 homolog,
Bik1p, in regulating nuclear positioning, (178, 179), delineation of the core elements of
this microtubule-based TORC1 trafficking pathway still seems in a early stage relative to
other TORC1 pathways.
IV. mTORC1 signaling in disease
A. mTORC1 and Cancer
The TSC complex is a heterodimer of the proteins tuberin (TSC1) and hamartin
(TSC2). Before the TSC complex was associated with TOR signaling, they had already
been appreciated as tumor suppressor genes, and inactivation of either causes a
familial autosomal dominant disorder tuberous sclerosis complex (TSC) that affects
approximately 1:6000 individuals (180). A defining feature of TSC is the development of
hamartomous tumors in multiple tissues that can be severely disrupt tissue function but
are rarely metastatic (181). Loss of TSC2 is also strongly associated with
lymphangioleiomyomatosis (LAM), a rare multi-systemic disease that causes cystic
destruction of the lung parenchyma and abdominal tumors (182). LAM occurs almost
exclusively in young women, and the mechanistic connection to TSC is still not well
understood. There are several additional hamartoma syndromes that share pathological
features with TSC, including Cowden Disease, Peutz-Jeghers Syndrome,
neurofibromatosis and Birt-Hogg-Dube Syndrome (183). Like TSC1 and TSC2, the
tumor suppressor genes linked to these diseases (PTEN, LKB1, NF1 and FLCN
respectively) encode proteins that restrict mTORC1 signaling.
An interesting aside on TSC1/2 function concerns the benign nature of TSC
tumors. Due to downregulation of growth factor signaling, via S6K-mediated
downregulation of the insulin receptor substrate 1 (IRS-1) (184, 185) and/or
downregulation of platelet-derived growth factor receptor (PDGFR) (186), TSC1 or
TSC2 loss is known to inactivate signaling through P13K/Akt (186, 187), a kinase which
is known to be hyperactivated in most malignant tumors (188, 189). As a consequence,
it has been hypothesized that TSC tumors are less aggressive because of this impaired
P13KAkt signaling (186).
While TSC1/2 mutations are relatively uncommon cause of tumors in humans,
mTORC1 also sits at the nexus of many classical oncogenic signaling pathways. Its
most prominent connection is to the PTEN/PI3K pathway, which is activated by growth
factor signaling and is mutationally deregulated in a wide spectrum of sporadic cancers
(190, 191). PTEN alone is disrupted in 50-80% of sporadic cancers, which includes
endometrial carcinoma, glioblastoma and prostate, and 30-50% of breast, colon and
lung cancers (192). Both mTORC1 and mTORC2 pathways are hyperactivated by
PTEN inactivation and are increasingly blamed for many of its subsequent signaling
defects, such as deregulation of Akt (193).
A second class of cancers that have close connections with mTORC1 are those
characterized by hyperactive functioning of the translation initiation factor, eIF4E. In an
mTOR-dependent manner, eIF4E coordinates the translation of a subset of mRNAs with
extensive structure in the 5' untranslated region, including cyclin D1 and c-myc (194).
Highlighting the importance of eIF4E, cyclin D1, and c-myc in cancer, this translational
control is frequently lost or deregulated due to alteration of the 5' mRNA sequences or
amplification of genomic DNA including their genes in various tumors (195-197).
mTORC1 can also contribute to tumor growth by promoting angiogenesis.
Activation of mTORC1 increases levels of the transcription factor hypoxia-inducible
factor I alpha (HIF1c) by driving its expression and suppressing its degradation (198,
199). As HIF1ax accumulates, it drives angiogenesis through expression of the vascular
endothelial growth factor (VEGF) (200). Kaposi's sarcoma and certain sporadic or
hereditary kidney cancers show elevated VEGF signaling and increased HIF1 a levels,
respectively (193, 201, 202).
B. mTORCI, insulin sensitivity, and diet-induced obesity
Concurrent with the work in mouse fibroblasts showing that TSC1/ TSC2
deficiency negatively regulates PI3K/Akt signaling, a similar role for TSC1/TSC2 in
regulating Akt was shown in fruit flies (203). Moreover, this Drosophila work established
that dTSC1/dTSC2-dependent negative regulation of dAkt/PKB activity could be
reserved by the simultaneous loss of dS6K. Fittingly, when S6K1 knockout mice were
generated (204), these mice were also shown to have increased Akt phosphorylation
(184). The increased Akt in these mice was also shown to correlate with decreased
turnover of the insulin receptor substrate 1 (IRS-1). IRS-1 is known to promote Akt
phosphorylation by initiating a cascade whereby IRS-1 binding contributes to P13K
activation which promotes PIP3 formation and PIP3-mediated recruitment of Akt to
membranes where it can be phosphorylated by membrane-bound kinases (205, 206). It
has been the assembly of this pathway with the concurrent work with S6K-deficient flies
and mice that led to the now well-appreciated idea of a negative feedback loop from
TORC1-S6K to P13K-Akt signaling (207).
Despite decreased p-cell mass which lead to hypoinsulinemia (204), the S6K1
knockout mice also had increased glucose uptake upon insulin administration indicating
that these mice had increased insulin sensitivity, again consistent with increased Akt
phosphorylation in the tissues of these animals (184). Compared to age matched
controls, Um et al. also found in these S6K1 -null mice a five-fold increase in the rate of
fat lipolysis as well as an increase in metabolic rate as measured by oxygen
consumption. Loss of S6K1 converted white adipose tissue into an energy-consuming
tissue by increasing mitochondria number and expression of uncoupling protein 1
(UCP1), carnitine palmitoyltransferase 1 (Cpt1) and PGCIa. Interestingly, though
opposite to what one might expect, similar changes in gene expression to those of the
S6K1 -deficient adipocytes where seen in 4E-BP1 -deficient adipocytes (208). The
changes in Cpt1 gene expression in S6K1 -deficient adipocytes also occurred in S6K1-
deficient skeletal muscle leading to marked increase in fatty-acid p-oxidation in the
muscle. Consistent with this increased oxidative function, these mice were also resistant
to age-associated and high fat diet-induced obesity.
To directly study mTORC1 in mice, white adipose and skeletal muscle tissue
specific knockouts of raptor, an essential component of mTORC1, have also recently
been engineered (155, 209). Satisfyingly, these knockout mice have confirmed many of
the S6K1 knockout mice phenotypes. Loss of raptor in adipocytes led to decreased
adipocyte size and number (209). Similar to the S6K1 knockout mouse, the decrease in
fat storage upon loss of raptor was due to increased oxidative metabolism within the
white adipose tissue driven by increased expression of UCP1 (209). Both the fat- and
muscle-specific raptor knockout mice also had decreased PGC-a expression in their
respective mTORC1 -deficient tissues. Adipocyte-specific raptor deficient mice had
lower circulating levels of insulin, but were more insulin sensitive than wild type controls
resulting in lowered blood glucose, also similar to S6K1 knockout mice (209). Loss of
raptor in the fat also changed whole body metabolism in response to a high-fat diet. As
expected in the raptor mutant mice, fat deposition was countered by increased oxidative
capacity (Polak et al., 2008). Moreover, raptor mutant mice continued to be more insulin
sensitive under a high fat diet (209).
In summary, these studies show that mTORC1 has important energy storage and
utilization functions; in its absence in adipose tissue, there is both increased energy
uncoupling and fatty acid oxidation. Loss of mTORC1 signaling also leads to increased
insulin sensitivity and accompanying glucose uptake by muscle and prevents the onset
of insulin resistance on a high-fat diet.
C. mTORC1, hyperlipidemia, and hypercholesterolemia
Before mTOR had shown to be a key piece of the mechanism for the growth-
inhibitory effects of rapamycin, rapamycin was already in use as an immune
suppressive agent in transplantation settings (210, 211). Currently, rapamycin, which is
known by trade names, sirolimus, everolimus, and temsirolimus, is a common
therapeutic strategy for the prevention of kidney transplant rejection, restenosis in
coronary stents, and in the treatment of renal cell carcinoma, respectively (212-214).
While rapamycin has typically been shown to be a well-tolerated drug, it is also known
for common side effects, namely, hyperlipidemia and less commonly,
hypercholesterolemia (215, 216). The effects of rapamycin on plasma lipids and
cholesterol in human patients have also been found in experimental animal models.
Long-term treatment of mice with rapamycin has been shown to decrease muscle
PGC1 a expression and mitochondrial function and this was associated with these mice
developing hyperlipidemia as well as insulin resistance (154). These mice also
developed hypercholesterolemia though the mechanism for this effect was not clear.
To begin to think about why rapamycin might increase plasma cholesterol levels
in humans and mice, two key regulators of cholesterol homeostasis are important to
discuss, the low density lipoprotein receptor (LDLR) and 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGCR). LDLR is a cholesterol receptor prominently
expressed by liver cells that is critical for clearing the blood of plasma cholesterol (which
in the blood are complexed with proteins referred to as lipoproteins) (217). HMGCR is
the rate-liming enzyme in cholesterol biosynthesis and incidentally is the target of the
commonly used cholesterol-lowering drug, statins. Early studies by Brown and
I
Goldstein found that HMGCR activity is strongly reduced when cells are grown in media
containing cholesterol and the opposite is true when cholesterol is depleted (217).
These results suggested a feedback mechanism that involved coordination of cellular
cholesterol uptake and biosynthesis. Over the ensuing years, this feedback was shown
to occur because cells control cholesterol uptake and biosynthesis through a circuit
controlled by a transcription factor, SREBP, which potently regulates both LDLR and
HMGCR gene expression levels. The feedback works as follows: 1) in the presence of
cholesterol in the media, SREBP activity becomes downregulated which lowers
HMGCR and LDLR expression and cholesterol is subsequently not taken up by nor
made in cells. 2) the ensuing absence of cholesterol within cells causes the activation of
SREBP which then restores cholesterol uptake and biosynthesis. A recent study
suggests that this feedback regulation might be broken by rapamycin. In hepatocyte cell
line, it was shown that rapamycin downregulates LDLR expression while not perturbing
the levels of HMGCR (218). Therefore, one explanation for why rapamycin might induce
high blood cholesterol levels in humans and mice might be because their livers do not
clear the cholesterol (due to downregulated LDLR expression) and subsequently don't
downregulate its synthesis accordingly (HMGCR expression is maintained).
These effects of rapamycin in humans and in mice on plasma lipids and
cholesterol stand in contrast those recently observed with selective inhibiton of
mTORC1 by deleting raptor in adipose tissue of mice. Here, raptor loss specifically in fat
protects these animals from high fat diet-induced hyperlipidemia and
hypercholesterolemia (209). Importantly, these effects are similar to those seen in
SREBP1 knockout mice fed a western-diet (219). The above data suggests that further
investigation into how distinct mTOR inhibitors might differentially regulate these key
SREBP targets will be valuable in evaluating the utility of these agents in
treating/preventing hyperlipidemia and hypercholesterolemia.
D. mTORC1-based therapies
Cancer: The best rationale for therapeutic inhibition of mTOR in cancer is in the
hamartoma syndromes such as tuberous sclerosis complex (TSC). The constitutive
activation of mTORC1 that results from loss of TSC1/TSC2 function is thought to drive
many of the pathological features of TSC, thus establishing a compelling argument for
the therapeutic use of rapamycin (220). Clinical trials to treat TSC patients are currently
underway and early results have been promising (221). NF1 mutant cells also strongly
respond to rapamycin (222), and accordingly, preclinical studies to test the utility of
rapamycin in treating these tumors are ongoing (223). In sporadic cancers rapamycin
has been less successful. Indeed, the use of rapamycin and its analogues has had
modest successes in the treatment of mantle cell lymphoma, endometrial cancer, and
renal cell carcinoma (224). In these cases, it is possible that other modes of mTORC1
inhibition, such as using ATP-competitive mimetics to the active site of mTOR, might
prove more successful (225).
Metabolic disease: In addition to testing the utility of rapamycin as well as other
classes of mTOR inhibitors in treating cancer, these molecules also have emerging
potential for the treatment of metabolic diseases. Because metabolic disease and aging
are intertwined concepts, it would be first useful to briefly discuss what we know about
the mechanisms of aging. As a key regulator of growth-associated metabolism, TORC1
has gained notice as a potentially important regulator of aging (226). This role has
recently been substantiated in studies mice and humans. For example, S6K1 knockout
mice have been shown to live longer and are resistant to age-related pathologies such
as bone, immune and motor dysfunction as well as loss of insulin sensitivity. This result
is a genetic confirmation of another recent report describing the ability of oral rapamycin
treatment to extend lifespan in both male and female mice (227). As more studies
suggest the importance of TORC1 in aging, two metabolically-related themes begin to
emerge on the mechanisms for its effects: insulin signaling and mitochondrial
metabolism.
Insulin signaling was first implicated in aging through the isolation of mutant
worms which lived twice as long as normal worms (228). Subsequent work has not only
confirmed the importance of the insulin signaling as a conserved regulator of aging, but
has also placed TORC1 firmly as part of this pathway (226). While few genomic
alterations in canonical insulin signaling pathway components have been linked to
longevity of humans (229), mutations that are suspected to be causative in premature
aging of humans have been identified. Virtually all of these known mutations reside in a
gene which encodes a component of the nuclear matrix, lamin A (230). Lamin A
mutations are associated with a condition known as progeria, which is a premature
aging syndrome that is often associated with the deregulation of metabolically active
tissues such as fat and muscle (e.g., progeria patients often develop lipodystrophy
(alterations in adipose tissue distribution/accumulation) and insulin resistance). Lamin A
is farnesylated protein, therefore one approach to treat progeria patients has been to
use farnesyl transferase inhibitors (FTIs) which block maturation of the lamin A protein.
Though the initial studies are preliminary, early indications of the use of FTIs in progeria
appear to be encouraging. (231).
Whether FTIs might hold promise as a treatment for aging-related diseases
besides those caused by lamin A mutations is debatable. However, one practical
approach that could be useful to a wide variety of insulin/mTORC1 -related metabolic
diseases is the use of dietary restriction. The validity of dietary restriction as a means to
improve human health has received increased focus due to its profound effects in
multiple organisms in extending lifespan (232). That dietary restriction has been shown
to increase lifespan comparable to, or in a manner-dependent on TOR inhibition in
multiple organisms puts TORC1 at the center of this therapeutic strategy (233-235).
Therefore, it seems reasonable to suggest that dietary restriction could be considered a
viable alternative to mTOR-targeting pharmaceuticals for the treatment of mTORC1 -
related metabolic diseases.
V. Conclusions
One may reasonably assume that our understanding of disease is limited by the
experiments we are actually capable of performing. While model organisms such as
mice, fruit flies, and worms, have proven valuable for investigating mechanisms of
TORC1 signaling, it is worth considering that their applicability to treating human
disease can be limited and their implementation in the lab time-consuming. Because the
TORC1 pathway sits at the center of many clinically-relevant pathologies, immune
dysfunction, cancer, aging, it is important to continue to think of how we can approach
this pathway in novel ways. That the TORC1 pathway is highly conserved should
enable us to make connections across a growing number of eukaryotic species whose
genomes are being characterized. Recognizing 'deep homology' of TORC1 function in
diverse eukaryotic species is one such promising approach (236). By considering a
greater assortment of organisms, one may appreciate which shared or unique platforms
are utilized by TORC1 to control species with diverse signaling requirements. With this
knowledge more in mind, we should be better able to explain the logic of TORC1 and
provide better rationales for treating TORC1 -related diseases.
In the following document, we address in particular three key questions of how
mTORC1 signaling is controlled by its localization:
1) How is mTORC1 activated?
2) How does mTORC1 regulate cell division?
3) How does mTORC1 promote sterol/lipogenesis?
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Summary
The mTOR Complex 1 (mTORC1) pathway regulates many processes
that control growth, including protein synthesis, autophagy, and lipogenesis.
Through unknown mechanisms, mTORC1 promotes the function of SREBP, a
master regulator of lipo- and sterolgenic gene transcription. Here, we
demonstrate that mTORC1 regulates SREBP by controlling the nuclear entry of
lipin 1, a phosphatidic acid phosphatase. When coordinately phosphorylated by
mTORC1 and GSK3, lipin 1 resides in the cytoplasm and mTORC1 inhibition
causes its translocation to the nucleus, which is required for SREBP inhibition.
Inhibition of mTORC1 in the liver significantly impairs SREBP function and
makes mice resistant, in a lipin 1-dependent fashion, to the hepatic steatosis and
hypercholesterolemia induced by a high fat and cholesterol diet. The
phosphatase activity of nuclear localized lipin 1 promotes nuclear eccentricity
and juxtaposition of SREBP with lamin A, a nuclear location that suppresses
gene transcription. Like lipin 1, lamin A is required for the full downregulation of
SREBP-target genes that occurs upon mTORC1 suppression. Our results
establish lipin 1 and lamin A as key mediators of the effects of mTORC1
inhibition on SREBP, and suggest the existence of a novel nuclear signaling
system for the epigenetic regulation of gene expression.
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Introduction
mTOR is an evolutionarily conserved, P13K-related family (PIKK)
serine/threonine kinase that regulates cell growth together with multiple
interacting partners. An essential component of the mTOR-containing protein
complex, mTORC1, in the control of protein synthesis is raptor. Raptor is
required for the mTOR-catalyzed phosphorylation of the translation regulators,
S6K1 and 4E-BP1, yet the mechanism(s) by which raptor regulates mTOR
phosphorylation of these substrates remain largely unknown. However, an
emerging view, at least in the case of 4E-BP1, is that its binding affinity for raptor
is critical in determining its ability to be phosphorylated by mTOR (1). Evidence
that mTORC1 not only phosphorylates, but also can stably associate with 4E-
BP1, has acquired further relevance as additional TORC1 substrates have been
identified by virtue of their copurification with TORC1. For example, in
Saccharomyces cerevisiae, TORC1 was found to interact in a rapamycin-
sensitive manner with and directly phosphorylate Sfpl (2), findings which filled a
prominent gap in our understanding of how this transcription factor controls
TORC1-dependent ribosome biogenesis.
Previously, lipin 1, which generates the rate limiting precursor in
triacylglycerol synthesis, diacylglycerol (3, 4), was shown to be phosphorylated in
an amino-acid and growth factor-stimulated, rapamycin-sensitive manner (5).
This result, following the identification of lipin 1 as the gene responsible for the
phenotype of the fatty liver dystrophy (fld) mouse (6), generated considerable
interest as a potential connection between mTOR and lipid homeostasis.
However, since these results preceded the identification of raptor (7, 8) and
because subsequent investigation into the function of lipin 1 using rapamycin
failed to identify a role for mTOR in regulating lipin 1 activity (9), the significance
of the mTOR-dependent phosphorylation of lipin 1 has remained elusive.
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Results
In revisiting a potential functional link between mTOR and lipin 1, we
noted that cell cycle-regulated phosphorylations of lipin 1, the related protein,
lipin 2, and their yeast homolog, Pahl/Smp2, negatively regulate their Mg2+-
dependent phosphatidic acid phosphatase (a.k.a., PAPI) activities (10).
However, because rapamycin lacked an effect on PAP1 activity, we explored the
possibility that mTORC1 might regulate some other aspect of Lipin I function,
such as its intracellular localization. Strikingly, treatment of cells with the ATP-
competitive mTOR inhibitor, Torinl (11), which potently inhibits mTORC1, as
measured by T37/T46 and S65 4E-BP1 phosphorylation, caused a complete
redistribution of lipin 1 from the cytoplasm to the nucleus (Fig. 1A and B). This
complete redistribution was also seen with LY294002 at a concentration, 25 pM,
which also potently inhibits mTORC1 signaling (Fig. 1A and B) (12). Rapamycin,
on the other hand, while abolishing the phosphorylation of the mTORC1 target,
S6K1, largely lacked an effect on lipin 1 localization and did not affect 4E-BPI
phosphorylation at the time point examined (Fig. 1A and B). That rapamycin
lacked an effect on lipin 1 localization is in disagreement with that recently
observed by another group in a different cell type, 3T3-L1 adipocytes (13).
However, as it is known that the completeness of inhibition of rapamycin on
mTORC1 signaling varies considerably between cell types (14), we reasoned
that the discrepancy on lipin 1 localization might be explained by the differing
rapamycin sensitivities of mTORC1 in the cell types assessed. In support of this,
in HEK-293T cells, unlike in NIH3T3 fibroblasts (Fig. 1A and B), lipin 1 nuclear
translocation was partially sensitive to rapamycin and this correlated with partial
inhibition of S65 4E-BP1 phosphorylation (Fig. SIA and SIB). Consistent with
lipin 1 nuclear translocation correlating with the extent of mTORC1 inhibition, a
P13K inhibitor, PI-1 03, caused only a partial accumulation of lipin 1 in the nucleus
and this correlated with the extent of 4E-BP1 and S6K1 dephosphorylation
caused by this agent (Fig. 1A and B). Torini also caused lipin 1 nuclear
translocation in cells lacking mTORC2 (i.e., rictor deficient), consistent with
mTORC1 regulating lipin I localization (Fig. 1 C). Reminiscent of the effects of
mTORC1 inhibition on 4E-BP1 phosphorylation and the regulation of cap-
dependent translation as recently reported (11, 14), the above data suggest that
lipin 1 cytoplasmic-nuclear distribution is controlled in a largely rapamycin-
resistant, yet mTORC1 -dependent manner.
We next tested known physiological inputs into mTORC1 signaling for
their effect on lipin 1 localization. Growth factors, such as insulin, strongly
promote mTORC1 activation (15), therefore it was surprising that serum
deprivation only caused partial lipin 1 nuclear accumulation (Fig. I D). However,
because this partial effect was similar to that caused by the effects of the P13K
inhibitor, PI-103 (Fig. 1A), we wondered whether serum deprivation might
activate a signaling event that precludes the full nuclear accumulation of lipin 1.
The GSK3a/P kinases were attractive candidates to mediate this resistance
because these kinases are activated by growth factor deprivation/P13K inhibition
by loss of phosphorylation at a site, (Ser9/Ser2l in GSK3a/0, respectively) which
is catalyzed by the growth-factor/PI3K-activated kinase Akt (16). GSK3a/P
inhibition with the specific ATP competitive GSK3a/p (hereafter referred to as
GSK3) inhibitor, GSK3-IX (a.k.a. BIO), did not cause redistribution of lipin 1 (Fig.
1 D), consistent with these kinases already being inactivated by the presence of
serum. However, when GSK3 was inhibited concomitantly with growth factor
deprivation, lipin 1 fully accumulated in the nucleus (Fig. 1 D). The assertion that
combined P13K/GSK3 inhibition phenocopies the effects of mTORC1 inhibition
on lipin 1 nuclear translocation was further supported by a time course of Torin1
treatment. After acute (1 hour) treatment, lipin 1 partially accumulated in the
nucleus, which correlated with the downregulation of P13K signaling, as judged
by T308 Akt phosphorylation, yet the activation of GSK30, as judged by loss of
S9 phosphorylation, at this early time point (Fig. 1 D and E). However, at later
times (>3 hours), lipin 1 became fully retained in the nucleus, and this then
correlated with the restoration of P13K signaling and the inhibition of both
mTORC1 and GSK3@ activities (Fig. 1 E and F).
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Because mTORC1 is also regulated by nutrient status, we assessed
whether glucose and amino acids regulated lipin 1 localization. Unlike with serum
deprivation, serum deprivation combined with glucose deprivation promoted the
full nuclear accumulation of lipin 1, an effect which correlated with a greater
degree of 4E-BP1 dephosphorylation caused by this treatment in comparison to
serum alone (Fig. S1 C and S1 D). Similar to the effect of glucose deprivation,
complete amino acid deprivation, which abolishes the activation of mTORC1 by
growth factors (17), caused a complete nuclear accumulation of lipin 1 (Fig.
S1 E). Lastly, because the phosphorylation state of lipin 1, lipin 2, and
Pah1/Smp2 is regulated by cell cycle activity (18, 19), we tested whether various
cell cycle perturbations would affect lipin 1 localization. Neither G1 arrest by a
double thymidine block, nor CDK or MEK inhibition affected lipin 1 localization
(Fig. S1 F). Taken together, these results suggest that lipin 1 cytoplasmic
retention is positively promoted, albeit in a hierarchal manner, by the mTORC1
and GSK3 kinases: inputs which promote mTORC1 activity prevent lipin 1
nuclear localization regardless of the presence of growth factors, whereas GSK3
requires a ,priming" signal provided by the absence of serum to regulate lipin 1
cytoplasmic-nuclear distribution.
We next sought to gain insight into the mechanisms by which lipin 1
translocation is regulated by mTORC1 and GSK3. Because mTORC1 and GSK3
are protein kinases, we focused on the lipin 1 phosphorylation state and the 19
phosphorylation sites previously identified on it (9). In our mass spectrometry
analysis, we detected 17 of the 19 published sites as well as 2 novel sites, S237
and T335 and observed that most of these 21 sites could be categorized into two
phosphorylation motif groups (Fig. 2A). Nine of the sites fell within "proline-
directed" motifs (S/T-P) like those in 4E-BP1 (Fig. 2A) (20-22), which are known
to be phosphorylated by mTOR (20), whereas 7 sites are part of a
phosphorylation cassette conforming to the canonical GSK3 motif, ((Ser/Thr)-
XXX-(Ser(P)/Thr(P))) (Fig. 2A). This motif is unique in that GSK3 is known to
require its substrates with this motif, such as glycogen synthase, to be first
primed by phosphorylation by a distinct kinase on a residue 4 amino acids c-
terminal to the site GSK3 phosphorylates (23, 24).
Rapamycin is known to regulate the insulin-stimulated phosphorylation of
the proline-directed lipin 1 site, S106, (9), therefore we assessed whether this
phosphorylation was also sensitive to Torin1. Indeed, insulin-stimulated
phosphorylation of S106 lipin 1 was blocked by both rapamycin and Torin1 (Fig.
2B). Using a phospho-specific antibody we raised to the proline-directed S472
residue of lipin 1, we also detected a pattern of S472 phosphorylaton that was
similar to that of S106 lipin 1 (Fig. 2B). Interestingly, treatment with Torin1, but
not rapamycin, reduced phosphorylation of S106 and S472 lipin 1 and S65 4E-
BP1 to levels below those seen in serum-depleted cells, suggesting that the
insulin-independent phosphorylations of S106 and S472 lipin 1 and S65 4EBP1
occur in a rapamycin-resistant, yet mTORC1-dependent manner. Because S106
and S472 phosphorylation were partially sensitive to acute (1 hour) rapamycin
treatment (Fig. 2B), we next sought to determine whether the lipin 1
phosphorylation state would be regulated by prolonged inhibition of mTORC1.
Analogous to the lack of effect of prolonged rapamycin treatment on 4E-BP1
phosphorylation (25), S237 and S472 lipin 1 phosphorylation were not impaired
by a prolonged course (12 hours) of rapamycin, but were sensitive to Torin1 (Fig.
S2A). Therefore, similar to 4E-BP1 phosphorylation (11, 25), this result suggests
that multiple proline-directed lipin 1 phosphorylation sites are regulated in a
rapamycin-resistant, yet mTORC1 -dependent manner.
To determine if lipin 1 can be directly phosphorylated at S106 and S472 in
an mTORC1 -dependent manner, we isolated mTOR via mLST8/GPL from control
or raptor knockdown cells and performed in vitro kinase assays on purified lipin
1. An mTORC1 -containing mLST8/GpL purification, but not one where raptor
was depleted in cells by RNAi, readily phosphorylated S106 and S472 lipin 1
(Fig. 2C). Importantly, this activity was lost when mTOR kinase activity was
inhibited with Torin1 (Fig. 2C). These findings were similar to those seen with the
established mTORC1 substrate 4E-BP1 (Fig. 2C) and suggest that mTORC1 is a
bona fide lipin 1 kinase.
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As multiple TORC1 substrates have been shown to remain bound to
TORC1 when purified from cells (2, 26, 27) we assessed lipin 1 for this behavior.
Indeed, raptor and co-expressed raptor and mTOR copurified with lipin 1 but not
with the metap2 or rap2a control proteins (Fig. 2D). That lipin 1 did not interact
with mTOR alone and that mTOR did not increase the abundance of raptor
copurifying with lipin 1 suggested that lipin 1 interacts with mTORC1 via raptor.
Overexpressed lipin 1 also interacted with endogenous mTOR and raptor, but not
rictor, in a manner sensitive to inhibition of mTOR kinase activity (Fig. S2B), a
finding also in common with other established TORC1 substrates (2, 26, 28).
To test the involvement of GSK3 in regulating lipin 1 phosphorylation, we
focused on the S468/S472 phosphorylation cassette sites because: 1) we
previously established regulation of its putative GSK3 priming site, S472 (Fig. 2B
and C); 2) we could not readily detect phosphorylation of the doubly
phosphorylated species, which again would putatively require GSK3, in the
presence of serum (a condition which activates PI3K-Akt signaling and thus
represses GSK3 activity (16)) (Fig. 2E). To investigate if GSK3 regulates the
doubly phosphorylated S468/S472 form of lipin 1, we exploited the fact that
Torin1 and PI-103 differentially inhibit mTORC1 and P13K signaling. At 250 nM,
both Torin1 and PI-103 inhibited P13K and activated GSK3 signaling, as judged
by T308 Akt and S9 GSK3p phosphorylation, respectively (Fig. 2E). However,
only Torin1 significantly downregulated mTORC1 signaling, as judged by
T37/T46 4E-BP1 phosphorylation, and affected the abundance of the singly
phosphorylated S472-containing peptide (Fig. 2E). On the other hand, PI-103
induced S468/S472 phosphorylation, and this doubly phosphorylated species
was eliminated by GSK3 IX (Fig. 2E). These results suggest that GSK3 regulates
one of these two sites in cells and does so only under the condition that the other
site is already phosphorylated. To determine if GSK3 directly regulates lipin 1 by
this mechanism, we purified GSK3p and performed in vitro kinase assays on
purified lipin 1. Using a phospho-specific antibody we raised to the doubly
phosphorylated S468/S472 cassette, we detected robust GSK3p-catalyzed
S468/S472 lipin 1 phosphorylation only when GSK3p was obtained from cells
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pretreated with Torin1 and not vehicle (Fig. 2F). This is consistent with GSK3p
kinase activity being indirectly regulated by mTORC1 through S6K1 -dependent
regulation of GSK3p S9 phosphorylation (29). As a reflection of the specificity of
our S468/S472 phospho-antibody, mutating the S468/S472 sites to alanine (as
part of a mutant where 15 of the 19 other lipin 1 phosphorylation sites, including
S106, were mutated to alanine, hereafter referred to as "17xS/T->A"), abolished
Torin1 -stimulated, GSK3p-dependent S468/S472 phosphorylation. Additionally,
Torin1-stimulated, GSK3p-mediated phosphorylation of S468/S472 lipin 1 was
significantly decreased by in cell pretreatment of lipin 1 with Torin1 suggesting
that mTORC1-dependent lipin 1 phosphorylation (likely of S472) serves as a
,,priming" event for its phosphorylation by GSK3p (likely at S468) (Fig. 2F). In
aggregate, these data establish GSK3P as a kinase for the S468/S472
phosphorylation cassette and is consistent with mTORC1 regulating GSK3p
activity toward lipin 1 by two mechanisms: 1) indirectly by controlling GSK3P
through its regulatory site phosphorylation; 2) directly likely by controlling the
priming phosphorylation of lipin 1 for its subsequent phosphorylation by GSK3p.
Because mTORC1 and GSK3 signaling regulate lipin 1 localization, we
reasoned that a mechanism through which lipin 1 localization might be regulated
is by its phosphorylation at mTORC1- and GSK3-catalyzed sites. Indeed, the
17xS/T->A lipin 1 mutant, which renders most of the proline-directed as well as
GSK3 motif sites non-phosphorylatable, including the S106, S468, and S472
sites, was sufficient to promote the full nuclear accumulation of lipin 1 in multiple
cell types (Fig 2G). Mutation only of the mTORC1 -catalyzed site, S1 06, to
alanine lacked an effect on lipin 1 localization (Fig. S2C). Therefore, coordinated
inactivation of mTORC1 and GSK3 leads to nuclear sequestration of lipin 1 by a
mechanism which requires its dephosphorylation at numerous mTORC1- and
GSK3-catalyzed sites.
Previously, it was shown that mTORC1 positively regulates the activity of
SREBP1 (30, 31), a member of the SREBP family of transcription factors that
critically regulate fatty acid and cholesterol biosynthetic gene expression (32).
Studies by Brown, Goldstein, and colleagues elucidated key parts of the
mechanism by which cholesterol sensing is coupled to the activity of SREBP
(33). However, the mechanism(s) by which mTORC1 promotes SREBP function
remains largely unknown. Because lipin 1 has been shown to regulate the
expression of many genes involved in lipid homeostasis in divergent organisms
(34-36), we were interested in whether lipin 1 might contribute to the effects of
mTORC1 on the SREBP pathway. We first determined to what extent rapamycin
and Torin1 regulated the mRNA expression of numerous genes which are known
to be induced by SREBP1 and/or SREBP2 (37), such as fatty acid synthase
(FASN), ATP-citrate lyase (ACLY), acetyl-CoA carboxylase alpha (ACACA),
stearoyl CoA-desaturase (SCD1), HMG-CoA reductase (HMGCR), farnesyl
diphosphate synthase (FDPS). In a time-dependent manner, Torin1 strongly
down-regulated the gene expression of all SREBP targets we examined, yet
rapamycin was largely ineffective at decreasing the expression levels of these
same targets at the latest time point (Fig. 3A). On the contrary, neither Torin1 nor
rapamycin decreased SREBP1 mRNA expression under the same conditions
(Fig. S3). Correlating with the differential effects of rapamycin and Torin1 on lipin
1 localization, these results suggest that the redistribution of cytoplasmic lipin 1
to the nucleus might be important in the regulation of SREBP-target gene
expression by mTORC1. To test this, we monitored SREBP-target mRNA levels
over a time course of Torin1 in wild-type and lipin 1 deficient cells (fld) (6). At
time points after which Torin1 caused lipin 1 to fully enter the nucleus (Fig. 1 E),
fld cells were completely refractory to the effects of Torin1 on SREBP-target
expression (Fig. 3B). We observed similar results with combined P13K/GSK3
inhibition (Fig. 3C), which taken together with the effects of Torin1 (Fig. 3B),
indicate that lipin 1 is required for the downregulation of the SREBP pathway
caused by loss of either input from mTORC1 or GSK3. To assess whether
mTORC1- and GSK3-catalyzed lipin 1 phosphorylation sites are critical in the
repression SREBP-target gene expression caused by loss of mTORC1 and
GSK3 activities, we stably expressed either the wild-type or the 17xS/T->A
mutant lipin 1 in fld cells. While wild-type lipin 1 had no effect on SREBP-target
mRNA levels, the 17xS/T->A lipin 1 mutant repressed, in a manner dependent on
its catalytic activity, all SREBP targets examined (Fig. 3D). In total, these results
establish nuclear lipin 1 as both necessary and sufficient for mediating the effects
of mTORC1 and GSK3 inhibition on the SREBP pathway.
Because the aforementioned studies were performed in cultured cells, we
wanted a more physiologically meaningful context to test a role for mTORC1 and
lipin 1 in the regulation of the SREBP pathway. For this purpose, we developed a
conditional null (LoxP) allele (38) of the raptor gene to ablate raptor expression in
mice in a temporally-defined, tissue-specific manner (Fig. S4A and S4B). We
deleted raptor in the post-natal liver in floxed raptor mice by expressing Cre
recombinase under the control of the Albumin promoter (39). The liver appeared
to be a particularly relevant organ in which to manipulate mTORC1 and lipin 1
function because it plays a vital role in maintaining whole body fatty acid and
cholesterol homeostasis (32). We first confirmed that raptor expression,
mTORC1, and P13K/Akt signaling were altered specifically in the liver (Fig. 4A).
Surprisingly, despite strongly perturbing mTORC1/PI3K signaling in their livers,
liver-specific raptor knock-out (raptorLi-/-) mice developed normally and at 4
months of age were of comparable body weight and glycemia as control mice
(Fig. 4B and S4C). Therefore, we challenged the wild-type and raptoru-/- mice
with a high fat and high cholesterol "western" diet. The effects of raptor loss were
now clear: unlike with chow-feeding, where both groups gained weight at a
similar rate over the course of our study, western diet-fed raptoru-/- mice were
fully protected from hyperglycemia and gained substantially less weight than
wild-type animals despite similar food intake (Fig. S4C, 4B, and S4D). Gross and
microscopic examination of the livers of both groups also revealed striking
western diet-specific effects. Namely, the livers of western diet, but not chow-fed
raptor -/- were substantially reduced in size and were less yellowish in
appearance and disorganized by intracellular droplets compared with the livers of
control mice (Fig. 4C). We next measured SREBP-target gene expression in
chow and western diet-fed wild-type and raptorU-/- mice. As expected, the
expression of FASN and HMGCR were repressed by raptor loss, though the
degree of inhibition was substantially greater on the western diet, particularly for
FASN (Fig. 4D). The elevations in liver triglycerides and plasma cholesterol in
wild-type animals on the western compared with the chow diet were also largely
blocked by raptor loss (Fig. 4E), results which notably, phenocopy those seen in
SREBP1 knock-out mice (40).
We suspected that lipin 1 would be important in the resistance of raptor u+
animals to some of the phenotypic consequences caused by the western-diet
because fld fibroblasts were resistant to the effects of Torin1 on SREBP- target
gene expression (Fig. 3B). Indeed, using two distinct adenovirally-delivered
shRNAs to lipin 1, we depleted lipin 1 from the livers of western diet-fed raptoru i-
mice (Fig. 4F) and this largely restored SREBP-target gene expression to the
levels seen in control mice (Fig 4G). Correspondingly, the levels of liver
triglycerides and plasma cholesterol in western diet-fed raptorLi-- mice were also
re-elevated, after the lipin 1 knock-down, to the levels seen in raptorl+/+ mice
(Fig. 4H). Therefore, the SREBP pathway in the liver is positively regulated by
mTORC1 in a manner that is opposed by lipin 1 and this regulation is critical for
the development of hepatic steatosis and hypercholesterolemia caused by
prolonged high fat and high cholesterol feeding.
In trying to understand how the nuclear localization of lipin 1 regulates
SREBP-target gene expression, we noticed a strong correlation between the
inputs which promoted lipin 1 nuclear accumulation and downregulated the
SREBP pathway (i.e., inhibited mTORC1 and GSK3 signaling) and those which
changed the circumference shape of the DNA and/or lipin 1 distribution in the
nucleus (Fig. 1A, C and D; Fig. 2G; Fig. SIA, S1C, and S1E). More specifically,
in cells where lipin 1 was redistributed from the cytoplasm to the nucleus, the
nuclei appeared to be noticeably more eccentric, a term which when applied to
circular objects indicates that the major and minor axes (the apopasis and
periapsis, respectively) of the circle differ in length (Fig. 5A). Interestingly, it has
previously been shown that overexpression of the lipin 1 homolog, Ned1, in
Schizosaccharomyces pombe causes nuclear eccentricity, though the
physiological relevance of this finding has not been determined (41). To pursue
this phenotype, we focused on the shape of the nuclear matrix and in particular
on one of its core components, lamin A, for two reasons: 1) lamin A has
previously been shown to physically interact with SREBP1 and SREBP2 and its
overexpression downregulates the mRNA expression of the adipogenic SREBP
target, PPARy2 (42, 43); 2) lamin A mutations in humans commonly result in a
lipodystrophy, a condition characterized by abnormal adipose tissue that is also
seen in adipocyte-specific SREBP1 transgenic mice (44, 45). By visual
inspection or with automated image analysis-based quantification, it was evident
that either mTORC1 or combined P13K/GSK3 inhibition increased the eccentricity
of the lamin A matrix (Fig. 5B and C). Moreover, either Torin1 or combined serum
and glucose deprivation increased lamin A eccentricity in a time-dependent
manner (Fig. 5D). The time-dependent, increased lamin A eccentricity caused by
Torin1 was absent in fid cells indicating that lipin 1 was necessary for this effect
(Fig. S5A). Lastly, the expression of the catalytically active 17xS/T->A mutant
lipin 1, but not its catalytic dead or the wild-type form, was sufficient to increase
lamin A eccentricity, suggesting that the effects of mTORC1 and GSK3 on lamin
A eccentricity are driven, at least in part, by nuclear localized lipin 1 (Fig. 5B and
C).
As mTORC1/GSK3/lipin 1-mediated increases in lamin A eccentricity
correlated with the repression of SREBP-target gene expression, we next
focused on whether lamin A was required for this regulation. In cells with lamin A,
Torin1 or the expression of the 17xS/T->A lipin 1 mutant strongly repressed
SREBP targets as expected, yet cells lacking lamin A were resistant to these
effects (Fig. 5E and F). As a measure of the specificity of the effects of lamin A
on mTORC1 -dependent gene expression, the mRNA levels of Cytochrome C
(CytC), a PGC1a target whose mRNA expression is promoted by mTORC1
signaling (46), were equally repressed by Torin1 in lamin A wild-type and null
cells (Fig. 5E). We then tested the converse of the aforementioned findings, i.e.,
whether the mTORC1 -dependent induction of SREBP-target gene expression
was impaired in Hutchison Gilford Progeria Syndrome (HGPS) cells which harbor
a lamin A mutation that, as with other lipodystrophy-causing lamin A mutations,
dominantly interferes with SREBP-target expression (Fig. S5B) (43). Loss of
TSC2 function, which stimulates the TORC1-S6K1 pathway (47-50), obtained
using two independent shRNAs targeted to TSC2, activated SREBP-target gene
expression as expected in unaffected cells, however HGPS cells were fully
resistant to these effects (Fig. 5G). This result, together with those using lamin A-
deficient cells, suggests that the integrity of the nuclear matrix is critical in the
regulation of the SREBP pathway in response to activating or inhibitory inputs to
mTORC1.
A growing body of work suggests that A- and B-type lamins physically
interact with both transcriptional regulators and regions of transcriptionally
inactive chromatin (44, 51-54), however less is known if and how these
interactions might be regulated. Because mTORC1/lipin 1 signaling strongly
altered the structure of the lamin A-containing nuclear matrix and because lamin
A is known to bind SREBP in cells (42), this raised the possibility that SREBP
and/or its target gene promoters might bind lamin A in a lipin 1-regulated manner.
To test this, we immunoprecipitated lamin A from chemically cross-linked cells
containing or lacking nuclear lipin 1 and quantified the abundance of genomic
fragments containing the FASN gene promoter that copurified with it (55). The
amount of FASN sterol response element (SRE)-containing DNA present in lamin
A immunoprecipitates was enriched in wild-type cells above the background
signal obtained in lamin A null cells and was reproducibly increased by either
Torin1 treatment or with expression of 17xS/T->A lipin 1 compared with their
respective controls (Fig. S5C and S5D). To determine whether SREBP itself
might be localized to the nuclear lamina in a regulated fashion, we assessed its
localization upon manipulating mTORC1 activity. In untreated cells, full-length
SREBP1 appeared diffusely localized, but was more prominently extranuclear
consistent with that previously reported (Fig. 5H) (56). Strikingly, in the presence
of Torin1, SREBP1 rapidly redistributed to the nucleus and became strongly co-
localized with lamin A (Fig. 5H). Interestingly, this localization of SREBP1 is
similar to that seen in cells expressing mutant forms of lamin A that are impaired
in their proteolytic processing (57). Therefore, one explanation for the
mTORC1/lipin 1/lamin A-dependent effects on SREBP-target gene expression
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could be that nuclear localized lipin 1 promotes the association(s) of the lamin A-
containing nuclear matrix with SREBP and/or SREBP-target gene promoters in a
manner that inhibits the function of the SREBP transcriptional machinery.
Discussion
In summary: 1) mTORC1 and GSK3 coordinately phosphorylate lipin 1
which prevents its nuclear entry; 2) inhibited mTORC1/nuclear lipin 1 repress
SREBP-target gene expression in a manner dependent on lamin A and that, 3)
correlates with the structural alteration of the lamin A-containing matrix and the
relocalization of SREBP and SREBP-target promoters into proximity to lamin A.
While we have not yet established a causal role of these latter findings in
regulating SREBP-target gene expression, our work does support a genetic
model whereby mTORC1 and GSK3 function as positive regulators and lipin 1
and lamin A function as negative regulators of the SREBP pathway (Fig. 51).
That mTORC1 and lipin 1 have key roles in regulating triglyceride and
cholesterol homeostasis is supported by our results that liver-specific mTORC1
deletion has potent protective effects against western diet-induced, hepatic
steatosis and hypercholesterolemia that are reversed by lipin 1 depletion.
Surprisingly, rapamycin is known to cause numerous features of metabolic
syndrome: hyperlipidemia, hypercholesterolemia, and insulin resistance in
humans and in mice (46, 58). Considering the discrepancies between the effects
of rapamycin and the phenotypes of western-diet fed raptorLi- mice (noting that
rapamycin, unlike liver-specific raptor loss, perturbs mTORC1 function in many
tissues) and that rapamycin is significantly less potent than Torin1 in regulating
lipin 1 and SREBP pathway in cells, it is clear that further examination of the
differential effects of various mTORC1 inhibitors on cellular and organismal lipid
and glucose homeostasis is required. Regardless, one no longer unexpected
implication from our work is that unlike rapamycin, potent mTORC1 inhibiting
drugs, such as Torin1, might eventually be useful in the treatment of metabolic
syndrome.
P13K and TOR signaling have been shown to be important determinants of
lifespan in model organisms (59-61), though the mechanism(s) by which these
pathways control aging are incompletely understood. Considering the prevalence
of lamin A mutations in humans who prematurely age (44), it is tempting to
speculate that the mTORC1/PI3K-dependent regulation we describe on lamin A
by lipin 1 might make an important contribution to the effects of the P13K and
TOR pathways on eukaryotic cellular and/or organismal lifespan. The
mTORC1/lipin 1-dependent interaction(s) between lamin A and the FASN
promoter is, to our knowledge, a first example of TOR/Pl3K-regulated
interaction(s) between the nuclear matrix and chromatin. In future work, it will be
interesting to test the importance of this regulation not only in cellular and
organismal aging, but more generally as a mechanism in controlling gene
expression.
Figure legends
Fig. 1. Effect of mTORC1 and P13K/GSK3 inhibition on lipin I
cytoplasmic/nuclear distribution. (A) NIH3T3 cells overexpressing FLAG-lipin 1
were treated with the indicated inhibitors (100 nM rapamycin, 250 nM Torinl, 25
pM LY294002, 250 nM PI-1 03) or vehicle for 8 hours. Cells were then processed
in an immunofluorescence assay to detect FLAG (green), costained with DAPI
for DNA content (blue), and imaged (A) or analyzed by immunoblotting (B) for the
levels and phosphorylated forms of the specified proteins. (C) FLAG-lipin 1
overexpressing p53 ~'~ or rictor-'~; p53-- MEFs were treated with 250 nM Torin1 or
vehicle for 8 hours and analyzed as in (A). (D) FLAG-lipin 1 overexpressing
NIH3T3 cells were grown in the presence or absence of serum and treated with
1.4 pM GSK3 IX or vehicle for 8 hours. (E) FLAG-lipin 1 overexpressing NIH3T3
cells were treated with 250 nM Torin1 for the specified times. The overlap of
FLAG immunoreactivity with DAPI staining was analyzed by image analysis
software (62) for three independent fields for each condition (>500 cells total).
Error bars indicate standard error for n=3. (F) NIH3T3 treated with 250 nM Torin1
for the specified times were analyzed by immunoblotting for the phosphorylation
states and levels of the specified proteins.
Fig. 2. mTOR-dependent phosphorylation of lipin 1 by mTORC1 and GSK3p.
(A) Schematic of location of lipin 1 phosphorylation sites. HEK-293T cells were
transfected with FLAG-lipin 1, lysed, and FLAG immunoprecipitates were
prepared and lipin 1 phosphorylation sites were identified by mass spectrometry.
NLIP, N-terminal lipin 1 conserved region. CLIP, C-terminal lipin 1 conserved
region. NLS, Nuclear Localization Signal. Capitalized serine or threonine
residues (in red) indicate that phosphorylation was detected at this site. Putative
serine or threonine phosphorylation sites (in red) are in lower case. (B) HEK-
293E cells were deprived of serum for 4 hours and then stimulated for 20
minutes with 150 nM insulin in the presence of 100 nM rapamycin, 250 nM
Torin1, or vehicle. Cell lysates were prepared and analyzed by immunoblotting
for the phosphorylation states and levels of the specified proteins. (C) HEK-293T
cells overexpressing FLAG-mLST8/GPL were infected with lentivirus expressing
a shRNA targeting raptor or GFP. FLAG immunoprecipitates were prepared from
cell lysates and analyzed for mTOR kinase activity toward lipin 1 or 4E-BP1 in
the presence of 250 nM Torin1 or vehicle. (D) HEK-293T cells were transfected
with the indicated cDNAs in expression vectors, cell lysates prepared, and
lysates and FLAG-immunoprecipitates were analyzed by immunoblotting for the
amounts of the specified recombinant proteins. (E) HEK-293T cells were
transfected with FLAG-lipin 1 and treated with the indicated inhibitors (250 nM
Torin1, 1.4 pM GSK3 IX and/or 250 nM PI-103) for 1 hour, and cell lysates and
FLAG immunoprecipitates were prepared. FLAG immunoprecipitates were
trypsin digested and the ratio of peptides containing the phosphorylated versus
non-phosphorylated forms of S468 and S472 lipin 1 were quantified by mass
spectrometry. ,-,, indcates the phosphorylated form is absent, ,,+" indicates the
phosphorylated form is present, the number of ,,+"s indicate the relative
abundance of the phosphorylated form. Cell lysates were immunoblotted for the
levels and phosphorylation states of the specified proteins. (F) HEK-293T cells
were transfected with myc-GSK3p, myc-rap2a, or FLAG-lipin 1 and treated
Torin1 or vehicle for 1 hour. Myc and FLAG immunoprecipitates were prepared
from cell lysates and myc immunoprecipitates were analyzed for kinase activity
toward lipin 1 or for the levels and phosphorylated forms of the specified proteins.
(G) FLAG-Wt or 17xS/T->A lipin 1 overexpressing NIH3T3 or AML1 2 cells were
processed in an immunofluorescence assay to detect FLAG and imaged.
Fig. 3. Effect of lipin 1 on mTORC1- and P13K/GSK3-dependent regulation of
SREBP-target gene expression. (A) NIH3T3 cells were treated with 100 nM
rapamycin, 250 nM Torin1, or vehicle for the indicated times. All mRNAs were
measured by qRT-PCR and normalized to 36B4 mRNA levels. Error bars
indicate standard error for n=4. * indicates p<0.04 in comparing Torin1 to vehicle
treated cells. " indicates p<0.02 in comparing Torin1 to rapamycin treated cells.
(B) Wild-type or fld MEFs were treated with 250 nM Torin1 or vehicle for the
indicated times. All mRNAs were analyzed as in (A). * indicates p<0.04 in
comparing equivalently treated fld to wild-type cells. (C) Wild-type or fld MEFs
were treated with 250 nM PI-103, 250 nM PI-103 in addition to 1.4 pM GSK3 IX,
or vehicle for the indicated times. All mRNAs were analyzed as in (A). * indicates
p<0.02 in comparing equivalently treated fld to wild-type cells. (D) Indicated lipin
1 lentiviral expression vectors were stably introduced into fld cells and RNA was
isolated 5 days post-infection. All mRNAs were analyzed as in (A). * indicates
p<0.01 in comparing catalytically active, 17xS/T->A and wild-type lipin 1
expressing cells.
Fig. 4. Response of liver-specific raptor knock-out (raptorLi-/-) mice to a high fat
and high cholesterol (western) diet is lipin 1-dependent. (A) RaptorLi+/+ (floxed
raptor; Albumin-CRE-) and raptorLi- (floxed raptor; Albumin-CRE+) were starved
of chow overnight and re-fed for 45 minutes. Liver and muscle tissue were
isolated from which cell lysates prepared and analyzed by immunoblotting for the
phosphorylation states and levels of specified proteins. (B) 4 month old male
raptor+/+ and raptoru-- mice were fed chow or a western diet for two months.
Body weights were measured bi-monthly. Error bars indicate standard error for
n=6. (C) Representative 1x or 20x images of raptorLi+/+ and raptorU-- livers taken
from chow and western diet-fed mice. (D) Liver tissue was isolated and RNA was
extracted from the indicated mice fed their respective diets for 6-8 weeks. All
mice were starved for 4 hours prior to liver harvesting. All mRNAs were
measured by qRT-PCR and normalized to 36B4 mRNA levels. Error bars
indicate standard error for n=4-6. C, Chow, W, Western. indicates p<0.02, #
p<0.04 A p<0.05, respectively. (E) Liver tissue, from which lipids were extracted,
and plasma for cholesterol measurements were obtained from mice fed the
indicated diets for 6-8 weeks. All mice were starved for 4 hours prior to liver and
plasma harvesting. Error bars indicate standard error for n=4 (liver triglycerides),
n=6 (plasma cholesterol). * indicates p<0.004, 4 indicates p<0.05. (F) Western
diet-fed raptorL+/+ and raptorL-l- were infected with adenovirus expressing
shRNAs targeting lacZ or lipin 1. Liver was harvested 5 days after infection and
lysates prepared and immunoblotting was performed for the indicated proteins
and (G) mRNA was isolated and analyzed as in (D). * indicates p<0.01, *
indicates p<0.05 in comparing LacZ shRNA versus lipin 1 shRNA treated raptorL-
~ mice. (H) Liver triglycerides and plasma cholesterol were measured as in (E).
indicates p<0.05, # indicates p<0.05.
Fig. 5. Inhibition of SREBP-target gene expression by mTORC1 and lipin 1
requires lamin A. (A) Explanation of eccentricity. The eccentricity of an elliptical
object is a measure of how much the shape of the ellipse deviates from being
circular. Defined mathematically, eccentricity=1-2/((a/p)+1), where a is the radius
at apopasis, i.e., the farthest distance from the edge of the ellipse to its center,
and p is the radius at periapsis, i.e., the closest distance to ellipse center. The
eccentricity of an ellipse is necessarily between 0 and 1; a circle has an
eccentricity of 0. As the eccentricity tends to 1, the ellipse becomes more
MVMM
elongated, and the ratio of a/p tends to infinity. (B) NIH3T3 cells treated with the
indicated inhibitors (100 nM rapamycin, 250 nM Torinl, 1.4 pM GSK3 IX, 250 nM
PI-1 03) or vehicle for 12 hours; or fld cells overexpressing specified FLAG-lipin 1
or -metap2 constructs were processed in an immunofluorescence assay to detect
lamin A and imaged. Illustrative nuclei for each condition are shown. (C) Images
processed in (B) were analyzed for mean lamin A eccentricity by image analysis
software (62) for three independent fields for each condition (>500 cells total).
Error bars indicate standard error for n=3. * indicates p<0.0003, " indicates
p<0.02. (D) NIH3T3 cells were treated with Torin1 or deprived of serum and
glucose for indicated times and analyzed as in (C). (E) Lamin A*' and - MEFs
were treated with 250 nM Torin1 for 12 hours. Protein lysates were prepared and
immunoblotting for lamin A was performed. All mRNAs were measured by qRT-
PCR and normalized to 36B4 mRNA levels. Error bars indicate standard error for
n=4. * indicates p<0.03. N.S., Not Significant. (F) Lamin A+'+ and -'- MEFs
overexpressing Wt or 17xS/T->A mutant lipin 1 were analyzed for FLAG levels
and the indicated mRNAs as in (E). * indicates p<0.005. (G) Human fibroblasts
from a Hutchinson Gilford Progeria Syndrome patient or an unaffected relative
were transduced with shRNAs targeting TSC2 or GFP. Protein lysates were
prepared and immunoblotting was performed for the indicated proteins. mRNAs
were measured by qRT-PCR and normalized to GAPDH mRNA levels. Error bars
indicate standard error for n=4. * indicates p<0.02. (H) NIH3T3 cells
overexpressing FLAG-SREBP1 were treated with 250 nM Torin1 or vehicle for 8
hours. Cells were then processed in an immunofluorescence assay to detect
lamin A (green), FLAG (red) and costained with DAPI for DNA content (blue),
and imaged. (1) Schematic of the genetic interactions characterized between
mTORC1, GSK3, lipin 1, lamin A and SREBP. Arrows (->) indicate positive
relationships, hatched bars (-I) indicate negative relationships.
Fig. S1. Further characterization of the regulation of lipin 1 localization upon
mTORC1 or cell cycle perturbation. (A) FLAG-lipin 1 overexpressing HEK-293T
cells were treated with 100 nM rapamycin, 250 nM Torin1 for 8 hours. Cells were
WAWMKW '
then processed in an immunofluorescence assay to detect FLAG, and imaged
(A) or analyzed by immunoblotting (B) for the levels and phosphorylation state of
4E-BPI. (C) FLAG-lipin 1 overexpressing NIH3T3 cells were starved for serum
and/or glucose for 8 hours. Cells were then processed and analyzed as in (A)
and (B). (E) HEK-293T cells overexpressing FLAG-lipin 1 were starved of amino
acids for 2 hours. and imaged as in (A). (F) FLAG-lipin 1 overexpressing NIH3T3
were treated with the indicated compounds (14 pm roscovitine, 10 pM
PD184352) or vehicle for 12 hours. Double thymidine block was performed as
follows: 2 mM thymidine for 12 hours-> 12 hours re-fresh media without
thymidine-> 12 hours 2 mM thymidine.
Fig. S2. Further characterization of lipin 1 phosphorylation, the mTORC1-Lipin 1
interaction, and lipin 1 localization. (A) HEK-293T cells overexpressing FLAG-
lipin 1 were treated with the indicated inhibitors (100 nM rapamycin or 250 nM
Torin1) or vehicle for 12 hours. FLAG immunoprecipitates were prepared, trypsin
digested, and the ratio of peptides containing the phosphorylated versus non-
phosphorylated forms of S237 lipin 1 were quantified by mass spectrometry (,,,,
indicates the phosphorylated form was not detected, ,,+" indcates the
phosphorylated form was detected). (B) AML12 cells expressing FLAG-lipin 1 or
FLAG-metap2 were treated with 250 nM Torin1 or vehicle for 12 hours. FLAG
immunoprecipitates and cell lysates were analyzed by immunoblotting for
indicated proteins. (C) AML12 cells overexpressing FLAG-tagged Wt or S106A
lipin 1 were processed in an immunofluorescence assay to detect FLAG and
imaged.
Fig. S3. Further characterization of the regulation of mTORC1 on the SREBP
pathway. NIH3T3 cells were treated with 100 nM rapamycin, 250 nM Torin1, or
vehicle for the indicated times. SREBP1 mRNA was measured by qRT-PCR and
normalized to 36B4 mRNA levels. Error bars indicate standard error for n=4.
Fig. S4. LoxP-raptor-LoxP conditional allele design and further phenotypic
characterization of raptoru-/ mice. (A) Schematic of the raptor gene and targeted
allele. Recombinant genomic DNA including exon 6 of the raptor gene flanked
with LoxP sites (black arrows) and intronic sequence was introduced into the
endogenous locus by homologous recombination. FRT sites to excise the
neomycin resistance gene (neo) are indicated by white arrows. Localization and
size of DNA fragment generated by Bgl 11 restriction digest of the targeted allele
is indicated. Probe used for southern blot analysis is shown as a wavy line (ww).
Localization of PCR primers (,,&") and size of DNA amplified using these primers
on the targeted allele are indicated. (B) Genotyping assays to identify proper
raptor exon 6 targeting. Bgl Il genomic DNA digestion and Southern blot analysis
was used to identify ES clones that had undergone a homologous recombination
event between the linearized targeting vector and genomic DNA. The presence
of the neo gene, FRT sites, and LoxP sites increases the size of the targeted
locus by -2 kb. PCR of mouse tail genomic DNA was performed to distinguish
between untargeted raptor intronic sequence and that containing the 3" LoxP site.
wt, wild-type; m, DNA marker. Representative samples are shown in the
analyses in (B). (C) Liver-specific raptor knock-out mice are protected from
western diet-induced hyperglycemia. Blood glucose measurements were made
from 4 hour starved, 6 month old mice fed indicated diets for 2 months. Error
bars indicate standard error for n=6. C, chow; W, western. * indicates p<0.01. (D)
Daily food consumption is unaffected by raptor genotype or diet. Error bars
indicate standard error for n=6.
Fig. S5. Further characterization of mTORC1/lipin 1-dependent regulation of
lamin A and lamin A-dependent regulation on SREBP-target gene expression or
promoter binding. (A) Wild-type or fld MEFs were treated with 250 nM Torin1 or
vehicle for the indicated times. Cells were then processed in an
immunofluorescence assay to detect lamin A and images were analyzed for
mean lamin A eccentricity by image analysis software for three independent
fields for each condition (>500 cells total). Error bars indicate standard error for
n=3. (B). SREBP-target expression levels from fibroblast cell lines from HGPS
patients or matched unaffected individuals were obtained from microarray
expression profiles deposited in NCBI GEO database by (63). mRNA from three
control and affected individuals were probed in triplicate. Error bars indicate
standard error for n=9. * indicates p<0.007 in comparing HGPS to unaffected
cells. (C) Lamin A+'+ and -1- MEFs were treated with 250 nM Torin1 or vehicle for
12 hours. Cell lysates and lamin A immunoprecipitates were immunoblotted for
lamin A or protease digested and genomic DNA was measured by PCR. For
each condition, immunoprecipitated DNA was normalized to its corresponding
whole cell lysate DNA. Error bars indicate standard error for n=4. * indicates
p<0.03. (D) Lamin A*'+ and - MEFs overexpressing Wt or 17xS/T->A mutant lipin
1 were prepared and analyzed as in (C). * indicates p<0.03.
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Experimental procedures
Materials
Reagents were obtained from the following sources: antibodies to lamin A
(sc-20680, sc-6215), as well as HRP-labeled anti-mouse, anti-goat, and anti-
rabbit secondary antibodies from Santa Cruz Biotechnology; rabbit polyclonal
and monoclonal antibodies to phospho-S106 lipin 1, phospho-S472 lipin 1,
phospho-S468/S472 lipin 1, phospho-T389 S6K1, phospho-T37/T46 4E-BP1,
phospho-S65 4E-BP1, phospho-T308 Akt, phoshpo-S473 Akt, phospho-S9-
GSK3p, TSC2, 4E-BP1, raptor, rictor, and mTOR from Cell Signaling
Technology; rabbit polyclonal antibody to myc from Bethyl Laboratories; Flag M2
affinity gel, Flag M2 antibody, ATP, amino acids, Thymidine, SYBR Green
JumpStart Taq ReadyMix, insulin, dexamethasone, and selenium from Sigma
Aldrich; protein G Sepharose from Pierce; DMEM from SAFC Biosciences; amino
acid-free RPMI from US Biological; rapamycin from LC Labs; PI-103, GSK3 IX,
LY294002, and Roscovitine from Calbiochem, PD184352 from Axon Medchem;
FuGENE 6 and Complete Protease Cocktail from Roche; SuperScript 11 Reverse
Transcriptase, Alexa Fluor 488 and 594 secondary antibodies, Platinum Pfx,
Platinum Taq DNA Polymerase, transferrin, and inactivated fetal calf serum (IFS)
from Invitrogen. Antibodies to lipin 1 (LAb-1 used in HEK-293E cells and LAb-2
used on mouse livers) were previously described (1). GST-4E-BP1 was
previously described (2).
Cell Lines and Cell Culture
Lamin A null and wild-type mouse fibroblasts were kindly provided by
Colin Stewart (Institute of Medical Biology, Singapore). HEK-293E were kindly
provided by John Blenis (Harvard Medical School). NIH3T3 and AML12 cells
were obtained from ATCC. HGPS (AG01972) and wild-type (AG08469) human
fibroblasts were obtained from the Coriell Institute. HEK-293E, HEK-293T, and all
fibroblast cell lines were cultured in DMEM with 10% IFS unless otherwise
stated. AML12 were cultured in 50%/50% DMEM/Ham's F-12 with 10% FBS
supplemented with 5pg/ml insulin, 5pg/ml transferrin, 40ng/ml dexamethasone,
5ng/ml selenium. Fld and wild-type MEFs were generated from fld/+ mice
obtained from Jackson Laboratories.
cDNA Manipulations and Mutagenesis
The cDNA for lipin 11P used was cloned by Huffman TA et al.(1) and has
the NCBI identifier: AAL07798. The cDNA for full-length SREBP1 was cloned
from a NIH3T3 fibroblast cDNA library. The cDNA for mLST8/GpL was generated
as previously described (3). The cDNA for full-length GSK3p was cloned from a
HEK-293T cDNA library. The cDNA for the control genes, rap2a and metap2,
were previously described and validated (4). For expression studies, lipin 1,
SREBP1, mLST8/GPL, GSK3p, rap2a, metap2 cDNAs were amplified by PCR
and the product was subcloned into the Sal 1 and Not 1 sites of pRK5 and/or
pLKO. All constructs were verified by DNA sequencing. For the catalytic site
mutant analysis, the lipin 1 cDNA was mutagenized using a QuikChange
mutagenesis XLII kit (Stratagene) with oliogonucleotides obtained from
Integrated DNA Technologies. The catalytic site residues were mutated as
follows: 712 D->E, 714 D->E. The 17xS/T->A mutant encompasses the following
residues: S106, S150, S281, T282, S285, S287, S293, T298, S328, S353, S356,
S392, S468, S472, S483, S634, S635, S647, S648, S921, S923. The 17xS/T->A
mutant has wild-type PAP1 activity (Harris TE et al., manuscript in preparation).
Cell Lysis, Immunoprecipitations, and Kinase Assays
For protein studies, all cells were rinsed twice with ice-cold PBS before
lysis. All cells, with the exception of those used to isolate mTOR-containing
complexes, were lysed with Triton-X 100 containing lysis buffer (40 mM HEPES
[pH 7.4], 2 mM EDTA, 10 mM sodium pyrophosphate, 10 mM sodium
glycerophosphate, 150 mM NaCI, 50 mM NaF, 1% Triton-X 100, and one tablet
of EDTA-free protease inhibitors [Roche] per 25 ml). The soluble fractions of cell
lysates were isolated by centrifugation at 13,000 rpm for 10 minutes in a
microcentrifuge. For myc immunoprecipitations, primary antibodies were added
to the lysates and incubated with rotation for 1.5 hours at 40C. A 50%/50% slurry
of protein G Sepharose/lysis buffer was then added, and the incubation
continued for an additional 1 hour. For FLAG purifications, cells were lysed in ice-
cold CHAPS-containing lysis buffer lacking added NaCl (40 mM HEPES [pH 7.4],
2 mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, 0.3% CHAPS,
and one tablet of EDTA-free protease inhibitors [Roche] per 25 ml). FLAG M2
resins were incubated with pre-cleared cell lysates and incubated with rotation for
1.5 hours at 4*C. FLAG immunoprecipitates were washed three times with
CHAPS lysis buffer containing 150 mM NaCl. For coimmunoprecipitation
experiments, immunoprecipitated proteins were then denatured by the addition of
sample buffer and by boiling for 5 minutes, resolved using 4%-12% SDS-PAGE
(Invitrogen), and analyzed by immunoblotting as described (5). For kinase
assays, myc or FLAG immunoprecipitates were additionally washed twice in 25
mM HEPES (pH 7.4), 20 mM KCL after the 3 washes in their respective 150mM
NaCI-containing lysis buffers. For elution of FLAG-tagged proteins, beads were
incubated in elution buffer (50mM HEPES pH 7.4, 500mM NaCl, 0.1% CHAPS,
50pg/ul FLAG peptide) for 15 min at 250C. Kinase assays were performed as
described (6).
Mass Spectrometric Analysis
Lipin 1 phosphorylation sites were identified by mass spectrometry of
trypsin-digested FLAG-lipin 1 purified from HEK293T cells transiently
overexpressing FLAG-lipin 1. The amino acid position of all lipin 1
phosphorylation sites were numbered according to NCBI M. musculus lipin 1p
protein sequence NP_056578.
Label-free quantification of lipin 1 phosphorylation sites were performed
with BioWorks Rev3.3 software according to the methodology utilized in (7).
Mammalian Lentiviral Transduction
The GFP control shRNA was previously described and validated (4). The
raptor shRNA was previously described and validated (8). The TSC2 shRNAs
were obtained from the collection of The RNAi Consortium (TRC) at the Broad
Institute (9). These shRNAs are named with the numbers found at the TRC
public website:
(http://www.broad.mit.edu/genomebio/trc/publicSearchForHairpinsForm.php)
Human TSC2_1 shRNA NM_000548.x-2330s1 ci TRCT0000001 182
Human TSC2_1 shRNA NM000548.2-4551s1c1 TRCT0000001182
To generate virus, shRNA or mRNA-encoding plasmids were co-
transfected with the Delta VPR envelope and CMV VSV-G packaging plasmids
into actively growing HEK-293T using FuGENE 6 transfection reagent as
previously described (8). Virus containing supernatants were collected at 48
hours after transfection, centrifuged to eliminate cells, and target cells (100,000-
400,000) infected in the presence of 8 pg/mI polybrene. 24 hours after infection,
the cells were given or split into fresh media. The metap2 or lipin 1 over-
expressing fld cells and HGPS and control cells expressing TSC2 or GFP shRNA
were additionally selected with 1 pg/ml puromycin. shRNA or mRNA-expressing
cells were analyzed 2-5 days post-infection.
Immunofluorescence Assays
25,000-100,000 cells were plated on fibronectin-coated glass coverslips in
12-well tissue culture plates, rinsed with PBS once and fixed for 15 minutes with
4% paraformaldehyde in PBS warmed to 370C. The coverslips were rinsed three
times with PBS and permeabilized with 0.2% Triton X-100 in PBS for 15 minutes.
After rinsing three times with PBS, the coverslips were blocked for one hour in
blocking buffer (0.25% BSA in PBS), incubated with primary antibody (FLAG M2
mouse and/or lamin A sc-20680) in blocking buffer overnight at 4*C, rinsed twice
with blocking buffer, and incubated with secondary antibodies (diluted in blocking
buffer 1:1000) for one hour at room temperature in the dark. The coverslips were
then rinsed twice more in blocking buffer and twice in PBS, mounted on glass
slides using Vectashield containing DAPI (Vector Laboratories), and imaged with
a 1 Ox or 63X objective using epifluorescence microscopy.
Nuclear/Cytoplasmic Ratio and Eccentricity Measurements
Quantification of lipin 1 nuclear/cytoplasmic ratio was performed with
CellProfiler (www.cellprofiler.org) using 10x images. After illumination correction,
the nuclei were automatically identified using the DAPI staining. The cytoplasmic
compartment was then defined by expanding the edges of the nuclei 20 pixels in
every direction. The nuclear/cytoplasmic ratio was then measured as total
nuclear intensity/ total cytoplasmic intensity. Lamin A eccentricity was also
quantified by CellProfiler, with the eccentricity measurement being made on
nuclei identified via lamin A staining.
Gene Expression Analysis
For mRNA expression quantification, total RNA was isolated from cells or
liver sections grown in the indicated conditions and reverse-transcription was
performed. The resulting cDNA was diluted in DNase-free water (1:20) before
quantification by real-time PCR. mRNA transcript levels were measured using
Applied Biosystems 7900HT Sequence Detection System v2.3 software. All Data
are expressed as the ratio between the expression of target gene to the
housekeeping genes 36B4 or GAPDH. Each treated sample was normalized to
the level of the vehicle controls of the same cell type. The following primers were
used for quantitative real-time PCR:
FASN (M. musculus)
Forward: CAG CAG AGT CTA CAG CTA CCT
Reverse: ACC ACC AGA GAC CGT TAT GC
ACLY (M. musculus)
Forward: CTC ACA CGG AAG CTC ATC AA
Reverse: ACG CCC TCA TAG ACA CCA TC
ACACA (M. musculus)
Forward: GCC TCT TCC TGA CAA ACG AG
Reverse: TGA CTG CCG AAA CAT CTC TG
Lipin 1 (M. musculus)
Forward: CCCTCGATTTCAACGTACCC
Reverse: GCAGCCTGTGGCAATTCA
SCD1 (M. musculus)
Forward: ACGCCGACCCTCACAATTC
Reverse: CAGTTTTCCGCCCTTCTCTTT
HMGCR (M. musculus)
Forward: CTTGTGGAATGCCTTGTGATTG
Reverse: AGCCGAAGCAGCACATGAT
FDPS (M. musculus)
Forward: ATGGAGATGGGCGAGTTCTTC
Reverse: CCGACCTTTCCCGTCACA
SREBP1 (M. musculus)
AAGCAAATCACTGAAGGACCTGG
AAAGACAAGGGGCTACTCTGGGAG
CytC (M. musculus)
TGGACCAAATCTCCACGGTCTGTT
TAGGTCTGCCCTTTCTCCCTTCTT
36B4 (M. musculus)
TAAAGACTGGAGACAAGGTG
GTGTACTCAGTCTCCACAGA
FASN (H. sapiens)
Forward: GAAACTGCAGGAGCTGTC
Reverse: CACGGAGTTGAGGCGCAT
HMGCR (H. sapiens)
Forward: GGACCCCTTTGCTTAGATGAAA
Reverse: CCACCAAGACCTATTGCTCTG
GAPDH (H. sapiens)
Forward: GAAGGTGAAGGTCGGAGTC
Reverse: GAAGATGGTGATGGGATTTC
Lamin A Chromatin Immunoprecipitation (ChIP)
Protocol was adapted from (10). Cells were cross-linked with 1/10 volume
of 11 % Formaldehyde (in PBS) for 3.5 minutes at room temperature and
quenched with 1/20 volume of 2.5 M glycine. Cross-linked cells were rinsed twice
with PBS and lysed in RIPA buffer (40 mM HEPES [pH 7.4], 2 mM EDTA, 50mM
NaF, 10mM pyrophosphate, 10 mM glycerophosphate, 1% sodium deoxycholate,
1 % NP40, 0.1 % SDS, and one tablet of EDTA-free protease inhibitors per 25 ml).
Cell lysates were sonicated 3x10 seconds (separated by 1 minute intervals)
using a Tekmar Sonic Disruptor at 35% duty cycle with power output level 3.5.
Lysate protein concentrations were normalized by Bradford assay (Bio-Rad),
4 0pl of lamin A/C antibody (sc-6215) was added, and incubated with rotation for
2 hours at 40C. A 50% slurry of protein G Sepharose (40 pl) was then added, and
the incubation continued for an additional 1 hour. Immunoprecipitates were
washed 3 times in RIPA buffer and twice in wash buffer (20mM HEPES pH 7.4,
25mM KCI). 1/5 of the immunoprecipitate was denatured with sample buffer and
by boiling for 5 minutes, and analyzed by immunoblotting and the remaining 4/5
was eluted in 200pl of elution buffer (50mM Tris-HCI pH 7.4, 10mM EDTA, 1 %
SDS) at 65*C for 5 hours. Genomic DNA was isolated from eluates using a High
Pure PCR template Purfication Kit (Roche) according to the manufacturer's
protocol. DNA was quantified by quantitative PCR using conditions described
above with the following primers:
FASN
Forward: GCGCAGCCCCGACGCTCATT
Reverse: CGGCGCTATTTAAACCGCGG
P-Globin
Forward: ACCCATGATAGCAGAGGCAG
Reverse: GGTGCTTGGAGACAGAGGTC
Design of the LoxP Conditional Raptor Knock-out Mice
A BAC clone (identifier: RP24-125C1 1, strain: C57BL/6J) containing raptor
exon 6 was obtained from the RPCI-24 mouse genomic DNA library (11).
Standard PCR and cloning procedures were used to generate fragments
spanning 4.3 kb upstream of raptor exon 6 and 2.6 kb downstream of and
including raptor exon 6 (as well as a 3' LoxP site downstream of raptor Exon 6)
that were subsequently assembled together into the PGKneoF2L2DTA vector
(12). In the final targeting construct, the neomycin resistance (neo) cassette was
flanked by one 5' LoxP site, a 5' and 3' Flp recognition target (Frt) recombination
sites, and raptor exon 6 was flanked by a 5' and 3'-LoxP site located 111 bp or
547 bp upstream or downstream, respectively. The targeting vector was
linearized and electroporated into ES cells derived from 129/SvEv mice (13).
Clones were analyzed for correct integration by Southern blot and PCR analysis.
Chimeric mice were obtained by microinjection of the correctly targeted clones
into BALB/C blastocysts. Chimeric mice were crossed with C57BL/6 mice to
obtain germline transmission. Mice analyzed in this study were backcrossed to
C57BL/6 for 4 generations. The backcrosses involved mice constitutively
expressing the FLP recombinase to excise the neo cassette from the targeted
allele (14). Heterozygous floxed raptor mice lacking the neo cassette were then
bred to albumin-CRE+ mice to obtain the final genotypes. PCR genotyping of
raptor'"' and raptorLi--; Albumin-CRE-/+ mice was performed with the following
primers:
3' LoxP targeted raptor allele:
Forward: CTCAGTAGTGGTATGTGCTCAG
Reverse: GGGTACAGTATGTCAGCACAG
resulting in an amplicon of 174 bp in the case of presence of the 3' LoxP site and
of 140 bp in case of the wild-type allele.
Albumin-CRE transgene:
Forward: GTTAATGATCTACAGTTATTGG
Reverse: CGCATAACCAGTGAAACAGCATTGC
resulting in an amplicon of -500 bp.
Animal Experiments
All mice were maintained in a mixed strain background (129/C57BL/6) and
housed in a temperature-controlled environment with 12 hour light/dark cycles.
Age-matched mice had free access to water and were fed ad libitum unless
otherwise stated with either a standard chow diet (Prolab RMH 3000, 5P00)
providing 3.46 kcal g-1physiological fuel value, 26% of which is from protein, 14%
from fat and 60% from carbohydrates or a Western-style diet (Harlan Teklad TD
88137) containing 21% (w/w) total lipid (42% calories as anhydrous milk fat [65%
saturated, 32% monounsaturated, 3% polyunsaturated fats]) and 0.2% (w/w)
total cholesterol (of which 0.05% is contributed by milk fat and 0.15% is added).
Body weights were recorded bi-monthly, and food intake was measured tri-
weekly. Blood glucose was measured from tail vein blood (Ascensia Elite). At the
end of the feeding period, mice were euthanatized prior to organ harvest. Tissues
were harvested for analyses as described below. All experiments were approved
by the Committee on Animal Care at the Massachusetts Institute of Technology
and conform to the legal mandates and federal guidelines for the care and
maintenance of laboratory animals.
Determination of Liver Triglycerides
Liver sections (25-50mg) were homogenized in 900pl of a 2/1
chloroform/methanol mixture. 300pl of methanol was added to the homogenate,
which was then vortexed and centrifuged for 15 minutes at 3,000 rpm. 412.5 pl of
the supernatant was transferred to a new glass tube, to which 200pl of
chloroform and 137.5pl of 0.73% NaCl was added and the resulting mixture was
vortexed for 30 seconds and centrifuged at 5,000 rpm for 3 minutes. The upper
phase was then removed and 400ul of a 3/48/47 mixture of
chloroform/methanol/NaCI(0.58%) was added to wash the lower phase and
subsequently centrifuged at 5,000 rpm for 3 minutes. After 3 washes, the lower
phase was evaporated and re-suspended in 1ml of isopropanol. Triglyceride
levels were determined with using a standard assay kit (InfinityTM Triglycerides
Reagent TR22421) from Thermo Scientific according to the manufacturer's
instructions. Liver triglycerides were normalized by liver section weight.
Determination of Plasma Cholesterol Content
Mouse plasma was obtained from tail vein blood which was chelated with
EDTA and centrifuged at 5,000 rpm for 10 minutes to remove red blood cells.
Levels of plasma cholesterol were determined using a standard assay kit
(InfinityTM Cholesterol Reagent TR1 3421) from Thermo Scientific according to
manufacturer's instructions.
Adenoviral shRNA Delivery
Lipin 1 shRNA constructs targeting nucleotides 594-613 (lipin 1_1) or
896-915 (lipin 1_2) of the mouse lipin 1 transcript and an shRNA construct
targeting LacZ were generated as previously described (15). Hepatic shRNA-
mediated knockdown was achieved by intravenous administration of adenoviral
vectors as previously described (16).
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DEPTOR is an mTOR inhibitor frequently overexpressed in multiple
myeloma cells and required for their survival.
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SUMMARY
The mTORC1 and mTORC2 pathways regulate cell growth, proliferation,
and survival. We identify DEPTOR, also called DEPDC6, as an mTOR-
interacting protein whose expression is negatively regulated by mTORC1 and
mTORC2. Loss of DEPTOR activates S6K1, Akt, and SGK1; promotes cell
growth and survival; and activates mTORC1 and mTORC2 kinase activities.
DEPTOR overexpression suppresses S6K1 but, by relieving feedback inhibition
from mTORC1 to P13K signaling, activates Akt. Consistent with many human
cancers having activated mTORC1 and mTORC2 pathways, DEPTOR
expression is low in most cancers. Surprisingly, DEPTOR is highly
overexpressed in a subset of Multiple Myelomas harboring Cyclin D1/D3 or c-
MAF/MAFB translocations. In these cells, high DEPTOR expression is necessary
to maintain P13K and Akt activation and a reduction in DEPTOR levels leads to
apoptosis. Thus, we identify a novel mTOR-interacting protein whose
deregulated overexpression in Multiple Myeloma cells represents a new
mechanism for activating P13K/Akt signaling and promoting cell survival.
INTRODUCTION
Mammalian TOR (mTOR) is an evolutionarily conserved serine/threonine
kinase that integrates signals from growth factors, nutrients, and stresses to
regulate multiple processes, including mRNA translation, cell cycle progression,
autophagy, and cell survival (reviewed in (1)). It is increasingly apparent that
deregulation of the mTOR pathway occurs in common diseases, including cancer
and diabetes, emphasizing the importance of identifying and understanding the
function of the components of the mTOR signaling network. mTOR resides in two
distinct multiprotein complexes referred to as mTOR complex 1 (mTORC1) and 2
(mTORC2) (reviewed in (2)). mTORC1 is composed of the mTOR catalytic
subunit and three associated proteins, raptor, PRAS40, and mLST8/GpL.
mTORC2 also contains mTOR and mLST8/GPL, but instead of raptor and
PRAS40, contains the proteins rictor, mSinl, and protor.
mTORC1 controls cell growth in part by phosphorylating S6 Kinase 1
(S6K1) and the elF-4E-binding protein 1 (4E-BP1), key regulators of protein
synthesis. mTORC2 modulates cell survival in response to growth factors by
phosphorylating its downstream effectors Akt/PKB and Serum/Glucocorticoid
Regulated Kinase 1 (SGK1) (reviewed in (2)).
In addition to directly activating Akt as part of mTORC2, mTOR, as part of
mTORC1, also negatively regulates Akt by suppressing the growth factor-driven
pathways upstream of it. Specifically, mTORC1 impairs P13K activation in
response to growth factors by downregulating the expression of Insulin Receptor
Substrate 1 and 2 (IRS-1/2) and Platelet-Derived Growth Factor Receptor-Beta
(PDGFR-p) (reviewed in (3)). The activation of Akt that results from treating cells
with the mTORC1 inhibitor rapamycin may contribute to the limited success to
date of this drug and its analogs as cancer therapies.
While most information concerning the involvement of the mTOR pathway
in human cancers is consistent with a role for mTOR in directly promoting tumor
growth, there are also indications in the literature that mTOR possesses tumor
suppressor-like properties. Thus, the tumors that develop in patients with
Tuberous Sclerosis Complex (TSC), a syndrome characterized by mTORC1
hyperactivation, are thought to have a limited growth potential due to the P13K
inactivation caused by the aforementioned feedback loop (4, 5). In addition,
partial loss of function alleles of mTOR confer susceptibility to plasmacytomas in
mice, though the mechanism for this effect has not been clarified (6).
Here, we identify DEPTOR as an mTOR binding protein that normally
functions to inhibit the mTORC1 and mTORC2 pathways. When greatly
overexpressed, DEPTOR inhibits mTORC1, and, unexpectedly, this leads to the
activation of the P13K/mTORC2/Akt pathway. This indirect mode of P13K
activation is important for the viability of a subset of Multiple Myeloma cells which
otherwise lack P13K-activating mutations. We propose that DEPTOR is an
endogenous inhibitor of mTOR whose deregulated overexpression promotes cell
survival in a subset of Multiple Myelomas.
RESULTS
DEPTOR is an mTOR Interacting Protein
Using low-salt purification conditions designed to isolate PRAS40 (7), we
identified within mTOR immunoprecipitates a 48 kDa protein assigned the NCBI
Gene Symbol DEPDC6 (NCBI Gene ID: 64798) (Figure 1A). The gene for
DEPDC6 is found only in vertebrates, and encodes a protein with tandem N-
terminal DEP (Dishevelled, Egl-10, Pleckstrin) domains and a C-terminal PDZ
(Postsynaptic density 95, Discs large, Zonula occludens-1) domain (reviewed in
(8, 9) (Figure 1 B). Because no previous studies refer to the function of the
DEPDC6 gene product, we named it DEPTOR in reference to its DEP domains
and its specific interaction with mTOR (see below). In purified preparations of
recombinant DEPTOR stably expressed in HEK-293E cells, we detected via
mass spectrometry endogenous mTOR, as well as raptor and rictor, mTORC1
and mTORC2-specific components, respectively. Analogous preparations of
recombinant PRAS40, a raptor binding protein, contained only mTORC1 (Figure
1C). Consistent with DEPTOR being part of mTORC1 and mTORC2,
endogenous DEPTOR was also detected in immunoprecipitates prepared from
HEK-293E (Figure 1 D) or HeLa cells (Figure 1 E) using antibodies that recognize
endogenous mTOR, raptor, or rictor, but not actin. As was the case with PRAS40
(7), buffers with increased salt concentrations reduced the amounts of DEPTOR
recovered in the immunoprecipitates (Figure 1 D). Reciprocal experiments
confirmed that endogenous mTOR specifically co-immunoprecipitates with
DEPTOR (Figure 1 E).
As the above results indicate that DEPTOR is part of mTORC1 and
mTORC2, we expected DEPTOR to interact with mTOR and/or mLST8/GPL, the
only proteins common to both mTORC1 and mTORC2. To test this, we co-
overexpressed DEPTOR with epitope-tagged mTOR or mLST8/GPL and
analyzed mTOR or mLST8/GpL immunoprecipitates for the presence of
DEPTOR. The results indicate that DEPTOR is an mTOR interacting protein:
DEPTOR co-immunoprecipitated with mTOR irrespective of whether or not
mLST8/GPL was co-expressed with it, while DEPTOR co-immunoprecipitated
with mLST8/GPL only when it and mTOR were expressed together (Figure 1 F).
DEPTOR interacts with a C-terminal portion of mTOR (a.a. 1483-2000) that is
upstream of its kinase domain and does not encompass the mLST8/GPL binding
site (a.a. 2001-2549) (Figure 1 G, 11), providing further evidence that, within
mTORC1 and mTORC2, DEPTOR interacts specifically with mTOR and not with
mLST8/G3L. Finally, reciprocal experiments showed that the PDZ domain of
DEPTOR mediates its interaction with mTOR (Figure 1 H, 11).
DEPTOR Depletion Activates mTORC1 and mTORC2 signaling in Intact
Cells and Enhances the In Vitro Kinase Activities of the Complexes
To test the idea that DEPTOR regulates mTOR function, we measured the
activity of the mTOR pathway in cells with RNAi-mediated reductions in DEPTOR
expression. Human or mouse cells expressing either of two shRNAs targeting
DEPTOR, but not control proteins, had increased mTORC1 and mTORC2
signaling as judged by the phosphorylation states of the mTORC1 and mTORC2
substrates, S6K1 and Akt, respectively (Figure 2A, 2C). Concomitant with the
increase in mTORC1 signaling, mTORC1 immunopurified from cells depleted of
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DEPTOR had increased in vitro kinase activity towards two known substrates,
S6K1 and 4E-BPI (Figure 2B). Likewise, mTORC2 isolated from DEPTOR-
depleted cells had increased in vitro kinase activity towards its substrate Akt1
(Figure 2D). Taken together, the loss of function data indicate that within cells
DEPTOR is an inhibitor of mTORC1 and mTORC2 activities.
DEPTOR Depletion Increases Cell Size and Protects Cells from Apoptosis
To determine if the effects of DEPTOR loss on mTORC1/2 signaling are
physiologically significant, we measured in DEPTOR-deficient cells key outputs
of mTORC1 and mTORC2 function, namely cell growth and survival,
respectively. Cells with reduced DEPTOR expression were larger than control
cells and rapamycin treatment reversed this phenotype, consistent with DEPTOR
acting upstream of mTORC1 (Figure 3A). The size of the DEPTOR-deficient
cells was comparable in magnitude to, although slightly smaller than, those with
reduced expression of TSC2, a well-established negative regulator of mTORC1
(reviewed in (3)) (Figure 3B).
Because Akt promotes cell survival (10) and DEPTOR suppression within
cells causes an increase in Akt phosphorylation (Figure 2C), we tested whether
DEPTOR-deficient cells are resistant to apoptosis induction. In HeLa cells
expressing a control shRNA, reductions in the serum concentration of the media
caused a dose-dependent decrease in Akt phosphorylation and a concomitant
increase in the cleaved forms of caspase-3 and PARP, two hallmarks of
apoptosis (11, 12) (Figure 3C). In contrast, DEPTOR-deficient cells were
resistant to PARP and caspase-3 cleavage in a manner that correlated with the
efficiency of DEPTOR suppression (Figure 3C). However, in contrast to what is
observed in the presence of serum, in the absence of serum DEPTOR-deficient
HeLa cells did not have higher levels of Akt phosphorylation than control cells
(Figure 3C). This suggests that, despite the capacity of DEPTOR suppression to
protect cells from apoptosis, the effect was unlikely to be mediated by Akt. As Akt
shares some of its pro-survival functions with the related family of SGK kinases
(reviewed in (13)) and recent evidence indicates that mTOR activates SGK1 by
directly phosphorylating it (14, 15), we reasoned that DEPTOR suppression
might protect HeLa cells from apoptosis by promoting SGK1 activity. Consistent
with this, the DEPTOR-deficient HeLa cells had, at all serum concentrations,
increased phosphorylation levels of NDRG1, an established SGK1 substrate (16)
(Figure 3C). Because it is still controversial if SGK1 is an mTORC2 and/or
mTORC1 substrate (14, 15), we determined if DEPTOR-deficient cells could be
re-sensitized to pro-apoptotic stimuli by inhibiting mTORC1 with rapamycin or by
inhibiting both mTORC1 and mTORC2 with Torin1, a highly selective and potent
ATP-competitive inhibitor of mTOR (17). Consistent with mTORC2 mediating the
pro-survival effects of DEPTOR suppression, treatment of the serum-deprived
and DEPTOR-deficient HeLa cells with Torin1, but not rapamycin, restored
caspase-3 and PARP cleavage and reversed the hyperphosphorylation of
NDRG1 caused by DEPTOR loss (Figure 3D). In accord with the results obtained
with Torin1, a knockdown of rictor, but not raptor, abolished NDRG1
hyperphosphorylation and re-activated apoptosis in DEPTOR knockdown cells
deprived of serum (Figure 3E). Lastly, a reduction in SGK1 levels in the DEPTOR
knockdown HeLa cells reduced NDRG1 phosphorylation and re-sensitized the
cells to apoptosis induction upon serum deprivation (Figure 3F). DEPTOR
suppression also prevented caspase-3 cleavage in serum-deprived HT-29 cells,
though in this cell type the anti-apoptotic effects of DEPTOR loss correlated with
a partial rescue of Akt phosphorylation (Figure SI). Other perturbations that
promote Akt activation, such as suppression of raptor expression (18), also
protected HT-29 cells from apoptosis induced by serum withdrawal (Figure Si).
Thus, analyses of DEPTOR-deficient cells indicate that DEPTOR physiologically
controls cellular processes regulated by mTOR signaling.
mTOR Negatively Regulates DEPTOR Expression at the Transcriptional and
Post-Translational levels
In our previous experiments, we noted that prolonged serum withdrawal
caused an increase in DEPTOR protein expression (Figure 3C). To gain insight
into the temporal regulation of DEPTOR expression, we starved and stimulated
HeLa cells with serum for various time intervals. Serum stimulation led to a time-
dependent retardation in DEPTOR migration in SDS-PAGE until about 6 hours
after serum addition, at which point DEPTOR expression began to fall, and by 12
hours, almost disappeared (Figure 4A). Interestingly, these qualitative and
quantitative changes in DEPTOR correlated with inflections in mTORC1 and
mTORC2 pathway activities as measured by the phosphorylations of S6K1 and
Akt, respectively. As expected, the amount of DEPTOR bound to mTORC1 and
mTORC2 (Figure 4B) reflected the serum-induced changes in DEPTOR
expression detected in cell lysates (Figures 4A and 4B). Serum starvation and
stimulation also regulated DEPTOR expression in a variety of other cancer cell
lines in addition to HeLa cells (Figure 4C). We noted that cell lines known to have
serum-independent mTORC1 and mTORC2 signaling, such as HEK-293T, PC3,
and U87 cells (19) have markedly reduced levels of DEPTOR that are largely
insensitive to serum (Figure 4C).
As both PC3 and U87 cells lack PTEN (SANGER COSMIC database), a
negative regulator of P13K signaling that controls the responsiveness of the
mTORC1 and mTORC2 pathways to growth factors (reviewed in (20)), it seemed
likely that PTEN loss suppresses DEPTOR expression. Consistent with this, in
PTEN-null MEFs DEPTOR was virtually absent in the presence or absence of
serum, while serum still regulated DEPTOR expression in MEFs that express
PTEN (Figure 4D). As PTEN loss activates both mTORC1 and mTORC2
signaling we determined if DEPTOR expression is also sensitive to perturbations
that only activate mTORC1. Indeed, MEFs lacking TSC2, a tumor suppressor
whose loss leads to activation of only mTORC1, had reduced levels of DEPTOR
even when cultured in the absence of serum (Figure 4D).
The above findings suggested that both mTORC1 and mTORC2
negatively regulate DEPTOR expression (Figures 4A-D). Supporting this idea,
treatment of cells with the mTORC1 and mTORC2 inhibitor Torin1 fully blocked
the mobility shift and decrease in expression of DEPTOR caused by serum
stimulation, while treatment with the mTORC1 inhibitor rapamycin had only
partial effects on DEPTOR mobility and expression (Figure 4E). To determine at
which regulatory level(s) cells control DEPTOR expression we measured the
amounts of DEPTOR protein and mRNA in HeLa cells treated in various ways
(Figure 4F and 4G). The drop in DEPTOR protein caused by serum stimulation
correlated with a significant decrease in the mRNA for DEPTOR (Figure 4F),
suggesting that transcriptional regulation contributes to the control of DEPTOR
expression. However, it was clear that post-transcriptional mechanisms are also
in play because the partial rescue by rapamycin treatment of the serum-induced
decrease in DEPTOR protein amounts occurred in the absence of any change in
DEPTOR mRNA levels (Figure 4F). Moreover, treatment of cells with the
proteasome inhibitor MG132 (21) blocked the serum-induced decrease in
DEPTOR protein without increasing the DEPTOR mRNA, indicating that the
degradation of DEPTOR is a key step in the regulation of its expression (Figure
4F). Treatment of cells with Torin1 blocked the serum-induced drop in DEPTOR
protein levels and, in contrast to rapamycin, also partially prevented the decrease
in the DEPTOR mRNA (Figure 4F).
A comparison of the effects of rapamycin with those of Torin1 on DEPTOR
expression suggested that both mTORC1 and mTORC2 negatively regulate
DEPTOR protein expression, but that only mTORC2 negatively regulates
DEPTOR mRNA expression. To further test this, we depleted mTORC1 or
mTORC2 using shRNAs targeting raptor or rictor, respectively, and examined
DEPTOR protein and mRNA levels. As expected, both the raptor and rictor
knockdowns increased DEPTOR protein levels in serum-replete cells (Figure
4G). However, both knockdowns also increased DEPTOR mRNA (Figure 4G),
indicating that the regulation of DEPTOR mRNA expression by mTORC1 is
rapamycin resistant, consistent with the increasing evidence that only some
mTORC1 functions are sensitive to rapamycin (17, 22, 23). Thus, both mTOR
complexes negatively regulate DEPTOR mRNA expression, explaining why cell
lines with high mTORC1 and mTORC2 activity, such as the PTEN-null PC3 or
U87 cells, have low levels of DEPTOR mRNA (Figure S2A). In aggregate, these
results suggest that the regulation of DEPTOR expression is complex and
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involves post-translational and transcriptional mechanisms mediated by both
mTORC1 and mTORC2.
DEPTOR is Phosphorylated in an mTOR-dependent Fashion
Because the mTOR inhibitor Torin 1 prevents the serum-induced
degradation and SDS-PAGE mobility shift of DEPTOR, we reasoned that a
mechanism through which mTORC1 and mTORC2 might regulate DEPTOR is by
controlling its phosphorylation. To investigate this, we purified DEPTOR from
serum-stimulated cells and analyzed it by mass spectrometry for the presence of
phosphorylated residues. This led to the identification of 13 serine and threonine
phosphorylation sites, all of which are located in the linker between the C-
terminal DEP domain and the PDZ domain (Figure S3A). Interestingly, many of
the phosphorylation sites fall within "proline-directed" motifs like those in 4E-BP1
(24) which are known to be phosphorylated by mTOR (25-27). Extensive
characterization of DEPTOR from serum-stimulated cells supported the notion
that DEPTOR is heavily phosphorylated in an mTOR-dependent manner (Figures
S3B-D). We changed all 13 phosphorylation sites to alanine to generate a non-
phosphorylatable mutant protein that we call DEPTOR 13xS/T->A. In serum-
stimulated cells the mutant protein did not undergo a mobility shift on SDS-PAGE
(Figure S3E). When overexpressed, neither wild-type nor 13xS/T->A DEPTOR
decreased in expression upon serum stimulation of cells (compare Figures 4B
and S3E), suggesting that the machinery that degrades DEPTOR is readily
saturated. Consistent with this, stable and modest 2-5 fold overexpression of
epitope-tagged wild-type DEPTOR severely inhibited the loss of endogenous
DEPTOR that normally occurs upon serum stimulation (Figure S3F). Because
overexpression of DEPTOR impaired the regulation its expression (Figure S3E-
F), we focused on other functions for DEPTOR phosphorylation that could be
relevant to DEPTOR turnover and, in particular, examined the potential role of
DEPTOR phosphorylation on regulating the DEPTOR-mTOR interaction.
Compared to wild-type DEPTOR, the 13xS/T->A DEPTOR mutant bound better
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to mTOR within mTORC1 and mTORC2 (Figure 5A). These results suggest that
the phosphorylation of DEPTOR promotes its release from mTOR and correlates
with its loss. In addition, experiments described below indicate that DEPTOR
phosphorylation is necessary to reverse the inhibitory effects of DEPTOR on
mTORC2 activity.
DEPTOR Overexpression Inhibits mTORC1 but Activates PI3K/Akt
Signaling
Because our loss-of-function experiments indicate that DEPTOR is an
mTOR inhibitor, we hypothesized that DEPTOR overexpression should suppress
both the mTORC1 and mTORC2 pathways. Indeed, transient overexpression of
wild-type DEPTOR, but not a control protein, in MEFs reduced the
phosphorylation of T389 of co-expressed S6K1, an established mTORC1
substrate, to a similar degree as overexpression of PRAS40, a known mTORC1
inhibitor (Figure 5B). DEPTOR overexpression also strongly inhibited mTORC1
in MEFs lacking TSC2 or rictor (Figure 5B). Overexpression of just the PDZ
domain of DEPTOR, the region of DEPTOR that binds mTOR (Figure 1 H), but
not of the tandem DEP domains of DEPTOR, also inhibited mTORC1 signaling
(Figure 5B).
In contrast to the expected effects we observed with regards to mTORC1,
DEPTOR overexpression led to an apparent increase instead of inhibition of
mTORC2 signaling as monitored by Akt S473 phosphorylation (Figures 5C and
Figure S4). We suspected that because DEPTOR overexpression inhibits
mTORC1, it relieves the inhibitory feedback signal normally transmitted from
mTORC1 to P13K. This would lead to hyperactive P13K signaling, which then
overcomes the direct inhibitory effects of DEPTOR on mTORC2, just as the
hyperactive rheb found in TSC2 null cells can overcome the inhibitory effects of
PRAS40 on mTORC1 (7). Consistent with this interpretation, overexpression of
DEPTOR, like that of PRAS40, not only caused an increase in the
phosphorylation of Akt at S473 but also at T308, the PDK1 -catalyzed site which
serves as a read-out of P13K activity (28) (Figure 5C and Figure S4). The
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activation of Akt by DEPTOR overexpression was not observed in the absence of
serum, as expected from the known requirement for growth factors for mTORC1
to P13K feedback signaling (29) (Figure 5D). As was the case with wild-type
DEPTOR, overexpression of the non-phosphorylatable DEPTOR mutant inhibited
mTORC1 signaling (Figure 5B) and triggered feedback activation of P13K as
detected by T308 phosphorylation of Akt (Figure 5C). However, unlike wild-type
DEPTOR, the 13xS/T->A DEPTOR mutant did not promote Akt phosphorylation
on S473, indicating that P13K activation cannot activate mTORC2 when
DEPTOR cannot be phosphorylated (Figure 5C).
We propose that the effects of DEPTOR overexpression on the mTOR
pathway-inhibition of mTORC1 signaling but activation of mTORC2 signaling-
result from DEPTOR-mediated inhibition of mTORC1, which then leads to the
hyperactivation of P13K and Akt. In agreement with this model, in many cell types
treatment with rapamycin or overexpression of PRAS40 (Figure 5C) has similar
effects on mTOR signaling as DEPTOR overexpression (19, 29). However, both
rapamycin and PRAS40 are predominantly mTORC1 inhibitors, while our loss of
function data indicates that DEPTOR inhibits mTORC1 and mTORC2. To gain
evidence that a dual mTORC1 and mTORC2 inhibitor can also lead to a stable
cell state characterized by inhibition of mTORC1 signaling but and activation of
P13K/mTORC2/Akt signaling we explored the time- and dose-dependent effects
of the mTOR inhibitor Torinl (30). As expected, acute Torin1 treatment of cells
for 10 minutes led to a dose-dependent inhibition of both mTORC1 and mTORC2
signaling, as monitored by S6K1 and Akt phosphorylation, respectively (Figure
5E). By 48 hours of Torin1 treatment, however, mTORC1 signaling was still
inhibited but was now accompanied by increased T308 and S473 Akt
phosphorylation and IRS-1 levels, molecular phenotypes consistent with the loss
of the inhibitory feedback signal from mTORC1 to the P13K pathway (Figure 5E).
At a higher concentration (250 nM) of Torin1, Akt T308 phosphorylation and IRS-
1 expression were very high indicating that, at this dose, P13K signaling was still
hyperactive. However, like overexpression of a non-phosphorylatable DEPTOR
mutant (Figure 5C), the higher dose of Torini eliminated Akt S473
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phosphorylation, revealing that mTORC2 was now fully inhibited. PP242, a
distinct ATP-competitive inhibitor of mTOR (23), had similar time- and dose-
dependent effects on mTOR and P13K signaling as Torin1 (Figure S5). Thus,
because of the inhibitory feedback signal from mTORC1 to the P13K pathway,
partial mTOR inhibition caused by either DEPTOR overexpression or chemical
inhibitors leads to an asymmetrical state of mTOR signaling characterized by an
inhibition of mTORC1 but an activation of mTORC2-dependent outputs.
In a Subset of Multiple Myelomas DEPTOR Overexpression is Necessary
for Akt Activation and Cell Survival
The dynamic nature of DEPTOR expression and the interesting
consequences of DEPTOR overexpression on mTORC1 and P13K/mTORC2/Akt
signaling prompted us to examine the levels of DEPTOR mRNA in databases of
transcriptional profiles of human tumors and cancer cell lines. Consistent with
mTORC1 and mTORC2 being active in many cancers (reviewed in (3)), the
levels of DEPTOR mRNA were significantly lower in most cancer types
compared to the normal tissues from which they are derived (Figure 6A, Table
SI). Anomalously, this was not the case for Multiple Myelomas (MM), a
malignancy of antibody-producing plasma cells (reviewed in (31)), in which the
DEPTOR mRNA is overexpressed (Figure 6A, Table SI).
To expand upon these findings, we measured DEPTOR mRNA levels in a
collection of 581 human Multiple Myelomas and found that 28% (160/581) of the
MMs had mRNA levels that were 4-fold or greater than those in normal plasma
cells (see methods and Table SI). Multiple Myelomas can be grouped into two
broad types: (1) hyperdiploid MMs, which are associated with multiple trisomies
of 8 chromosomes and bi-allelically deregulate Cyclin D1/D2 mRNA expression,
and (2) non-hyperdiploid MMs, which mono-allelically deregulate Cyclin D1/D3,
c-MAF/MAFB, or FGFR3/MMSET expression through translocation events
involving these genes (32) (In Figure 6B these two types are referred to as "Bi-
allelic deregulation" and "Translocation"). We noted that many of the MMs with
high levels of DEPTOR mRNA were of the non-hyperdiploid type and had
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translocations involving the genes for Cyclin D1 or D3, or, in particular, for the c-
MAF or MAFB transcription factors (Table SI). In these MMs, the mean level of
DEPTOR mRNA is significantly higher than in those without the translocations
(Figure 6B).
We next examined DEPTOR mRNA and protein expression and mTORC1
and P13K/mTORC2/Akt signaling in a set of MM cell lines. Many MM cell lines,
particularly those with c-MAF/MAFB translocations, have levels of DEPTOR
protein and mRNA expression that are many folds greater than those found in
non-MM cancer cell lines, such as HeLa and PC3 cells (Figures 6D, S6A-B, and
Table SI). Consistent with our exogenous DEPTOR overexpression studies
(Figure 5), DEPTOR expression across the cell lines correlated positively with
the phosphorylation of Akt on T308 and S473 (PDK1/P13K and mTORC2
outputs, respectively), but negatively with S6K1 T389 phosphorylation (an
mTORC1 output) (Figure 6C). The sole exception was the 147 cell line, which is
one of the few MM cell lines that lack PTEN and thus has high levels of S6K1
and Akt phosphorylation (Figure 6C). Remarkably, the MM cell lines with high
DEPTOR expression had levels of S473, and, particularly, T308 Akt
phosphorylation comparable to those in the PTEN-null 147 cell line.
As PTEN inactivation and P13K-activating mutations are rare in MM (33)
(Kuehl et al., unpublished), we considered the possibility that overexpression of
endogenous DEPTOR might also be a mechanism to promote activation of P13K
and Akt and cell survival in a subset of human MMs. To test this, we used RNAi
to suppress the very high levels of DEPTOR expression in 8226 and OCI-MY5
Multiple Myeloma cell lines to levels comparable to those in HeLa cells (Figure
6D). DEPTOR suppression led to an increase in mTORC1 activity as detected by
S6K1 T389 phosphorylation, IRS1 levels, and IRS1 phosphorylation, but to a
drop in P13K/PDK1 and mTORC2 outputs as measured by T308 and S473 Akt
phosphorylation, respectively (Figure 6E). Even though the DEPTOR knockdown
decreased the cellular levels of phospho-S473 Akt, it caused an increase in the
in vitro kinase activity of mTORC2 isolated from the DEPTOR knockdown cells
(Figure S7), a result consistent with DEPTOR being a negative regulator of
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mTORC2 kinase activity (Figure 2D). DEPTOR suppression had similar inhibitory
effects on T308 and S473 Akt phosphorylation in OCI-MY5 cells except that in
this cell line IRS-1 was not detected and decreased Akt phosphorylation instead
correlated instead with a loss of PDGFR-i levels (Figure 6E, see also Figure
S8). Lastly, co-knockdown of raptor with DEPTOR partially reversed the effects
of the DEPTOR knockdown on T308 and S473 Akt phosphorylation, suggesting
that mTORC1 activation mediates the reduction in P13K signaling seen in the
8226 cells upon a reduction in DEPTOR expression (Figure S9).
Consistent with the pro-survival role of P13K/Akt signaling, suppression of
DEPTOR in 8226 cells abolished cell proliferation over a 7-day culture period
(Figure 6F) and caused apoptosis as detected by the presence of numerous cell
fragments in the culture media (Figure 6G) and increased cleaved caspase-3 and
PARP (Figure 6H). Thus, in a subset of Multiple Myeloma cell lines, high
expression of DEPTOR contributes to Akt activation and is an endogenous
mechanism for maintaining cell survival.
Because P13K/mTORC2/Akt signaling represses DEPTOR mRNA levels
(Figures 4F-G and Figures S2A-B), we wondered how certain Multiple Myeloma
cells can keep DEPTOR at elevated levels in the face of hyperactive P13K
signaling. DEPTOR mRNA levels are highest in MM tumors and cell lines in
which chromosomal translocations cause the overexpression of c-MAF or MAFB.
Moreover, a transcriptional profiling study shows that DEPTOR is highly induced
upon forced MAFB overexpression (34, 35). To test if deregulated
overexpression of c-MAF or MAFB drives DEPTOR expression, we used RNAi to
reduce c-MAF expression in 8226 cells, a MM cell line with a translocation
involving the c-MAF gene (36). Indeed, loss of c-MAF substantially diminished
DEPTOR mRNA and protein levels and, by activating mTORC1 and inhibiting
mTORC2 outputs, recapitulated the effects of a DEPTOR knockdown on the
mTOR pathway (Figure 61, 6J). As expected, the knockdown of c-MAF
decreased the expression of the mRNA for Integrin p7, a known c-MAF target
(Figure 61). These results are consistent with deregulated overexpression of c-
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MAF or MAFB driving DEPTOR expression to high levels and, thus,
hyperactivating P13K signaling.
DISCUSSION
Our loss of function data indicate that DEPTOR inhibits both the mTORC1
and mTORC2 pathways. However, by inhibiting mTORC1, DEPTOR
overexpression relieves mTORC1-mediated inhibition of P13K, causing an
activation of P13K and, paradoxically, of mTORC2-dependent outputs, like Akt.
mTOR interacts with DEPTOR via its PDZ domain and so far there is no
information about the function of the tandem DEP domains the protein also
contains. In other proteins DEP domains mediate protein-protein interactions (37,
38), but in numerous DEPTOR purifications we have failed to identify additional
DEPTOR-interacting proteins besides the known components of mTORC1 and
mTORC2 (data not shown). Therefore, based on our current evidence, DEPTOR
appears dedicated to mTOR regulation, and we propose that in vertebrates it is
likely to be involved in regulating other outputs of the mTOR signaling network
besides the growth and survival pathways we have examined. The mTOR
complexes and DEPTOR negatively regulate each other, suggesting the
existence of a feedforward loop in which the loss of DEPTOR leads to an
increase in mTOR activity, which then further reduces DEPTOR expression. This
type of regulatory circuit should result in DEPTOR expression being tightly
coupled to mTOR activity, and, interestingly, we have noted that DEPTOR mRNA
levels strongly anti-correlate with cell size, a readout of mTORC1 activity (Figure
S6B).
We find that about 28% of human Multiple Myelomas (MM) overexpress
DEPTOR. Our results are consistent with a published survey of 67 MM tumors
and 43 MM cell lines, in which 21 % were shown to possess copy number gains
and associated expression increases of the genes within a 6 Mb region of
chromosome 8q24 that contains DEPTOR (39). Furthermore, it appears that
deregulated overexpression of c-MAF and MAFB is an additional, perhaps even
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more prevalent, mechanism for increasing DEPTOR expression in MMs. The
related c-MAF and MAFB transcription factors are expressed--frequently as the
result of chromosomal translocations--in a large fraction of MMs, but not in the
plasma cells from which they are derived (reviewed in (40)). Consistent with c-
MAF playing a key role in promoting DEPTOR expression, a knockdown of c-
MAF in a MM cell line having a c-MAF translocation decreases the expression of
DEPTOR and mimics the effects of a DEPTOR knockdown on mTOR and P13K
signaling. The levels of the DEPTOR and c-MAF or MAFB mRNAs highly
correlate with each other (35) and, importantly, DEPTOR expression correlates
with poor survival in patients with Multiple Myeloma (39).
In many Multiple Myeloma cell lines DEPTOR is massively overexpressed
compared to the levels found in other cancer cell lines, such as HeLa cells. In
these cells, the great overexpression of DEPTOR inhibits mTORC1 growth
signaling and drives outputs dependent on P13K. Interestingly, a reduction in
DEPTOR expression to the lower levels seen in non-Multiple Myeloma cell lines
causes cell death via apoptosis. This suggests that a pharmacologically induced
reduction in DEPTOR expression or disruption of the DEPTOR-mTOR interaction
could have therapeutic benefits for the treatment of Multiple Myeloma. There has
been progress in developing small molecule inhibitors of protein-protein
interactions mediated by PDZ domains (41, 42), so it is conceivable that blockers
of the DEPTOR-mTOR interaction could be made.
Although a number of other cancer cell lines have high levels of DEPTOR
(data not shown), as a class only Multiple Myelomas appear to consistently
overexpress it. Besides activating PI3K/Akt signaling, DEPTOR overexpression
in MM cells may provide these cells with benefits that are not relevant in other
cancer types or perhaps even detrimental. For example, the high demand that
MM cells place on the protein synthesis machinery to produce large amounts of
immunoglobulins (reviewed in (43)), causes a significant ER stress which renders
these cells susceptible to apoptosis-induction via agents which induce further ER
stress, such as proteasome inhibitors (44, 45). DEPTOR overexpression, by
partially inhibiting protein synthesis through the suppression of mTORC1, may
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reduce the levels of ER stress below the threshold that triggers apoptosis. In
contrast, in other cancer cells in which ER stress is not a significant factor,
DEPTOR overexpression may be selected against because reduced rates of
protein synthesis may not be tolerated. That mTORC1-stimulated protein
synthesis leads to ER stress is already appreciated as TSC1 or TSC2 null cells
have increased sensitivity to ER stress-induced death (46).
It is curious that DEPTOR is overexpressed mostly in MMs characterized
by chromosomal translocations instead of those which are hyperdiploid because
of aneuploidy (Figure 6B) (32). Elevated DEPTOR expression might be tolerated
better in the non-hyperdiploid MMs because aneuploidy itself increases
sensitivity to conditions, like mTORC1 inhibition, that interfere with protein
synthesis (47). Moreover, the state of high mTORC2 and low mTORC1 signaling
that our work indicates some MM cells prefer, cannot be achieved by mutations
that activate P13K signaling, perhaps explaining why Multiple Myelomas exhibit
low rates of PTEN-inactivating or P13K-activating mutations (33)(Kuehl et al.,
unpublished).
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FIGURE LEGENDS
Figure 1. DEPTOR is an mTOR-interacting Protein
(A) Silver stain of SDS-PAGE analysis of mTOR immunoprecipitates prepared
from HEK-293E cells.
(B) Schematic representation of structural features of human DEPTOR and its
mouse and chicken orthologues.
(C) Endogenous mTOR, raptor, and rictor co-immunoprecipitate with epitope-
tagged DEPTOR. FLAG immunoprecipitates from HEK-293E cells expressing
FLAG-DEPTOR, FLAG-PRAS40, or FLAG-tubulin were analyzed by SDS-PAGE
followed by silver staining.
(D) Interaction of endogenous DEPTOR with endogenous mTORC1 and
mTORC2 is sensitive to high salt-containing buffers. mTOR, raptor, rictor, or
actin immunoprecipitates were prepared from HEK-293E cells, washed with
buffers containing indicated amounts of NaCl and analyzed by SDS-PAGE
followed by immunoblotting for indicated proteins.
(E) Endogenous DEPTOR co-immunoprecipitates endogenous mTOR. DEPTOR
immunoprecipitates were prepared from HeLa cells, washed in a buffer
containing 150 mM NaCl, and analyzed as in (D).
(F) DEPTOR interacts with mTOR and not mLST8/GpL. Indicated cDNAs in
expression vectors were co-expressed in HEK-293T cells,
cell lysates prepared, and used to prepare anti-HA immunoprecipitates and anti-
myc immunoprecipitates. Both immunoprecipitates and cell lysates were
analyzed as in (D).
(G) Myc-tagged mTOR, its indicated fragments, or rap2a were co-expressed in
HEK-293T cells with FLAG-DEPTOR, and anti-myc immunoprecipitates were
analyzed as in (D).
(H) The PDZ domain of DEPTOR interacts with mTOR. FLAG-tagged DEPTOR,
its fragments, or metap2 were co-expressed in HEK-293T cells with myc-mTOR,
and anti-FLAG immunoprecipitates were analyzed as in (D). Asterisks (*) indicate
non-specific bands.
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(1) Schematic indicating the regions of mTOR and DEPTOR that mediate their
interaction. The abbreviations for and residues that define known mTOR domains
are: HEAT Repeats, 1-1382; FAT, 1383-2014; R (FKBP12-Rapamycin Binding),
2015-2114; KD (P13K-like Kinase Domain), 2115-2431; C (FATC), 2432-2549.
Figure 2. DEPTOR Depletion in Cells Activates mTORC1 and mTORC2
signaling and In Vitro Kinase Activities
(A) Knockdown of DEPTOR activates the mTORC1-S6K1 pathway. HeLa cells or
p53-/- MEFs were infected with lentiviruses expressing shRNAs targeting the
indicated genes. Cell lysates were analyzed by immunoblotting for the levels of
the indicated proteins and phosphorylation states.
(B) Knockdown of DEPTOR activates mTORC1 kinase activity towards S6K1
and 4E-BP1. HeLa cells were infected with lentiviruses expressing shRNAs
targeting the indicated genes. mTOR immunoprecipitates were prepared from
cell lysates (1 mg total protein) and analyzed for mTORC1 kinase activity toward
S6K1 and 4E-BP1 and for levels of mTOR, raptor, and DEPTOR.
(C) Knockdown of DEPTOR activates the mTORC2-Akt pathway. The
experiment was performed as in (A) except that Akt phosphorylation and levels
were measured.
(D) Knockdown of DEPTOR activates mTORC2 kinase activity towards Akt1. The
experiment was performed as in (B) except that mTORC2 activity towards Akt
was measured.
Figure 3. DEPTOR Depletion Increases Cell Size and Protects Cells from
Apoptosis Induced by Serum Deprivation
(A) Knockdown of DEPTOR increases cell size in an mTORC1 -dependent
fashion. Cell size distributions (graphs) and S6K1 phosphorylation
(immunoblot) are shown for HeLa cells stably expressing shRNAs targeting
DEPTOR or luciferase. Where indicated, cells were pre-treated with 100 nM
rapamycin or vehicle before infection. 72 hours after infection, cell size was
measured using a Coulter counter.
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(B) A knockdown of DEPTOR has similar effects on cells size as a TSC2
knockdown. p53 null MEFs were infected with shRNAs and cell size measured
as in (A).
(C) DEPTOR knockdown protects against apoptosis induced by serum
withdrawal. HeLa cells expressing shRNAs targeting luciferase or DEPTOR were
grown in media containing the indicated concentrations of serum for 30 hours.
Cell lysates were then analyzed by immunoblotting for the levels of the indicated
proteins and phosphorylation states.
(D) mTOR inhibition re-sensitizes DEPTOR knockdown cells to apoptosis
induced by serum withdrawal. HeLa cells expressing shRNAs targeting luciferase
or DEPTOR were serum deprived for 30 hours in the presence of 100 nM
rapamycin, 250 nM Torin1, or vehicle. Cell lysates were then analyzed as in (C).
(E) Rictor but not raptor inhibition re-sensitizes DEPTOR knockdown cells to
apoptosis induced by serum withdrawal. HeLa cells co-expressing shRNAs
targeting luciferase or DEPTOR along with shRNAs targeting luciferase or rictor
or raptor were serum deprived for 30 hours. Cell lysates were then analyzed as
in (C).
(F) SGK1 inhibition re-sensitizes DEPTOR knockdown cells to apoptosis induced
by serum withdrawal. HeLa cells co-expressing shRNAs targeting luciferase or
DEPTOR along with shRNAs targeting luciferase or SGK1 were analyzed as in
(C).
Figure 4. mTOR Negatively Regulates DEPTOR Protein and mRNA
Expression
(A) Serum starvation and stimulation regulates DEPTOR protein expression.
HeLa cells were serum starved for 30 hours and stimulated with serum (10% final
concentration) for the indicated times. Cell lysates were analyzed by
immunoblotting for the levels of indicated proteins and phosphorylation states.
(B) DEPTOR amounts in mTORC1 and mTORC2 correlate with its expression
within cells. HeLa cells were serum starved for 30 hours and stimulated with
serum (10% final concentration) for the indicated times. Cell lysates and raptor
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and rictor immunoprecipitates were analyzed by immunoblotting for indicated
proteins.
(C) DEPTOR protein expression is downregulated in cancer cell lines with
constitutive mTOR signaling. Cell lines were seeded at equal density and grown
in the presence or absence of serum for 30 hours and cell lysates analyzed as in
(A).
(D) DEPTOR protein expression is downregulated in PTEN null or TSC2 null
MEFs. Indicated MEF lines were seeded at equal density and grown in the
presence or absence of serum for 30 hours and cell lysates analyzed for levels of
DEPTOR, PTEN, TSC2, and raptor. An asterisk (*) indicates a non-specific band.
(E) Rapamycin treatment partially and Torin1 treatment fully rescues the serum-
induced decrease in DEPTOR protein. HeLa cells were serum-deprived for 30
hours, and then stimulated with serum in the presence of 100 nM rapamycin, 250
nM Torin1, or vehicle for the specified times. Cell lysates were analyzed as in
(A).
(F) Regulation of DEPTOR protein and mRNA expression. HeLa cells were
serum-deprived for 30 hours, and then stimulated with serum in the presence of
100 nM rapamycin, 10 uM of MG1 32, 250 nM Torin1, or vehicle for the specified
times. Cell lysates were analyzed by immunoblotting for the levels of indicated
proteins and phosphorylation states. DEPTOR mRNA was measured by qRT-
PCR and normalized to GADPH mRNA levels. Error bars indicate standard
deviation for n=3.
(G) Reductions in raptor or rictor expression increase DEPTOR protein and
mRNA levels. Five days after transductions with raptor or rictor shRNA-
expressing lentiviruses, HeLa cells were lysed and analyzed as in (A). DEPTOR
mRNA was prepared and analyzed as in (F).
Figure 5. DEPTOR Overexpression Inhibits mTORCI but Activates PI3KlAkt
Signaling
(A) The 13xS/T->A DEPTOR mutant binds mTORC1 and mTORC2 more tightly
than wild-type DEPTOR. HEK-293T cells were transfected with 500 ng of
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expression vectors encoding the indicated FLAG-tagged proteins for 48 hours.
Raptor or rictor immunoprecipitates were prepared from cell lysates, washed with
buffers containing 150 mM NaCl, and analyzed along with cell lysates by
immunoblotting for indicated proteins.
(B) Overexpression of DEPTOR inhibits T389 phosphorylation of S6K1. HeLa
cells or the indicated p53-/- MEFS were cotransfected with expression plasmids
encoding HA-GST-S6K1 as well as the indicated FLAG-tagged proteins. Cell
lysates were prepared 24 hours after transfection and were analyzed by
immunoblotting for the levels of the indicated proteins and phosphorylation
states.
(C) Overexpression of DEPTOR activates T308 and S473 Akt1 phosphorylation.
HeLa cells were cotransfected with expression plasmids encoding HA-GST-Aktl
as well as the indicated FLAG-tagged proteins. Cell lysates were analyzed as in
(B).
(D) Overexpression of DEPTOR activates T308 and S473 Akt1 phosphorylation
only in serum-replete cells. HeLa cells were transfected as in (B), serum starved
for 24 hours and stimulated for the indicated times and cell lysates were
analyzed as in (B).
(E) Partial inhibition of mTOR with Torin1 inhibits S6K1 phosphorylation but
activates P13K/mTORC2/Akt signaling. HeLa cells were treated with the specified
concentrations of Torin1 or vehicle for either 10 minutes or 48 hours and cell
lysates were analyzed as in (B).
Figure 6. DEPTOR is Overexpressed in a Subset of Multiple Myeloma Cells
and in these Cells Activates Pl3K/Akt signaling and Promotes Cell Survival
(A) DEPTOR mRNA expression is downregulated in most cancers, yet is up-
regulated in Multiple Myelomas. Relative DEPTOR mRNA expression in various
cancer types versus matched unaffected tissue was collated from publicly
available microarray studies. For all studies shown, p<0.05 for DEPTOR mRNA
downregulation or upregulation by one-tailed T-test.
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(B) DEPTOR mRNA is mostly highly expressed in the subset of Multiple
Myelomas which possess Cyclin D1/D3 or c-MAF/MAFB translocations.
DEPTOR mRNA levels were normalized by the summed mean values of the
housekeeping genes GAPDH, p-actin, and FIP (7 total probe-sets). Error bars
indicate standard error for n=7. The differences in mean DEPTOR mRNA levels
between plasma cells and MMs with Cyclin D1, Cyclin D3, or c-MAF/MAFB
translocations are significant to at least p<0.005.
(C) Human Multiple Myeloma cell lines with high DEPTOR protein expression
have activated P13K and suppressed mTORC1 signaling. Cell lysates were
analyzed by immunoblotting for the levels of the indicated proteins and
phosphorylation states. Cell lines with known translocations of c-MAF or MAFB
are indicated.
(D) RNAi-mediated knockdown of DEPTOR in 8226 and OCI-MY5 cells reduces
DEPTOR expression to levels similar to those in HeLa cells. Five days after
transductions with shRNA-expressing lentiviruses, cells were lysed and as in (C).
(E) DEPTOR suppression in 8226 and OCI-MY5 cells activates mTORC1
signaling, inhibits IRS-1 or PDGFR-p expression, and reduces
P13K/mTORC2/Akt signaling. Five days after transduction with shRNA-
expressing lentiviruses, cells were lysed and analyzed as in (C).
(F) DEPTOR suppression markedly decreases 8226 cell number. Cell number
was measured at indicated time points with a Coulter Counter. Error bars indicate
mean ± standard deviation for n=3 samples per time point.
(G) Representative 20x light microscopy images of 8226 cells expressing
shRNAs targeting DEPTOR, GFP, or luciferase at day 8 post-infection.
(H) DEPTOR suppression causes apoptosis. Three days after transduction with
shRNA-expressing lentiviruses, 8226 cells were lysed and analyzed as in (C).
(1) A reduction in c-MAF expression decreases DEPTOR mRNA levels. Five days
after transduction of 8226 cells with lentiviruses expressing the indicated
shRNAs, DEPTOR and Integrin P7 mRNA levels were measured by qRT-PCR
and normalized to GADPH mRNA levels. Error bars indicate standard deviation
for n=3.
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(J) A c-MAF knockdown activates mTORC1 and downregulates P13K signaling.
Five days after transductions with shRNA-expressing lentiviruses, lysates of
8226 cells were analyzed as in (C).
Figure S1. Similar to a Reduction in Raptor Expression, a Reduction in
DEPTOR Expression Protects Cells from Apoptosis Induced by Serum
Withdrawal.
HT-29 cells expressing shRNAs targeting DEPTOR, raptor, or luciferase were
serum starved for 6 hours. Cell lysates were analyzed by immunoblotting for the
levels of indicated proteins and phosphorylation states.
Figure S2. PTEN Positively Regulates DEPTOR mRNA Expression.
(A) PTEN Loss Reduces DEPTOR mRNA Expression. HeLa, PC3, and U87 cells
were seeded at equal density. 48 hours after seeding DEPTOR mRNA was
determined by qRT-PCR from total RNA samples and normalized to GADPH
mRNA levels. Error bars indicate mean ± standard deviation for n=3 per
condition.
(B) Expression of an shRNA targeting PTEN in HeLa cells reduces DEPTOR
mRNA expression. Five days after transductions with an shRNA-expressing
lentivirus, cells were lysed and analyzed by immunoblotting for PTEN levels.
DEPTOR mRNA was prepared and analyzed as in (A)
Figure S3. Further Characterization of DEPTOR Phosphorylation and its
Functions.
(A) Schematic representation of the location of phosphorylation sites identified in
DEPTOR by mass spectrometry. All 13 phosphorylation sites were mutated to
alanine as described in the methods.
(B) DEPTOR gel mobility is increased by Calf Intestinal Phosphatase (CIP)
treatment. Immunoprecipitated wild-type recombinant DEPTOR was incubated
without CIP or with active or heat-inactivated CIP for 30 minutes and analyzed by
SDS-PAGE followed by immunoblotting.
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(C) mTOR inhibitors decrease the recognition of DEPTOR by a phospho-specific
antibody. Serum-replete HEK-293T cells expressing FLAG-DEPTOR were
treated with vehicle, 50 nM rapamycin, or 250 nM Torin1 for 16 hours.
Immunoblotting was performed for the indicated proteins and phosphorylation
states. A phospho-specific antibody designed against phospho-S877 raptor
cross-reacts with DEPTOR and was used to detect phospho-DEPTOR.
(D) Proline-directed DEPTOR phosphorylation sites serines 244, 265, 293, and
299 are dephosphorylated in the presence of Torin1. Serum-replete HEK-293T
cells expressing FLAG-DEPTOR were treated with vehicle or 250nM Torin1 for
16 hours. After immunopurification from cell lysates, the extent of
phosphorylation at each of the indicated sites was measured using mass
spectrometry as described in the methods.
(E) Elimination of the DEPTOR phosphorylation sites impairs the serum-induced
mobility shift seen in SDS-PAGE analyses of wild-type DEPTOR. HeLa cells
were transfected with 50 ng of the indicated plasmids expressing FLAG-
DEPTOR. Three days later, cells were starved for serum for 30 hours and, where
indicated, stimulated with serum for the specified times. Cell lysates were
analyzed by immunoblotting for levels of recombinant DEPTOR and, as a loading
control, mTOR. Arrows indicate serum-induced mobility shifts of wild-type and
13xS/T->A mutant FLAG-DEPTOR.
(F) Overexpression of recombinant wild-type DEPTOR blocks serum-induced
degradation of recombinant and endogenous DEPTOR. Myc-tagged DEPTOR
was induced by treatment with 10 ng/ml doxycycline in Tet-On HeLa cells. Two
days post-induction, non-induced, and induced cells were serum starved for 30
hours and stimulated with serum for the specified times. Cell lysates were
analyzed by immunoblotting for the levels of the indicated proteins.
Figure S4. Overexpression of DEPTOR Activates Phosphorylation of T308
and S473 of Akti in a Dose-Dependent Manner.
p53-/- MEFs cells were cotransfected with expression plasmids encoding HA-
GST-Akt1 (200 ng) as well as 200 ng or 2 Dg of the indicated FLAG-tagged
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proteins. Cell lysates were prepared 24 hours after transfection and were
analyzed by immunoblotting for the levels of the indicated proteins and
phosphorylation states.
Figure S5. Effects of Prolonged Inhibition of mTOR with the ATP
Competitive Inhibitor PP242 on mTORCI and PI3K/mTORC2/Akt Signaling.
HeLa cells were treated with the specified concentrations of PP242 or vehicle for
either 1 hour or 48 hours. Cell lysates were prepared and analyzed by
immunoblotting for the levels of the indicated proteins and phosphorylation
states.
Figure S6. DEPTOR Expression across Human Cancer Cell lines Anti-
Correlates with Cell Size.
(A) Indicated cell lines were seeded at equal density and 48 hours later cell
lysates were prepared and analyzed by immunoblotting for DEPTOR. mTOR
expression was used as a loading control. Multiple Myeloma cell lines with or
without c-MAF/MAFB translocations are indicated where known.
(B) DEPTOR mRNA levels anti-correlate with cell size across a variety of human
cell lines. Mean values of DEPTOR mRNA levels and cell diameter are shown in
Table S1. Cell size was measured using a Coulter Counter. Non-Multiple
Myeloma cell lines (PC3, HEK-293T, and HeLa) are indicated by red squares.
Multiple Myeloma cell lines are indicated by black squares.
Figure S7. A Reduction in DEPTOR Expression in 8226 Cells Activates the
In Vitro Kinase Activity of mTORC2 Despite Decreasing Akt S473
Phosphorylation in Cells.
8226 cells were infected with lentiviruses expressing shRNAs targeting GFP or
DEPTOR. Six days post-infection, mTOR immunoprecipitates were prepared
from cell lysates (0.2 mg total protein) and analyzed for mTORC1/2 kinase
activities toward S6K1 and Akt1 and for levels of mTOR and DEPTOR.
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Figure S8. A Reduction in TSC2 Expression Increases mTORCI Signaling
but Represses PDGFRP Protein Levels.
OCI-MY5 cells were infected with a control shRNA or an shRNA targeting TSC2.
Five days after infection, cell lysates were analyzed for the indicated protein
levels and phosphorylation states.
Figure S9. Raptor Knockdown Restores P13K Signaling in DEPTOR
knockdown 8226 Cells. 8226 cells co-expressing shRNAs targeting luciferase
or DEPTOR along with shRNAs targeting luciferase or raptor were lysed five
days after infection and cell lysates were analyzed for the indicated protein levels
and phosphorylation states.
Table S1. DEPTOR mRNA Expression Analysis in Human Cancers
(A) Figure 6A worksheet. Listing of primary references used to generate meta-
analysis of DEPTOR mRNA expression in human cancers.
(B) Figure 6B worksheet. Raw data for DEPTOR and housekeeping mRNA
expression in MM tumor samples and plasma cells.
(C) Figure S6B worksheet. Raw data for DEPTOR mRNA expression and cell
size measurements in Multiple Myeloma cell lines.
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EXPERIMENTAL PROCEDURES
Materials
Reagents were obtained from the following sources: rabbit polyclonal
antibodies to DEPTOR (09-463), raptor (09-217), Akt (05-591), and phospho-
S877 raptor (09-107) from Upstate/Millipore; mouse monoclonal antibody to
DEPTOR from Novus Biologicals; mouse monoclonal antibodies to rictor and
raptor from Assay Designs; antibodies to mTOR, D-catenin, actin, S6K1, c-MAF,
as well as HRP-labeled anti-mouse, anti-goat, and anti-rabbit secondary
antibodies from Santa Cruz Biotechnology; antibodies to phospho-T389 S6K1,
phospho-T37/T46 4E-BP1, phospho-S473 Akt/PKB, phospho-T308-Akt,
phospho-T346-NDRG1, phospho-S307-IRS-1, IRS-1, PTEN, TSC2, 4E-BP1,
cleaved caspase-3, PARP, PDGFR-p, and the c-MYC epitope from Cell
Signaling Technology; antibodies to rictor, HA, c-MYC from Bethyl Laboratories;
Flag M2 affinity gel, Flag M2 antibody and SGKI antibodies, ATP, and SYBR
Green JumpStart Taq ReadyMix from Sigma Aldrich; mouse monoclonal
antibody to mTOR and recombinant IL-6 from BD Pharmingen; protein G
Sepharose and anti-sheep secondary antibody from Pierce; DMEM from SAFC
Biosciences; rapamycin from LC Labs; MG-132 from Biomol; PreScission
protease from Amersham Biosciences; pTREQ Tet-On vector from Clontech;
Adenoviral CRE and GFP from University of Iowa Gene Transfer Vector Core;
FuGENE 6 and Complete Protease Cocktail from Roche; 4E-BP1 from A.G.
Scientific; SuperScript II Reverse Transcriptase, Platinum Pfx Polymerase,
SimplyBlue Coomassie G, Silverquest Staining kit, and inactivated fetal calf
serum (IFS) from Invitrogen. An antibody to NDRG1 was kindly provided by Dario
Alessi (University of Dundee, UK). We have found that the phospho-S877 raptor
antibody also recognizes immunoprecipitated phosphorylated DEPTOR and can
be used to read out the DEPTOR phosphorylation state.
Cell Lines and Cell Culture
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HEK-293E cells were kindly provided by John Blenis (Harvard Medical
School). HeLa, HEK-293E, HEK-293T, HT-29, U87, PC3, MD-MBA-435, and
MEFs were cultured in DMEM with 10% Inactivated Fetal Bovine Serum (IFS).
The Human Multiple Myeloma cell lines: FR4, XG-7, U266, KMS-12BM, KMS-
12PE, PE2, 8226, OCI-MY5, KMS-28BM were provided by the Kuehl lab. The
EJM, MM-1 S, JJN-3, and A47 Human Multiple Myeloma cell lines were kindly
provided by Ken Anderson (Dana Farber Cancer Institute). Human Multiple
Myeloma cell lines were cultured in RPMI-1 640 with 10% Fetal Bovine Serum
(FBS) supplemented with 2 mM glutamine. XG-7 cells were additionally
supplemented with 2 ng/ml IL-6. TSC2-/-, p53-I- and TSC2+/+, p53-I- MEFs were
kindly provided by David Kwitakowski (Harvard Medical School). PTEN
LoxP/LoxP MEFs were generated from PTEN LoxP/LoxP mice kindly provided by
Hong Wu (UCLA). To produce PTEN -I- and PTEN +/+ MEFs, 1 El of Adenoviral
CRE or Adenoviral GFP at a titer of 1X10 10 PFU/mL was added to 500,000 PTEN
LoxP/LoxP MEFs. Cell lysates were generated 5 days post-infection. The HeLa
cell line with doxycycline-inducible DEPTOR expression was generated by
retroviral transduction of HeLa that were previously modified to express rtTA with
an inducible DEPTOR cDNA.
cDNA Manipulations, Mutagenesis, and Sequence Alignments
The cDNA for DEPTOR (NCBI gene symbol: DEPDC6) in the pCMV6-XL4
vector was obtained from Origene. The DEPTOR cDNA was amplified by PCR
and the product subcloned into the Sal I and Not 1 sites of pRK5, the Xho I and
Not I sites of pMSCV, or the BsiWI and BstB I sites of pTREQ. All constructs
were verified by DNA sequencing. The DEPTOR cDNA in pRK5 was
mutagenized using the QuikChange XLII mutagenesis kit (Stratagene) with
oliogonucleotides obtained from Integrated DNA Technologies. NCBI Blosum62
Blast searches were used to identify blocks of similar sequence between
DEPTOR orthologues. Amino acid sequence alignment of the phosphorylated
region of DEPTOR was performed using ClustaIX v1.81.
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Mass Spectrometric Analysis
mTOR or FLAG immunoprecipitates prepared from 30 million HEK-293E
cells were resolved by SDS-PAGE, Coomassie G-stained, and gel bands were
excised and processed as described in (7). In 4 independent experiments, a total
of 12 peptides corresponding to DEPTOR were identified while no DEPTOR
peptides were identified in control purifications.
DEPTOR phosphorylation sites were identified by mass spectrometry of
trypsin digested FLAG-DEPTOR purified from HEK-293E or HEK-293T cells
stably or transiently over-expressing FLAG-DEPTOR. All putative phosphorylated
residues on DEPTOR (highlighted in BOLD) were detected on the following
peptides (amino acid position according to NCBI DEPDC6 Protein Sequence
NP_073620):
234 KSPSSQETHDSPFCLR 249
257 KSTSFMSVSPSK 268
278 RSSMSSCGSSGYFSSSPTLSSSPPVLCNPK 311
Label-free quantification of DEPTOR phosphorylation sites were
performed using BioWorks Rev3.3 software following methodology utilized in
(48).
Mammalian Lentiviral shRNAs
Lentiviral shRNAs to human raptor, rictor, and mTOR were previously
described (49). All other shRNAs were obtained from the collection of The RNAi
Consortium (TRC) at the Broad Institute (Moffat et al., 2006). These shRNAs are
named with the numbers found at the TRC public website:
(http://www.broad.mit.edu/genome__bio/trc/publicSearchForHairpinsForm.php)
Human DEPTOR_1 shRNA: TRC candidate; NM_022783.1-877s1c1
Human DEPTOR 2 shRNA: TRC candidate; NM_022783.1-1101lsc1
Human TSC2_1 shRNA: TRCN0000040178; NM_000548.2-4551s1c1
Human PTEN 1 shRNA: TRCN0000002746; NM_000314.x-1320s1c1
Mouse DEPTOR_1 shRNA: TRCN0000110157; NM_145470.1-1164s1c1
Mouse DEPTOR_2 shRNA: TRCN0000110159; NM_145470.1-1165s1c1
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Mouse TSC2_1 shRNA: TRCN0000042727; NM_011647.1-1843s1 ci
Human SGK1_1 shRNA: TRCN0000040175; NM_005627.2-964s1c1
Human SGK1_2 shRNA: TRCN0000040176; NM_005627.2-252s1c1
Human c-MAF_1 shRNA: TRCN0000000255; NM_005360.x-1839s1c1
Human c-MAF_2 shRNA: TRCN0000000257; NM_005360.x-1067s1c1
shRNA-encoding plasmids were co-transfected with the Delta VPR
envelope and CMV VSV-G packaging plasmids into actively growing HEK-293T
using FuGENE 6 transfection reagent as previously described (49). Virus
containing supernatants were collected at 48 hours after transfection, filtered to
eliminate cells, and target cells (e.g., 300,000 HeLa cells or 500,000 8226 cells)
infected in the presence of 8 Oig/ml polybrene. For 8226 cells, infected cells were
spun at 300g for 1.5 hours before incubating at 37*C for 24 hours. For all cell
types, 24 hours after infection, the cells were split into fresh media (e.g.,
DMEM/10%lFS for HeLa/MEFs; RPMI/10%FBS for 8226/OCI-MY5), selected
with 1 ig/ml puromycin. Five days post-infection, shRNA-expressing cells were
analyzed or split again and analyzed 2-3 days later. For adherent cell lines,
shRNA-expressing cells were analyzed at 50-75% confluence.
Cell Lysis and Immunoprecipitations
All cells were rinsed with ice-cold PBS before lysis. All cells, with the
exception of those used to isolate mTOR-containing complexes, were lysed with
Triton-X 100 containing lysis buffer (40 mM HEPES [pH 7.4], 2 mM EDTA, 10
mM sodium pyrophosphate, 10 mM sodium glycerophosphate, 150 mM NaCI, 50
mM NaF, 1% Triton-X 100, and one tablet of EDTA-free protease inhibitors
[Roche] per 25 ml). The soluble fractions of cell lysates were isolated by
centrifugation at 13,000 rpm for 10 min in a microcentrifuge. For
immunoprecipitations, primary antibodies were added to the lysates and
incubated with rotation for 1.5 hr at 40C. A 50% slurry of protein G Sepharose (60
pl) was then added, and the incubation continued for an additional 1 hr.
Immunoprecipitated proteins were denatured by the addition of 20 pl of sample
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buffer and boiling for 5 min, resolved by 4%-12% SDS-PAGE, and analyzed by
immunoblotting as described (Kim et al., 2002). To observe gel mobility shifting in
DEPTOR, 8% Tris Glycine gels (Invitrogen) were used. For all other applications,
4-12% Bis-Tris gels (Invitrogen) were used. For immunoprecipitations of mTOR
containing complexes, cells were lysed in ice-cold CHAPS-containing lysis buffer
lacking added NaCI (40 mM HEPES [pH 7.4], 2 mM EDTA, 10 mM
pyrophosphate, 10 mM glycerophosphate, 0.3% CHAPS, and one tablet of
EDTA-free protease inhibitors [Roche] per 25 ml). Immunoprecipitates were
washed once each in the CHAPS lysis buffer and twice with CHAPS lysis buffer
containing 150 mM NaCI such that the immunopurified material would be rinsed
in a solution with a phyisiologically-relevant salt concentration. When specified,
the latter two washes contained 0 mM or 500 mM NaCI.
In Vitro Kinase Assay For mTORC1 and mTORC2 Activities
For kinase assays, immunoprecipitates were washed once in CHAPS lysis
buffer followed by two additional washes in CHAPS lysis buffer containing 150
mM NaCI. Immunoprecipitates were then washed twice in 25 mM HEPES (pH
7.4), 20 mM KCI. Kinase assays were performed as described (7).
cDNA Transfection-based Experiments
To examine the effects on mTOR signaling of DEPTOR overexpression,
500,000 HeLa; 300,000 p53-/- or rictor -/-, p53-/-; or 200,000 TSC2-/-, p53-/-
regularly passaged (every 2-3 days) cells were plated in 6 cm culture dishes in
DMEM/10%IFS. 12 hours later, cells were transfected with the pRK5-based
cDNA expression plasmids indicated in the figures in the following amounts: 2 Lg
for all FLAG tagged cDNAs and 200 ng of HA-GST S6k1 or Aktl. All cells were
lysed at 50-75% confluence 24 hours after transfection.
Gene Expression and Mutation Analysis in Human Cancers and Cancer Cell
Lines
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For quantification of DEPTOR, Integrin P7, and GAPDH mRNA expression
in HeLa, PC3, or 8226 cell lines, total RNA was isolated from cells grown in the
indicated conditions and reverse-transcription was performed. The resulting
cDNA was diluted in DNase-free water (1:25) before quantification by real-time
PCR. mRNA transcript levels were measured using Applied Biosystems 7900HT
Sequence Detection System v2.3 software. Data are expressed as the ratio
between the expression of DEPTOR or Integrin P7 and the housekeeping gene
GAPDH. The following primers were used for quantitative real-time PCR:
DEPTOR (H. sapiens):
Forward: TTTGTGGTGCGAGGAAGTAA
Reverse: CATTGCTTTGTGTCATTCTGG
GAPDH (H. sapiens):
Forward: CTCTCTGCTCCTCCTGTTCGAC
Reverse: TGAGCGATGTGGCTCGGCT
Integrin 07 (H. sapiens):
Forward: TGGAGCGCTGCCAGTCACCATT
Reverse: CGTCTGAAGTGAACACCAGCAGC
For meta-analysis of DEPTOR mRNA expression in human cancers,
"DEPDC6" was searched in NCBI GEO and Oncomine gene expression data
repositories. Only those studies where data from primary human tumors could
be compared with matched unaffected tissue were considered further. Fold
change in DEPTOR mRNA was measured by taking the quotient of the mean
level of DEPTOR mRNA in unaffected tissue versus that of the tumor sample.
Statistical significance was measured by one-tailed, unequal variance T test.
Only those studies with p<0.05 were included in the final analysis.
RNA isolation from primary Multiple Myelomas has been described (50).
Normalized DEPTOR mRNA expression was clustered according to the
translocation/Cyclin D groups classified in (32). The Multiple Myeloma gene
expression data used in this study was generated on an Affymetrix U133_Plus_2
platform and can be found in its entirety in the NCBI GEO database with the
140
following identifiers: GSE2658 for 559 newly diagnosed, untreated tumors and
GSE5900 for 22 normal plasma cells, 12 smoldering myeloma, and 44 MGUS.
Human Myeloma cell line mRNA data have been deposited in an MMRC
genomics portal website that is sponsored by the MMRF
(www.broad.mit.edu/mmqp).
PTEN mutation status in human cancer cell lines can be found at the
following URL: http://www.sanger.ac.uk/genetics/CGP/CellLines/.
Live Cell Imaging
8226 cells grown in 12 well dishes were imaged at 20x magnification using
a Canon Powershot 5 Megapixel digital camera.
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The Rag GTPases Bind Raptor and Mediate Amino Acid
Signaling to mTORC1
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Summary
The multiprotein mTORC1 protein kinase complex is the
central component of a pathway that promotes growth in response to
insulin, energy levels, and amino acids, and is deregulated in
common cancers. We find that the Ragproteins-a family of four related
small guanosine triphosphatases (GTPases)-interact with mTORC1 in an
amino acid-sensitive manner and are necessary for the activation of the
mTORC1 pathway by amino acids. A Rag mutant that is constitutively
bound to GTP interacted strongly with mTORC1, and its expression within
cells made themTORC1 pathway resistant to amino acid deprivation.
Conversely, expression of a GDP-bound Rag mutant prevented
stimulation of mTORC1 by amino acids. The Rag proteins do not directly
stimulate the kinase activity of mTORC1, but, like amino acids,
promote the intracellular localization of mTOR to a compartment that also
contains its activator Rheb.
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Introduction
The mTOR complex 1 (mTORC1) branch of the mammalian target of rapamycin
(mTOR) pathway is a major driver of cell growth in mammals and is deregulated in
many common tumors (1). It is also the target of the drug rapamycin, which has
generated considerable interest as an anticancer therapy. Diverse signals regulate the
mTORC1 pathway, including insulin, hypoxia, mitochondrial function, and glucose and
amino acid availability. Many of these are integrated upstream of mTORC1 by the
tuberous sclerosis complex (TSC1 -TSC2) tumor suppressor, which acts as an
important negative regulator of mTORC1 through its role as a guanosine triphosphatase
(GTPase)-activating protein (GAP) for Rheb, a small guanosine triphosphate (GTP)-
binding protein that potently activates the protein kinase activity of mTORC1 (2). Loss of
either TSC protein causes hyperactivation of mTORC1 signaling, even in the absence of
many of the upstream signals that are normally required to maintain pathway activity. A
notable exception is the amino acid supply, as the mTORC1 pathway remains sensitive
to amino acid starvation in cells lacking either TSC1 or TSC2 (3-5).
The mechanisms through which amino acids signal to mTORC1
remain mysterious. It is a reasonable expectation that proteins that signal the availability
of amino acids to mTORC1 are also likely to interact with it, but, so far, no good
candidates have been identified. Because most mTORC1 purifications rely on
antibodies to isolate mTORC1, we wondered if in previous work antibody heavy chains
obscured, during SDS-polyacrylamide electrophoresis (SDS-PAGE) analysis of purified
material, mTORC1 -interacting proteins of 45 to 55 kD. Indeed, using a purification
strategythat avoids this complication (6), we identified the 44-kD RagC protein as
copurifying with overexpressed raptor, the defining component of mTORC1 (Z-10).
RagC is a Ras-related small GTP-binding protein and one of four Rag proteins in
mammals (RagA, RagB, RagC, and RagD). RagA and RagB are very similar to each
other and are orthologs of budding yeast GtrI p, whereas RagC and RagD are similar
and are orthologs of yeast Gtr2p (1-3). In yeast and in human cells, the Rag and Gtr
proteins function as heterodimers consisting of one Gtrl p-like (RagA or RagB) and one
Gtr2p-like (RagC or RagD) component (14, 15). The finding that RagC copurifies
with raptor was intriguing to us because, in yeast, Gtrl p and Gtr2p regulatethe
144
intracellular sorting of the Gapi p amino acid permease (1) and microautophagy (17),
processes modulated by amino acid levels and the TOR pathway (8-20). The Gtr
proteins have been proposed to act downstream or in parallel to TORC1 in
yeast because their overexpression induces microautophagy even in the presence of
rapamycin, which normally suppresses it (17).
Results
To verify our identification of RagC as an mTORC1 -interacting protein, we
expressed raptor with different pairs of Rag proteins in human embryonic kidney (HEK)-
293T cells. Consistent with the Rags functioning as heterodimers, raptor copurified with
RagA-C orRagB-C, but not with RagA-B or the Rap2A control protein (Fig. 1A).
Because the nucleotide loading state of most GTP-binding proteins regulates their
functions, we generated RagB, RagC, and RagD mutants predicted (14, 16, 17) to be
restricted to the GTP- or guanosine diphosphate (GDP)-bound conformations (for
simplicity, we call these mutants RagBGTP, RagBGDP, etc.) (6). When expressed with
mTORC1 components, Rag heterodimers containing RagBGTP immunoprecipitated
with more raptor and mTOR than did complexes containing wild-type RagB or
RagBGDP (Fig. 1 B). The GDP-bound form of RagC increased the amount of copurifying
mTORC1, so that RagBGTP-CGDP recovered the highest amount of endogenous
mTORC1 of any heterodimer tested (Fig. 1 C). Giving an indication of the strength of the
mTORC1-RagBGTP-CGDP association, in this same assay, we could not detect
coimmunoprecipitation of mTORC1 with Rheb1 (Fig. 1 C), an established interactor and
activator of mTORC1 (1). When expressed alone, raptor, but not mTOR, associated
with RagBGTPDGDP, which suggests that raptor is the key mediator of the Rag-
mTORC1 interaction (Fig. 1 D). Consistent with this, rictor, an mTOR-interacting protein
that is only part of mTORC2 (1), did not copurify with any Rag heterodimer (Fig. 1C and
fig. S1). Last, highly purified raptor interacted in vitro with RagB-D and, to a larger
extent, with RagBGTP-DGDP, which indicates that the Rag-raptor interaction is most
likely direct (Fig. 1 E).
We tested whether various Rag heterodimers affected the regulation of the
mTORC1 pathway within human cells. In HEK-293T cells, expression of the RagBGTP-
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DGDP heterodimer, which interacted strongly with mTORC1, not only activated the
pathway, but also made it insensitive to deprivation for leucine or total amino acids, as
judged by the phosphorylation state of the mTORC1 substrate T389 of S6K1 (Fig. 2, A
and B). The wild-type RagB-C heterodimer had milder effects than RagB-GTPCGDP,
making the mTORC1 pathway insensitive to leucine deprivation, but not to the stronger
inhibition caused by total amino acid starvation (Fig. 2, A and B). Expression of
RagBGDPDGTP, a heterodimer that did not interact with mTORC1 (Fig. 1, C and D),
had dominant negative effects, as it eliminated S6K1 phosphorylation in the presence,
as well as absence, of leucine or amino acids (Fig. 2, A and B). Expression of
RagBGDP alone also suppressed S6K1 phosphorylation (fig. S2). These results
suggest that the activity of themTORC1 pathway under normal growth conditions
depends on endogenous Rag function.
To verify the actions of the Rags in a more physiological setting than that
achieved by transient cDNA transfection, we generated HEK- 293T cell lines stably
expressing Rheb1, RagB, or RagBGTP (attempts to generate lines stably expressing
RagBGDP failed). Under normal growth conditions, these cells were larger than control
cells and had higher levels of mTORC1 pathway activity (Fig. 3A). Unlike transient
Rheb1 overexpression (Fig. 2, A and B), stable expression did not make the mTORC1
pathway insensitive to leucine or amino acid starvation (Fig. 3, B and C), consistent with
evidence that transiently overexpressed Rheb may have nonphysiological
consequences on amino acid signaling to mTORC1 (4, 5). Stable expression of a
Rheb1 GTP mutant was also unable to make the mTORC1 pathway resistant to amino
acid deprivation (fig. S3). In contrast, stable expression of RagBGTP eliminated the
sensitivity of the mTORC1 pathway to leucine or total amino acid withdrawal, whereas
that of wild-type RagB overcame sensitivity to leucine but not to amino acid starvation
(Fig. 3, B and C). Thus, transient or stable expression of the appropriate Rag mutants
is sufficient to put the mTORC1 pathway into states that mimic the presence or absence
of amino acids.
To determine if the Rag mutants affect signaling to mTORC1 from inputs besides
amino acids, we tested whether in RagBGTP-expressing cells themTORC1 pathway
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was resistant to other perturbations known to inhibit it. This was not the case, as
oxidative stress, mitochondrial inhibition, or energy deprivation still reduced S6K1
phosphorylation in these cells (fig. S4).Moreover, in HEK-293E cells, expression of
RagBGTP-DGDP did not maintain mTORC1 pathway activity in the absence of insulin
(Fig. 2C). Expression of the dominant-negative RagBGDP-DGTP heterodimer did,
however, block insulin-stimulated phosphorylation of S6K1 (Fig. 2C), as did amino acid
starvation (Fig. 2D). Thus, although RagBGTP expression mimics amino acid
sufficiency, it cannot substitute for other inputs that mTORC1 normally monitors. This
evidence for a primary role of the Rag proteins in amino acid signaling to mTORC1
raised the question of where, within the pathway that links amino acids to mTORC1, the
Rag proteins might function. The existence of the Rag-mTORC1 interaction (Fig. 1), the
effects on amino acid signaling of the Rag mutants (Figs. 2 and 3), and the sensitivity to
rapamycin of the S6K1 phosphorylation induced by RagBGTP (fig. S4), strongly
suggested that the Rag proteins function downstream of amino acids and upstream
of mTORC1. To verify this, we took advantage of the established finding that
cycloheximide reactivates mTORC1 signaling in cells starved for amino acids by
blocking protein synthesis and thus boosting the levels of the intracellular amino acids
sensed by mTORC1 (21-23). Thus, if the Rag proteins act upstream of amino acids,
cycloheximide should overcome the inhibitory effects of the RagBGDP-CGTP
heterodimer on mTORC1 signaling, but if they are downstream, cycloheximide should
not reactivate the pathway. The results were clear: cycloheximide treatment of cells
reversed the inhibition of mTORC1 signaling caused by leucine deprivation, but not that
caused by expression of RagBGDP-CGTP (fig. S5). Given the place- ment of the Rag
proteins downstream of amino acids and upstream of mTORC1, we determined whether
amino acids regulate the RagmTORC1 interaction within cells. Initial tests
using transiently coexpressed Rag proteins and mTORC1 components did not reveal
any regulation of the interaction. Because we reasoned that pronounced overexpression
might overcome the normal regulatory mechanisms that operate within the cell, we
developed an assay (6), based on a reversible chemical cross-linker, that allows us to
detect the interaction of stably expressed FLAG-tagged Rag proteins with endogenous
mTORC1. With this approach, we readily found that amino acids, but not
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insulin, promote the Rag-mTORC1 interaction when we used either FLAG-tagged RagB
or RagD to isolate mTORC1 from cells (Fig. 3D and fig. S6A). As the GTP-loading state
of the Rag proteins also regulates the Rag-mTORC1 interaction (Fig. 1), we determined
whether amino acids modulate the amount of GTP bound to RagB. Indeed, amino acid
stimulation of cells increased the GTP loading of RagB (Fig. 3E). Consistent with this,
amino acids did not further augment the already high level of interaction between
mTORC1 and the RagBGTP mutant (Fig. 3D).
To determine whether the Rag proteins are necessary for amino acids to activate
them TORC1 pathway, we used combinations of lentivirally delivered short hairpin
RNAs (shRNAs) to suppress RagA and RagB or RagC and RagD at the same time.
Loss of RagA and RagB also led to the loss of RagC and RagD and vice versa, which
suggests that, within cells, the Rag proteins are unstable when not in heterodimers (Fig.
3F). In cells with a reduction in the expression of all the Rag proteins, leucine stimulated
phosphorylation of S6K1 was strongly reduced (Fig. 3G). The role of the Rag proteins
appears to be conserved in Drosophila cells as double-stranded RNA-mediated
suppression of the Drosophila orthologs of RagB or RagC eliminated amino acid-
induced phosphorylation of dS6K (Fig. 3H). Consistent with amino acids being
necessary for activation of mTORC1 by insulin, a reduction in Rag expression
also suppressed insulin-stimulated phosphorylation of S6K1 (fig. S6B). Thus, the
Rag proteins appear to be both necessary and sufficient for mediating amino acid
signaling to mTORC1.
Unlike Rheb (24, 25), the Rag heterodimers did not directly stimulate the kinase
activity of mTORC1 in vitro (fig. S7), so we considered the possibility that the Rag
proteins regulate the intracellular localization of mTOR. mTOR is found on the
endomembrane system of the cell, including the endoplasmic reticulum, Golgi
apparatus, and endosomes (26, 27). The intracellular localization of endogenous
mTOR, as revealed with an antibody that we validated recognizes mTOR in
immunofluorescence assays (fig. S8), was strikingly different in cells deprived of amino
acids than in cells starved and briefly restimulated with amino acids (Fig. 4A and fig.
S11) or growing in fresh complete media (fig. S9). In starved cells, mTOR was in tiny
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puncta throughout the cytoplasm, whereas in cells stimulated with amino acids for as
little as 3 min, mTOR localize to the perinuclear region of the cell, to
large vesicular structures, or to both (Fig. 4A). Rapamycin did not block the change in
mTOR localization induced by amino acids (Fig. 4A), which indicated that it is not a
consequence of mTORC1 activity but rather may be one of the mechanisms that
underlies mTORC1 activation. The amino acid-induced change in mTOR localization
required expression of the Rag proteins and of raptor (Fig. 4, B and C), and amino
acids also regulated the localization of raptor (fig. S10).
In cells overexpressing RagB, Rheb1, or Rheb1 GTP, mTOR behaved as in
control cells, its localization changing upon amino acid stimulation from small puncta to
the perinuclear region and vesicular structures (Fig. 4D). In contrast, in cells
overexpressing the RagBGTP mutant that eliminates the amino acid sensitivity of the
mTORC1 pathway, mTOR was already present on the perinuclear and vesicular
structures in the absence of amino acids, and became even more localized to them
upon the addition of amino acids (Fig. 4D). Thus, there is a correlation, under amino
acid-starvation conditions, between the activity of the mTORC1 pathway and the
subcellular localization of mTOR, which implies a role for Rag-mediated mTOR
translocation in the activation of mTORC1 in response to amino acids.
We failed to find an established marker of the endomembrane system that
colocalized with mTOR in amino acid-starved cells. However, in cells stimulated with
amino acids, mTOR in the perinuclear region and on the large vesicular structures
overlapped with Rab7 (Fig. 5A), which indicated that a substantial fraction of mTOR
translocated to the late endosomal and lysosomal compartments in amino acid-replete
cells. In cells expressing RagBGTP, mTOR was present on the Rab7-positive structures
even in the absence of amino acids (Fig. 5B). The perinuclear region and vesicular
structures on which mTOR appears after amino acid stimulation are similar to the Rab7-
positive structures where green fluorescent protein (GFP)- tagged Rheb localizes in
human cells (28, 29). Unlike mTOR, however, amino acids did not appreciably affect the
localization of Rheb, as GFP-Rhebl colocalized with Discosoma red fluorescent protein
(DsRed)-labeled Rab7 (DsRed- Rab7) in the presence or absence of amino acids (Fig.
5C). Unfortunately, it is currently not possible to compare, in the same cells, the
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localization of endogenous mTOR with that of Rheb, because the signal for GFP-Rheb
or endogenous Rheb is lost after fixed cells are permeabilized to allow access to
intracellular antigens (28, 29). Nevertheless, given that both mTOR and Rheb are
present in Rab7-positive structures after amino acid stimulation, we propose that amino
acids might control the activity of the mTORC1 pathway by regulating, through the Rag
proteins, the movement of mTORC1 to the same intracellular compartment that
contains its activator Rheb (see model in Fig. 5D). This would explain why activators of
Rheb, like insulin, do not stimulate the mTORC1 pathway when cells are deprived of
amino acids and why Rheb is necessary for amino acid-dependent mTORC1 activation
(4) (fig. S12). When Rheb is highly overexpressed, some might become mislocalized
and inappropriately encounter and activate mTORC1, which could explain why Rheb
overexpression, but not loss of TSC1 or TSC2, makes the mTORC1 pathway
insensitive to amino acids (4, 5).
Discussion
In conclusion, the Rag GTPases bind raptor, are necessary and sufficient to
mediate amino acid signaling to mTORC1, and mediate the amino acid-induced
relocalization of mTOR within the endomembrane system of the cell. Given the
prevalence of cancer-linked mutations in the pathways that control mTORC1
(1), it is possible that Rag function is also deregulated in human tumors.
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Figure legends
Fig. 1. Interaction of Rag heterodimers with recombinant and endogenous mTORC1 in
a manner that depends on the nucleotide binding state of RagB. In (A) through (D)
HEK-293T cells were transfected with the indicated cDNAs in expression vectors, cell
lysates were prepared, and lysates and hemagglutinin (HA)- or FLAG-tagged
immunoprecipitates were analyzed by immunoblotting for the amounts of the specified
recombinant or endogenous proteins. (E) In vitro binding of purified FLAG-raptor with
wild-type RagB-D or RagBGTP-DGDP
Fig. 2. Effects of overexpressed RagB GTP-containing heterodimers on the mTORC1
pathway and its response to leucine, amino acids, or insulin. Effects of expressing the
indicated proteins on the phosphorylation state of coexpressed S6K1 in response to
deprivation and stimulation with (A) leucine, (B) total amino acids, or (C) insulin. Cell
lysates were prepared from HEK-293T cells deprived for 50 min of serum and of (A)
leucine or (B) amino acids and, then, where indicated, stimulated with leucine or amino
acids for 10 min. HEK-293E cells (C) were deprived of serum for 50 min and, where
indicated, stimulated with 150 nM insulin for 10 min. Lysates and FLAG-
immunoprecipitates were analyzed for the levels of the specified proteins and the
phosphorylation state of S6K1. (D) Effects of amino acid deprivation on insulin-mediated
activation of mTORC1. HEK-293E cells were starved for serum and amino acids or just
serum for 50 min, and where specified, stimulated with 10 or 150 nM insulin. Cell
lysates were analyzed for the level and phosphorylation state of S6K1.
Fig. 3. Insensitivity of the mTORC1 pathway to amino acid deprivation in cells stably
expressing RagBGTP. (A) Cell size distributions (graphs) and S6K1 phosphorylation
(immunoblot) of cells stably expressing RagB, Rheb1, RagGTP, or Rap2A. Mean cell
diameters (pm) ± SD are Rap2A, 16.05 ± 0.07; Rhebl, 16.79 ± 0.06; RagB, 16.40 ±
0.08; and RagBGTP, 16.68 ± 0.06 (n = 4 and P < 0.0008 for all comparisons to Rap2A-
expressing cells). HEK-293T cells transduced with lentiviruses encoding the specified
proteins were deprived for 50 min for serum and (B) leucine or (C) total amino acids,
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and, where indicated, restimulated with leucine or amino acids for 10 min. Cell lysates
were analyzed for the levels of the specified proteins and the phosphorylation state of
S6K1. (D) Amino acid-stimulated interaction of the Rag proteins with mTORC1. HEK-
293T cells stably expressing FLAG-tagged RagB, RagD, or RagBGTP were starved for
amino acids and serum for 50 min and, where indicated, restimulated with amino acids
for 10 min. Cells were then processed with a chemical cross-linking assay, and cell
lysates and FLAG immunoprecipitates were analyzed for the amounts of the indicated
proteins. (E) Effects of amino acid stimulation on GTP loading of RagB. Values are
means ± SD for n = 3 (P < 0.02 for increase in GTP loading caused by amino acid
stimulation). (F) Abundance of RagA, RagB, RagC, and RagD in HeLa cells expressing
the indicated shRNAs. (G) S6K1 phosphorylation in HeLa cells expressing shRNAs
targeting RagC and RagD. Cells were deprived of serum and leucine for 50 min, and,
where indicated, were restimulated with leucine for 10 min. (H) Effects of double-
stranded RNA (dsRNA)-mediated knockdowns of Drosophila orthologs of RagB or
RagC on amino acid-induced phosphorylation of dS6K.
Fig. 4. Rag-dependent regulation by amino acids of the intracellular localization of
mTOR. (A) HEK-293T cells were starved for serum and amino acids for 50 min or
starved and then restimulated with amino acids for the indicated times in the presence
or absence of rapamycin. Cells were then processed in an immunofluorescence assay
to detect mTOR (green), costained with 4',6'-diamidino-2-phenylindole (DAPI) for DNA
content (blue), and imaged. Of these cells, 80 to 90% exhibited the mTOR localization
pattern shown. (B) and (C) mTOR localization in HEK-293T cells expressing the
indicated shRNAs and deprived and restimulated with amino acids as in (A).
Immunoblot of raptor expression levels. (D) mTOR localization in HEK-293T cells stably
expressing RagB, Rheb1, RagBGTP, or RhebIGTP and deprived and restimulated with
amino acids as in (A).
Fig. 5. Amino acids promote the localization of mTOR to a Rab7-positive compartment
that also contains Rheb. (A) mTOR and Rab7 localization in cells deprived or stimulated
with amino acids. HEK-293T cells transiently transfected with a cDNA for DsRed-Rab7
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were starved for serum and amino acids for 50 min and, where indicated, stimulated
with amino acids for 10 min. Cells were then processed to detect mTOR (green), Rab7
(red), and DNA content (blue), and imaged. Two examples are shown of mTOR
localization in the presence of amino acids. (B) HEK-293T cells stably expressing
RagBGTP and transiently transfected with a cDNA for DsRed-Rab7 were treated and
processed as in (A). (C) Rheb1 and Rab7 localization in cells deprived or stimulated
with amino acids. HEK-293T cells transiently transfected with 1 to 2 ng of cDNAs for
GFP-Rhebl and DsRed-Rab7 were treated as in (A), processed to detect Rheb1
(green), Rab7 (red), and DNA content (blue), and imaged. (D) Model for role of Rag
GTPases in signaling amino acid availability to mTORC1.
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Fig. SI. Rag heterodimers do not interact with rictor. HEK-293T cells were transfected
with the indicated cDNAs in expression vectors, cell lysates prepared, and lysates and
HA-immunoprecipitates analyzed for the levels of the specified proteins. This experi-
ment was performed side-by-side with that shown in Figure 1A and is displayed here
for space reasons.
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Fig S2. Expression of RagBGDP alone suppresses endogenous mTORC1 signaling.
Cell lysates were prepared from HEK-293T cells transfected with the indicated cDNAs
and deprived for 50 minutes of serum and amino acids, and where indicated, stimu-
lated with amino acids for 10 minutes. Lysates and FLAG-immunoprecipitates were
analyzed for the levels of the specified proteins and the phosphorylation state of S6K1.
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Fig S3. Stable expression of Rheb1 or Rheb1 GTP does not eliminate the sensitivity of
the mTORCI to amino acids. HEK-293T cells stably expressing the indicated proteins
were deprived of serum and amino acids for 50 minutes, and where indicated, stimulat-
ed with amino acids for 10 minutes. Lysates were analyzed for the levels of the speci-
fied proteins and the phosphorylation state of S6K1.
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Fig. S4. Effects of various insults on mTORC1 signaling in cells expressing RagBGTP.
HEK-293T cells stably expressing Rap2A or RagBGTP and growing in full media were un-
treated (control), or deprived of amino acids for 30 minutes, or treated for 30 minutes with
20 nM rapamycin, 100 mM 2-deoxyglucose (energy deprivation), 1 mM H202 (oxidative
stress), or 1 [M valinomycin (mitochondrial proton gradient inhibition). Cell lysates were
prepared and analyzed for the levels of the specified proteins and the phosphorylation state
of S6K1.
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Fig. S5. Inhibition of protein synthesis with cycloheximide does not prevent RagBGDP.CGTP
from inhibiting the mTORC1 pathway. HEK-293T cells were transfected with the indicated
cDNAs in expression vectors, and starved for 50 minutes for serum and leucine, and, where
indicated, stimulated with leucine or 10 [tg/ml cycloheximide for 20 minutes. Cell lysates
and FLAG-immunoprecipitates were analyzed for the levels of the specified proteins and the
phosphorylation state of S6K1.
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Fig. S6. (A) Insulin does not increase the interaction between mTORC1 and the Rag
proteins. Hela cells stably expressing FLAG-RagD were starved for serum for 50
minutes and, where indicated, stimulated with 100 nM insulin for 10 minutes. Cells
were then processed with a chemical cross-linking assay and cell lysates and FLAG-
immunoprecipitates analyzed for the levels of the indicated proteins. (B) Knockdowns
of RagC and RagD suppress insulin-stimulated phosphorylation of S6K1. HeLa cells
expressing shRNAs targeting RagC and RagD were prepared as in Figure 3. Cells
were deprived of serum for 50 minutes, and, where indicated, re-stimulated with 100
nM insulin for 10 minutes. Cell lysates were prepared and analyzed for the levels and
phosphorylation state of S6K1.
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Fig. S7. Rag heterodimers do not activate the in vitro kinase activity of mTORC1 in
assays in which Rheb1 does. In vitro kinase assays containing 300 ng of each of the
indicated proteins or Rag heterodimers were performed as described in the methods
using mTORC1 immunopurified from HEK-293T cells with a raptor antibody. Rap2A,
Rheb1, and the Rag heterodimers were expressed in HEK-293T cells and purified
under conditions where the endogenous nucleotides remained bound.
Figure S8
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Fig. S8. Validation that an mTOR antibody detects mTOR in an immunofluorescence
assay. HEK-293T cells expressing a control shRNA (sh-Luc) or an shRNA targeting
mTOR (sh-mTOR) that is known to reduce mTOR expression (see methods) were
processed in an immunofluorescence assay with an mTOR antibody (green) and co-
stained with DAPI for DNA content (blue).
Figure S9
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Fig. S9. Localization of mTOR in HEK-293T cells growing in normal growth media.
Where indicated, cells were deprived of amino acids for 50 minutes. For cells growing
in normal media, the media was replaced with fresh media 1 hour before process-
ing. Cells were processed in an immunofluorescence assay with an mTOR antibody
(green) and imaged.
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Fig. S10. Raptor localization in cells deprived or stimulated with amino acids. HEK-
293T cells stably expressing FLAG-raptor were deprived of serum and amino acids
for 50 minutes, and where indicated, stimulated with amino acids for 10 minutes. Cells
were processed in an immunofluorescence assay with a FLAG antibody (green), co-
stained with DAPI for DNA content (blue), and imaged.
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Fig. S11. mTOR localization in HeLa cells starved and stimulated for amino acids as
in Figure 4. Cells were processed in an immunofluorescence assay with an mTOR
antibody (green) and co-stained with DAPI for DNA content (blue).
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Fig. S12. Rheb is necessary for leucine to activate the mTORC1 pathway. (A) Valida-
tion that the two independent shRNAs targeting Rheb1 reduce its expression. Immuno-
blot analysis of Rheb1 in HEK-293T cells expressing the indicated shRNAs. (B) Cells
from (A) were deprived of serum and leucine for 50 minutes, and, where indicated,
re-stimulated with leucine for 10 minutes. Cell lysates were prepared and analyzed for
the levels and phosphorylation state of S6K1.
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Experimental procedures
Materials
Reagents were obtained from the following sources: antibody to raptor from Upstate/Millipore; HRP-
labeled anti-mouse, anti-goat, and anti-rabbit secondary antibodies from Santa Cruz Biotechnology; antibodies
to phospho-T389 S6K1, S6K1, RagA, RagB, RagC and RagD, mTOR, rictor, phospho-T398 dS6K, and the
myc epitope from Cell Signaling Technology; an antibody to the HA tag from Bethyl laboratories; an antibody
to RagB from Novus Biologicals; Cellulose PEI TLC plates, RPMI, FLAG M2 affinity gel, FLAG M2 antibody,
ATP, cycloheximide, valinomycin, H202, 2-deoxyglucose, amino acids, and human recombinant insulin from
Sigma Aldrich; DSP, protein G-sepharose, and immobilized glutathione beads from Pierce; DMEM from SAFC
Biosciences; FuGENE 6 and Complete Protease Cocktail from Roche; Alexa 488 or Texas-Red-X conjugated
secondary antibodies, Schneider's media, Express Five Drosophila-SFM, and Inactivated Fetal Calf Serum
(IFS) from Invitrogen; and amino acid-free RPMI, amino acid- and phosphate- free RPMI, and amino acid-
free Schneider's media from US Biological. The dS6K antibody was a generous gift from Mary Stewart (North
Dakota State University).
Cell lines and tissue culture
HEK-293E, HEK-293T, and HeLa cells were cultured in DMEM with 10% IFS. In HEK-293E, but not
HEK-293T, cells the mTORC1 pathway is strongly regulated by serum and insulin (1). The HEK-293E cell line
was kindly provided by John Blenis (Harvard Medical School).
Leucine or amino acid starvation and stimulation of cells
Almost confluent cultures in 10 cm culture plates were rinsed with leucine-free RPMI once, incubated
in leucine-free RPMI for 50 minutes, and stimulated with 52 pg/ml leucine for 10 minutes. For amino acid
starvation, cells in 10 cm culture dishes or coated glass cover slips were rinsed with and incubated in amino
acid-free RPMI for 50 minutes, and stimulated with a 1oX amino acid mixture for 3-30 minutes as indicated
in the figures. After stimulation, the final concentration of amino acids in the media was the same as in RPMI.
Cells were processed for biochemical or immunofluorescence assays as described below. The 1OX amino acid
mixture was prepared from individual amino acid powders.
Cell lysis, immunoprecipitations, and kinase assays
Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (40 mM HEPES [pH 7.4], 2
mM EDTA, 10 mM pyrophosphate, 10 mM glycerophosphate, and 0.3% CHAPS or 1% Triton X-100, and one
tablet of EDTA-free protease inhibitors (Roche) per 25 ml). The soluble fractions of cell lysates were isolated
by centrifugation at 13,000 rpm for 10 minutes by centrifugation in a microfuge. For immunoprecipitations,
primary antibodies were added to the lysates and incubated with rotation for 1.5 hours at 4*C. 60 pl of a
50% slurry of protein G-sepharose was then added and the incubation continued for an additional 1 hour.
Immunoprecipitates were washed three times with lysis buffer containing 150 mM NaCl. Immunoprecipitated
proteins were denatured by the addition of 20 pl of sample buffer and boiling for 5 minutes, resolved by
8%-16% SDS-PAGE, and analyzed by immunoblotting as described (2). For FLAG and GST purifications,
immobilized glutathione or Flag M2 affinity resins were washed with lysis buffer 3 times. 20 pl of a 50%
slurry of the resins was then added to pre-cleared cell lysates and incubated with rotation for 2 hours at 4*C.
Finally, the beads were washed 3 times with lysis buffer containing 150 mM NaCl. For elution of FLAG-tagged
proteins, beads were incubated in elution buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 0.5% CHAPS, 50
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pg/pl FLAG peptide) for 30 min at 30 *C. Elution of proteins from glutathione beads and kinase assays were
performed as previously described (1).
cDNA manipulations and mutagenesis
The cDNAs for human RagA, RagB, RagC and RagD were obtained from Open Biosystems. The
cDNAs were amplified by PCR and the products were subcloned into Sal I and Not I sites of HA-GST-pRK5,
HA-pRK5 and FLAG-pRK5. The cDNAs were mutagenized using the QuickChange XLII mutagenesis kit
(Stratagene) with oligonucleotides obtained from Integrated DNA Technologies. All constructs were verified
by DNA sequencing. The Rag mutants used in our experiments are: RagBGTP = Q99L RagB; RagBGDP = T54L
RagB; RagCGTP = Q120L RagC; RagCGDP = S75L RagC; RagDGTP = Q121L RagD; and RagDGDP = S77L RagD.
Rheb1GTP = Q64L Rheb1.
FLAG-tagged wild type and mutant RagB and RagD cDNAs or GFP-tagged Rheb1 were amplified by
PCR and cloned into the Age I and Bam HI sites of a modified pLKO.1 vector having a CMV promoter (pLJM1).
After sequence verification, these plasmids were used, as described below, in transient cDNA transfections or
to produce the lentiviruses needed to generate cell lines stably expressing the proteins. An expression plasmid
encoding DsRed-Rab7 was obtained from Addgene.
cDNA transfection-based experiments
For co-transfection experiments, 2 million HEK-293T or HEK-293E cells were plated in 10 cm culture
dishes. 24 hours later, cells were transfected with the prk5-based cDNA expression plasmids indicated in the
figures in the following amounts: 500 ng myc-mTOR (3); 50 ng myc- or HA-raptor (2); 100 ng myc-rictor (4);
100 ng HA-GST-, HA- or FLAG-tagged Rap2A (1); 100 ng HA-GST-, HA-, or FLAG-tagged Rhebl (1); 100 ng
HA-tagged RagA; 100 ng HA-GST- or HA-tagged RagB; 100 ng HA-GST- or HA-tagged RagC; 100 ng HA-
GST- or FLAG-tagged RagD; 1 ng of FLAG-S6K1. Transfection mixes were taken up to a total of 2 pg of DNA
using empty pRK5.
In-cell cross-linking assay
DSP was dissolved in DMSO to a final concentration of 250 mg/mI to make a 250X stock solution for
the in-cell cross-linking assay. HEK-293T cells stably expressing FLAG-tagged RagB, RagBGTP, or RagD and
growing in 10 cm culture dishes were starved for amino acids or starved and then stimulated as described
above. At the end of the starvation or stimulation period, cells were rinsed once with cold PBS and incubated
with 4 ml of PBS containing 1 mg/ml DSP for 7 minutes at room temperature. The cross-linking reaction was
quenched by adding 1 M Tris pH 8.5 to a final concentration of 100 mM followed by a 1-minute incubation. The
cells were rinsed once with ice cold PBS, and lysed with RIPA buffer (40 mM HEPES [pH 7.4], 2 mM EDTA, 10
mM pyrophosphate, 10 mM glycerophosphate, 1% sodium deoxycholate, 1% NP40, 0.1% SDS, and one tablet
of EDTA-free protease inhibitors per 25 ml). FLAG-immunoprecipitates were prepared as described above.
Identification of RagC as a raptor-associated protein
FLAG-raptor was immunoprecipitated with the FLAG M2 affinity gel from 30 million HEK-293T cells
stably expressing FLAG-raptor. Proteins eluted with the FLAG peptide from the affinity matrix were resolved by
SDS-PAGE, stained with silver, and the 45-55 kD region of the gel excised and digested with trypsin overnight.
The resulting peptides were separated by liquid chromatography (NanoAcquity UPLC, Waters) using a self-
packed Jupiter 3 micron C18 column. The eluting peptides were mass analyzed prior to collisionally induced
dissociation (CID) using a ThermoFisher LTQ linear ion trap mass spectrometer equipped with a nanospray
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source. Selected mass values from the MS/MS spectra were used to search the human segment of the NCBI
non-redundant protein database using Xcalibur Mass Spectrometry software (Thermo Fischer Scientific). In 4
independent purifications of FLAG-raptor performed as above, this procedure led to the identification of a total
of 20 peptides matching RagC that were not present in control FLAG-tubulin samples.
Cell size determinations
To measure cell size, 2 million cells were plated into 10 cm culture dishes. 24 hours later the cells were
harvested by trypsinization in a 4 ml volume, diluted 1:20 with counting solution (Isoton |1 Diluent, Beckman
Coulter), and cell diameters determined using a particle size counter (Coulter Z2, Beckman Coulter) with
Coulter Z2 AccuComp software.
Mammalian lentiviral shRNAs
TRC lentiviral shRNAs (5) targeting RagA, RagB, RagC and RagD were obtained from Sigma. The
TRC number for each shRNA is as follows:
Human RagA shRNA #1: TRCN0000047305
Human RagA shRNA #2: TRCN0000047307
Human RagB shRNA #1: TRCN0000047308
Human RagB shRNA #2: TRCN0000047311
Human RagC shRNA #1: TRCN0000072874
Human RagC shRNA#2: TRCN0000072877
Human RagD shRNA#1: TRCN0000059533
Human RagD shRNA #2: TRCN0000059534
The shLuc and shGFP control shRNAs and the shRNAs targeting mTOR and raptor are previously
described and validated (6). Lentiviral shRNAs targeting Rheb1 were cloned into LKO.1 vector as described
(6). The target sequences for the Rheb1 shRNAs are:
Human Rheb1 shRNA#1: CCTCAGACATACTCCATAGAT
Human Rheb1 shRNA#2: TTATGTTGGTTGGGAATAAGA
shRNA-encoding plasmids were co-transfected with Delta VPR envelope and CMV VSV-G packaging
plasmids into actively growing HEK-293T cells using FuGENE 6 transfection reagent as previously described
(6, 7). Virus-containing supernatants were collected 48 hours after transfection, filtered to eliminate cells
and target cells were infected in the presence of 8 pg/ml polybrene. 24 hours later, cells were selected with
puromycin and analyzed on the 2 nd or 3rd day after infection.
In vitro Rag-raptor binding assay
2 million HEK-293T cells were plated into 10 cm culture dishes. 24 hours later, the cells were
transfected with 2 pg HA-GST-Rap2a, 2 pg HA-GST-Rhebl, or 2 pg HA GST-RagB together with 2 pg of HA
GST-RagC (wild type or Rag mutants as indicated). 2 days after transfection, the cells were lysed in Rheb
lysis buffer containing 1 % Triton X-1 00 (1), and cleared lysates were incubated with glutathione beads for 1.5
hours at 4*C with rotation. The beads were washed 3 times with lysis buffer and two times with Rheb storage
buffer (1). 1/4 of the glutathione beads were incubated with 300 ng of FLAG-raptor in Rheb lysis buffer with
0.3% CHAPS for 30 min at 4*C with rotation. The glutathione beads were washed twice with Rheb lysis buffer
containing 0.3% CHAPS and proteins were denatured by the addition of 20 pl of sample buffer and boiling
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for 5 minutes and analyzed by SDS-PAGE and immunoblotting. FLAG-raptor was purified from HEK-293T
cells stably expressing FLAG-raptor. Following the affinity-tag purification, the protein was further purified as
described (1) by gel filtration using a Superose 6 10/300GL column (GE Healthcare) to obtain FLAG-raptor that
by silver and coomasie staining was 99% pure.
Determination of guanyl nucleotide binding state of RagB in cells
Determination of the guanyl nucleotides bound to RagB in cells was performed essentially as previously
described for Rheb (8). HEK-293T cells were cultured in fibronectin coated 6-well dishes until confluent,
rinsed once with phosphate-and serum-free DMEM, and then incubated in phosphate-and serum-free DMEM
containing 1 mCi 32P orthophosphate (Perkin Elmer) for 4 hours. After 4 hours, cells were rinsed once with
serum-, amino acid-, and phosphate-free RPMI, incubated with serum-, amino acid-, and phosphate-free
media containing 1 mCi 32P orthophosphate for 50 minutes, and stimulated with amino acids as described
above. After rinsing with ice-cold PBS, cells were lysed in 0.5 ml lysis buffer (50 mM HEPES KOH (pH 7.4),
100 mM NaCl, 1 mM KH2PO4, 1 mM ATP, 100 pM GDP, 100 pM GTP, 5 mM MgCl2, 1% Triton X-100), and
the lysate microcentrifuged for 10 minutes at 13,000 rpm at 40C. The supernatant was incubated with 15 pl of
RagB antibody (Novus Biologicals) for 1 hour at 40C. 20 pl of protein G beads were added to the lysates and
the incubation continued for another 45 minutes. The beads were washed 8 times with wash buffer (50 mM
HEPES KOH [pH 7.4], 500 mM NaCl, 5 mM MgCl2, 0.5% Triton X-100, 0.005% SDS) and bound nucleotides
were eluted in 23 pi of elution buffer (10 mM EDTA, 2 mM DTT, 0.2% SDS, 0.5 mM GDP, 0.5 mM GTP) at
60 0C for 10 minutes. 15 pl of the eluate was transferred to a clean tube. 60 pl of methanol and then 30 pl
of chloroform were added to the tube, each addition followed by brief vortexing and microcentrifugation.
After the addition of 45 pl of water, the samples were vortexed vigorously, microcentrifuged for 1 minute at
13,000 rpm and the aqueous phase transferred to a clean tube. Using a speedvac the samples were dried
and then re-suspended in 15 pl of deionized water. Samples were spotted on PEI cellulose TLC plates and
the plates developed with 1.2 mM ammonium formate and 0.8 mM HCI, and the radioactivity detected with a
phosphoimager. After background subtraction, the intensities of the GTP and GDP spots were determined. The
percent of GTP nucleotide was calculated using the following formula: [(GTP/3)/((GTP/3) + (GDP/2))] X 100%.
Immunofluorescence assays
150,000 HEK-293T cells were plated on fibronectin-coated glass coverslips in 12-well tissue culture
plates. 24 hours later cells were starved for and stimulated with amino acids as described above, rinsed with
PBS once and fixed for 5 minutes with 4% paraformaldehyde in PBS warmed to 370C. The coverslips were
rinsed twice with PBS and permealized with 0.2% Triton X-100 in PBS for 15 minutes. After rinsing twice
with PBS, the coverslips were blocked for one hour in blocking buffer (0.25% BSA in PBS) and incubated
with primary antibody in blocking buffer overnight at 4*C, rinsed twice with blocking buffer and incubated
with secondary antibodies (diluted in blocking buffer 1:1000) for one hour at room temperature in dark. The
coverslips were mounted on glass slides using Vectashield (Vector Laboratories) and imaged with a 63X
objective using epifluorescence microscopy.
Where indicated, 1-2 ng of plasmids encoding GFP-Rheb1 or dsRed-Rab7 were transfected per well of
a 12-well dish.
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Drosophila cell experiment
dsRNA transfection and amino acid starvation and stimulation
5 million S2 cells were plated in 6-cm culture dishes in 5 ml of Express Five SFM media. Cells were
transfected with 1 pg of dsRNA per million cells. 4 days later, cells were rinsed once with amino acid-free
Schneider's medium, and starved for amino acids by replacing the media with amino acid-free Schneider's
medium for 1.5 hours. To stimulate with amino acids, the amino acid-free medium was replaced with complete
Schneider's medium for 20 minutes. Cells were then washed with ice cold PBS twice, lysed, and processed as
described (1). The pH of the amino acid free media was made to match that (pH 6.70) of an opened bottle of
full Schneider's media.
Design and synthesis of dsRNAs
The control GFP dsRNA has been described (4). Other dsRNAs were designed to target all known
transcripts of the target Drosophila gene. In order to minimize off-target effects, we used the DRSC tool at
http://flyrnai.org/RNAi findfrag_free.html and excluded regions of 19-mer-or-greater identity to any Drosophila
transcripts. The Drosophila genome encodes for one RagA/B-like gene (CG11968) and one RagC/D-like gene
(CG8707). We designed and tested two distinct dsRNAs to each gene. Synthesis of dsRNAs was performed
as previously described (4) using the primers indicated below.
Primer sequences (including underlined 5' and 3' T7 promoter sequences)
dRagB (CG11968) dsRNA_1 forward primer:
GAATTAATACGACTCACTATAGGGAGACGCTCCATTATCTTTGCTAACTATAT
dRagB (CG11968) dsRNA_1 reverse primer:
GAATTAATACGACTCACTATAGGGAGACATCAAACACATAAATCAGCACTTC
dRagB (CG11968) dsRNA_2 forward primer:
GAATTAATACGACTCACTATAGGGAGAATAGAGCGCGACATCCATTACTAC
dRagB (CG11968) dsRNA_2 reverse primer:
GAATTAATACGACTCACTATAGGGAGACTTGATGATGTTGGACACCTTTT
dRagC (CG8707) dsRNA_1 forward primer:
GAATTAATACGACTCACTATAGGGAGAGAGTCGACCAGTAAGATCGTGAA
dRagC (CG8707) dsRNA_1 reverse primer:
GAATTAATACGACTCACTATAGGGAGATGTAGTCATCCTTGGCATCG
dRagC (CG8707) dsRNA_2 forward primer:
GAATTAATACGACTCACTATAGGGAGAAGTTCGAGGTGTTTATACACAAGGT
dRagC (CG8707) dsRNA_2 reverse primer:
GAATTAATACGACTCACTATAGGGAGAAAGATGGAGTGGTCGTATATGGAG
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mTORC1 regulates cytokinesis through activation of Rho-ROCK
signaling
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Summary
Understanding the mechanisms by which cells coordinate their size with their
ability to divide has long attracted the interest of biologists. The Target of Rapamycin
(TOR) pathway is becoming increasingly recognized as a master regulator of cell size,
however less is known how TOR activity might be coupled with the cell cycle. Here, we
establish that mTOR complex 1 (mTORC1) promotes cytokinesis through activation of a
Rho GTPase-Rho Kinase (ROCK) signaling cascade. Hyperactivation of mTORCI
signaling by depletion of any of its negative regulators: TSC1, TSC2, PTEN, or
DEPTOR, induces polyploidy in a rapamycin-sensitive manner. mTORC1
hyperactivation-mediated polyploidization occurs by a prolonged, but ultimately failed
attempt at abcission followed by re-fusion. Similar to the effects of ROCK2
overexpression, these mTORC1-driven aberrant cytokinesis events are accompanied
by increased Rho-GTP loading, extensive plasma membrane blebbing, and increased
actin-myosin contractility, all of which can be rescued by either mTORC1 or ROCK
inhibition. These results provide evidence for the existence of a novel mTORC1-Rho-
ROCK pathway during cytokinesis and suggest that mTORC1 might play a critical role
in setting the size at which a mammalian cell divides.
Introduction
Key to the proper transition of cells through the cell cycle is their passage
through multiple signaling 'checkpoints'. One of the first insights into the existence and
function of one of these checkpoints was the isolation and characterization of a mutation
in the Weel gene. Weel mutant cells were shown to abrogate a previously unknown to
exist cell size checkpoint strikingly, undergoing cell division at half the size of wild-type
cells (1). Since this discovery, our understanding of the mechanisms controlling cell size
and cell division have rapidly, though separately, evolved. The Rho pathway has
emerged as a central player in controlling the actin-myosin-based contractile events
required for cytokinesis (2, 3). Regarding the regulation of cell size, the TOR signaling
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pathway has received considerable attention, in particular for its role in controlling the
G1 growth phase of the cell cycle. Though it has largely become known as a controller
of protein synthesis and the G1 program, it has also long been clear that TOR has a
second, distinct essential function involving the cell-cycle dependent organization of the
cytoskeleton (4). Mutations in TOR2 do not arrest cells in GI as is the case with
rapamycin treated cells, but rather cause arrest at multiple points in the cell cycle (5)
accompanied by profound actin cytoskeletal disorganization (4). That the lethality of a
TOR2 mutation could be rescued by overexpression of components of the Rho pathway
hinted at the relationship between these pathways during the cell cycle (6). However,
the importance of such a coupling during cell division still remains largely unknown. To
address this question, we have investigated the involvement of mTOR signaling in
cytokinesis. We find that mTORC1 hyperactivation causes prolonged cytokinesis due to
Rho-ROCK hyperactivity and is associated with increased polyploidy, a condition
thought to underlie the malignancy of certain cancers.
Results
The mTOR pathway is repressed through the actions of multiple upstream
inhibitory proteins including TSC1, TSC2, PRAS40, PTEN, and REDD1 (7). We recently
identified a novel negative regulator of the mTOR pathway, DEPTOR, which binds
mTOR and inhibits both mTORC1 and mTORC2 signaling pathways (8). In
characterizing DEPTOR function, we noticed that its depletion in cells by RNAi
promoted their multinucleation (Fig. 1A-B). To quantify this phenomenon, we measured
the DNA content of DEPTOR knockdown cells compared with control cells. The results
were clear; DEPTOR knock-down increased the percentage of 8N cells relative to those
of control knockdown cells (Fig. 1 C). Because DEPTOR depletion activates both the
mTORC1 and mTORC2 pathways, we sought to determine whether either of these
pathways might be responsible for mediating the effects of DEPTOR on ploidy. First, we
knocked down known regulators of mTORC1 and/or mTORC2: raptor, rictor, mTOR,
TSC1, TSC2, and PTEN and measured their DNA content. Similar to that of DEPTOR
knockdown cells, cells with knockdown of any of the negative regulators of mTOR:
181
TSC1, TSC2, or PTEN increased the percentage of 8N cells relative to control
knockdown cells (Fig. 1C). Fittingly, the increased >4N DNA content of TSC1
knockdown was similar to those seen in a different cell type with complete loss of TSC1
(9). That neither mTORC1 nor mTORC2 inactivation by knockdown or raptor or rictor,
respectively increased the percentage of 8N cells is consistent with DEPTOR being a
negative regulator of mTOR signaling (Fig. 1 C). Finally, treatment of DEPTOR or TSC2
knock-down cells with rapamycin, which only significantly inhibits mTORC1 and not
mTORC2 in the cells we assessed (8), fully reduced the percentage of 8N cells (Fig.
1 C) suggesting that deregulation of mTORC1 is responsible for effects of mTOR on
polyploidy.
To explore at which point in their cell cycle mTORC1-hyperactivated cells
became polyploid, we visually monitored individual knockdown cells over time. Both
wild-type and DEPTOR knockdown cells progressed through interphase and through
early stages of mitosis similarly (Fig. 2A). However, upon daughter cell separation, the
surface of DEPTOR knockdown cells, unlike control cells, began to bleb massively and
this was subsequently followed after a prolonged period of blebbing by fusion of their
membranes and the creation of one cell containing both daughter nuclei (Fig. 2A). The
same prolonged period of surface blebbing pattern was also observed in cells deficient
in TSC1, TSC2, or PTEN but not in rictor knockdown cells (Fig. 2B-C) suggesting that
blebbing-associated multinucleation is due to hyperactivation of mTORC1 and not
mTORC2 (either directly or indirectly through the well-characterized mTORC1-P13K
feedback loop(10)). To strengthen the claim that this aberrant surface blebbing was
mediated by mTORC1, we treated DEPTOR knock-down cells with rapamycin
immediately preceding the point at which they began to separate into two daughter
cells. Rapamycin treatment dramatically reduced the time required for the separation of
DEPTOR-deficient daughter cells as well as the time of their surface blebbing (Fig. 2B,
2D). Correlating with the degree of polyploidy, these results suggest that surface
blebbing-associated cytokinesis defects in DEPTOR deficient cells are the result of
mTORC1 hyperactivation. During cytokinesis, cytoskeletal rearrangements are critical
for physically separating cells after their duplication (11). Both microtubules and the
actin are core components of the cytoskeleton driving this process (11), therefore we
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assessed their morphology with or without mTORC1 hyperactivation during multiple
stages of cell cycle. Control and DEPTOR knockdown cells had similar cortical actin
positioning and assembly of their a-tubulin-containing spindles in mitosis (Fig. 2E).
However, in cytokinesis, while control daughter cells had symmetrical actin cortices, in
DEPTOR depleted cells, their actin architecture was grossly disorganized and appeared
to be forming blebbing patterns similar to that which we observed in DEPTOR depleted
cells by light microscopy (Fig.2A-B, 2E).
Actin-myosin contractility provides critical mechanical force to promote cell
cleavage in cytokinesis and is known to be coordinated by many Rho-GTP-dependent
kinases which regulate this contractility by phosphorylating myosin light chain 2 (MLC2)
(12). To test a role for mTORC1 in regulating actin-myosin contractility, we first
confirmed in our cell system that the MLC2 phosphorylating kinase, Rho kinase 2
(ROCK2), regulates the morphology of the actin cytoskeleton (13). While
overexpression of kinase dead ROCK2 did not strongly perturb the actin cytoskeleton
compared with overexpression of a control protein, overexpression of wild-type ROCK2
produced strong actin blebbing much like that we had seen with DEPTOR knockdown
cells (Fig. 2E, 3A). As expected, ROCK2 overexpression also increased S19 MLC2
phosphorylation (Fig. 3B). To test whether DEPTOR regulated ROCK signaling during
cytokinesis, we measured MLC2 phosphorylation in DEPTOR and control knockdown
cells. Typical of metazoan cells in cytokinesis, we detected prominent S19 MLC2
phosphorylation in control cells that was reduced by inhibition of ROCK activity (Fig. 3C)
(14, 15). On the other hand, DEPTOR depleted cells, had substantially elevated levels
of S19 MLC2 phosphorylation compared with control cells (Fig. 3C). That the effects of
DEPTOR loss of S19 MLC2 phosphorylation were strongly reduced by ROCK inhibition
(Fig. 3C) suggests that DEPTOR loss activates ROCK signaling.
Because it is possible that DEPTOR knockdown activates ROCK signaling
independent of its effects on mTORC1, we tested whether mTORC1 inhibition would
reverse the effects of DEPTOR depletion on MLC2 phosphorylation. Indeed, treating
DEPTOR knockdown cells with either rapamycin or a concentration of Torin1 which only
potently inhibits mTORC1 signaling (8) reduced S19 MLC2 phosphorylation (Fig. 3D).
We next sought to determine whether the effects of DEPTOR on ROCK activity were
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direct. Because ROCK is activated by binding to the active, GTP-bound form of Rho
(16) and because TOR is known to regulate Rho GEF activity (6), we tested whether
DEPTOR knockdown regulates ROCK by altering the Rho-GTP/GDP state. DEPTOR
knockdown cells had higher levels of Rho-GTP than control cells and this increased
activity was reduced by rapamycin (Fig. 3E). These results are consistent with mTORC1
activating ROCK upstream of ROCK itself by promoting Rho activity. Because ROCK
directly phosphorylates many substrates besides MLC2, we checked whether other
ROCK outputs were also regulated by manipulation of mTORC1. Mypt1 is the targeting
subunit for the S19 MLC2 phosphatase and is known to be inhibited in its activity by
phosphorylation at its T696 site by ROCK (17, 18). DEPTOR knockdown increased and
mTOR knockdown decreased Mypt1 T696 phosphorylation consistent with mTORC1
positively regulating ROCK activity toward this substrate (Fig. 3F). Another target of
ROCK pathway is Cofilin. Cofilin is an F-actin severing protein which is inhibited through
its S3 phosphorylation by the ROCK-activated kinase, LIMK1 (19). Consistent with the
effects of DEPTOR knockdown on MLC2 and Mypt1 phosphorylation, S3 cofilin
phosphorylation was increased by DEPTOR knockdown above the levels seen in
control knockdown in multiple cell types (Fig. 3F-G). In total, these results suggest that
Rho-ROCK signaling toward multiple effector pathways is positively regulated by
mTORC1.
To better define how DEPTOR-mTORC1 controls Rho-ROCK activity, we
assessed DEPTOR localization in cells undergoing cytokinesis. We detected DEPTOR
throughout the cell, though it was clearly enriched at the centrosomes and the cleavage
furrow, two subcellular localizations, which interestingly are also enriched for ROCK and
RhoA, respectively (Fig. 4A) (20, 21). Previously, we have shown that DEPTOR
phosphorylation state and levels are regulated by growth factors in an mTOR-
dependent manner (8), therefore we assessed whether DEPTOR was also regulated in
a cell cycle-dependent manner. Arresting cells in mitosis with nocodazole, a microtubule
disrupting agent (22), significantly impaired the gel mobility of the DEPTOR protein, and
this gel mobility was restored when nocodazole was removed from the media (Fig. 4B).
This suggests that DEPTOR might be regulated by phosphorylation during completion
of the cell cycle. Because DEPTOR phosphorylation is known to regulate its ability to
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repress mTOR signaling (8), we wanted to determine we might be able to overcome this
reduction in DEPTOR function during cytokinesis by inducing its overexpression. To do
this, we measured histone phosphorylation, which regulates and provides a convenient
marker of mitotic progression (23). While nocodazole increased the percentage of
phosphorylated S10 Histone H3 (p-H3) positive control and DEPTOR overexpressing
cells similarly, release from mitotic arrest was slower in DEPTOR overexpressing cells
than control cells (Fig. 4C-D). In summary, this data suggests that DEPTOR is regulated
both post-translational and by localization during the later stages of the cell cycle and
that inactivation or hyperactivation of mTORC1 signaling both prolong the time
necessary to complete cytokinesis.
Discussion
Here we find that increased mTORC1 causes polyploidy due to defective
cytokinesis that is correlated with increased Rho-ROCK-mediated phosphorylation of
multiple effectors including MLC2, Mypt1, and Cofilin. While there is some evidence that
mTOR regulates Rho-dependent processes in mammalian cells (24, 25), our work, to
our knowledge, is the first to demonstrate that mTORC1 regulates cytokinesis via
activation of Rho-ROCK signaling. One question still remaining is whether mTORC1
and not mTORC2 controls all mTOR-dependent, Rho signaling processes. Recently, it
has been argued that, on the contrary, many of the effects of mTOR on the actin
cytoskeleton are due to regulation of TORC2 and not TORC1 signaling (24). While our
work does not directly address these claims, there is precedence with other TOR-
dependent outputs that TORC1 and TORC2 might overlap in function more than is
readily appreciated. In yeast, Sch9 is a target of TORC1 and controls longevity in a
manner analogous to one of its homologs in higher organisms, Akt, which is an
mTORC2, and not mTORC1, substrate (26-28). Also, loss-of-function alleles of LST8, a
component of both TORC1 and TORC2, regulates rapamycin-sensitive, GAP1
permease sorting in yeast, but in mammals, does not only significant impair mTORC1
function and rather is essential for mTORC2-Akt activity (29, 30).
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Future studies will undoubtedly be needed to better understand the mechanisms
by which TOR regulates Rho function. Recently, it has been shown that rapamycin
downregulates the translation of ROCK1 (31). Whereas, our data suggests that
mTORC1 also regulates the Rho pathway upstream of ROCK (Fig. 3E). Because TOR
is known to regulate numerous effectors by their phosphorylation (32), one interesting
possibility stemming from our work is to test whether mTORC1 regulates the
phosphorylation state of a Rho-GAP or Rho-GEF. By answering this as well as other
questions of how TOR and Rho work, it is exciting to consider that understanding of one
of biology's central questions 'how cell size is coordinated with cell division' will be
closer in reach.
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Figure Legends
Fig. 1. mTORCI hyperactivation causes polyploidy. (A) and (B) HeLa cells were
infected with lentivirus expressing shRNAs targeting DEPTOR or GFP. Cells were then
analyzed by immunoblotting for the levels of the specified proteins (A) or processed in
an immunofluorescence assay to detect ax-tubulin (green), costained with DAPI for DNA
content (blue), and imaged (B). (C) HeLa cells pretreated with 1 OOnM rapamycin or
vehicle were infected with lentivirus expressing the indicated shRNAs, stained with
propidium iodide, and analyzed for DNA content by flow cytometry. > 20,000 cells were
analyzed for each condition. Error bars indicate standard error for n=3.
Fig. 2. mTORCI hyperactivation distorts the actin cytoskeleton and prolongs
cytokinesis.
(A) and (B) HeLa cells were infected with lentivirus expressing shRNAs targeting
DEPTOR, TSC2, or GFP were analyzed by light microscopy (1Ox). Images were
captured once per minute. (C) and (D) All images from (A) and (B) were visually
inspected and manually counted to determine the % of cells blebbing and time of
blebbing in minutes. > 50 cells were analyzed for each sample. Error bars indicated
standard error for n=3. (E) HeLa cells were infected with lentivirus expressing a shRNA
targeting DEPTOR or GFP. Cells were then processed in an immunofluorescence
assay to detect a-tubulin (green), actin (red), costained with DAPI for DNA content
(blue), and imaged.
Fig. 3. mTORC1 hyperactivation activates Rho-ROCK signaling. (A) HeLa cells
transfected with the indicated cDNAs were processed in an immunofluorescence assay
to detect FLAG (red), actin (green), costained with DAPI for DNA content (blue), and
imaged. (B) HEK-293T cells transfected with the indicated cDNAs were analyzed by
immunoblotting for S19 MLC2 phosphorylation. (C) HeLa cells were infected with
lentivirus expressing shRNAs targeting DEPTOR or GFP, treated for 10 minutes with
1 OpM of Y-27632 or vehicle, and processed in an immunofluorescence assay to detect
a-tubulin (green), S19 MLC2 phosphorylation (red), costained with DAPI for DNA
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content (blue), and imaged. (D) HeLa cells were infected with lentivirus expressing
shRNAs targeting DEPTOR or GFP, treated for 10 minutes with 1OOnM rapamycin,
50pM Torin1, 10pM of Y-27632, or vehicle and processed in an immunofluorescence
assay to detect S19 MLC2 phosphorylation and imaged. (E) HeLa cells were infected
with lentivirus expressing shRNAs targeting DEPTOR or GFP, treated for 10 minutes
with 1 0OnM rapamycin or vehicle, immunoprecipitation of Rhotekin binding proteins was
performed, and immunoprecipitates and lysates were analyzed by immunoblotting for
the indicated levels of the specified proteins. (F) HeLa cells were infected with lentivirus
expressing the indicated shRNAs were analyzed by immunoblotting for the
phosphorylation states of the specified proteins. (G) Indicated p53-/- MEFs were
generated and analyzed as in (F).
Fig. 4. Further characterization of DEPTOR during cytokinesis. (A) HeLa cells were
processed in an immunofluorescence assay to detect DEPTOR (green), costained with
DAPI for DNA content (blue), and imaged. (B) HeLa cells were treated with 1 Ong/pI
nocodazole or vehicle for 16 hours and released for the indicated times, cell lysates
were prepared and analyzed by immunoblotting for DEPTOR or mTOR. (C) and (D)
HeLa cells treated as in (B) were processed in an immunofluorescence assay to detect
phosphorylated S10 Histone H3 (pink), myc-DEPTOR (green), costained with DAPI for
DNA content (blue), and imaged. Three images for each condition were analyzed by
image analysis software (CellProfiler) and mean measurements are shown in (C).
Representative images are shown in (D). (E) Depiction of mTORC1-DEPTOR activity
during the cell cycle.
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Experimental procedures
Materials
Reagents were obtained from the following sources: Rho Assay Reagent (Rhotekin
RBD agarose), and antibodies to DEPTOR, raptor, Rho, phospho-T696 Mypt1 from
Millipore; mouse monoclonal DEPTOR antibody from Novus Biologicals; antibodies to
phospho-Sl0 Histone H3, mTOR, actin, as well as HRP-labeled secondary antibodies
from Santa Cruz Biotechnology; antibodies to mTOR, phospho-S19 MLC2, phospho-S3
Cofilin, Cofilin, and the c-MYC epitope from Cell Signaling Technology; a-tubulin
antibodies, Y-27632, and nocodazole from Sigma Aldrich; DMEM from SAFC
Biosciences; rapamycin from LC Labs; PreScission protease from Amersham
Biosciences; pTREQ Tet-On vector from Clontech; FuGENE 6 and Complete Protease
Cocktail from Roche; Alexa Fluor 488 and 568 Phalloidin, Propidium Iodide, and
inactivated fetal calf serum (IFS) from Invitrogen. Torin1 was kindly provided by
Nathaniel Gray (Harvard medical School).
Cell Lines and Cell Culture
HeLa, HEK-293T, and MEFs were cultured in DMEM with 10% Inactivated Fetal Bovine
Serum (IFS). p53-I- MEFs were kindly provided by David Kwitakowski (Harvard Medical
School). The HeLa cell line with doxycycline-inducible DEPTOR expression was
generated by retroviral transduction of HeLa that were previously modified to express
rtTA with an inducible DEPTOR cDNA (8).
cDNA Manipulations, Mutagenesis, and Sequence Alignments
The cDNAs for DEPTOR and metap2 was previously described. The cDNA for full-
length wild-type ROCK2 was kindly provided by K. Kaibuchi (33).
Mammalian Lentiviral shRNAs
Lentiviral shRNAs to the indicated human and mouse genes were previously described
(8, 28).
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shRNA-encoding plasmids were co-transfected with the Delta VPR envelope and CMV
VSV-G packaging plasmids into actively growing HEK-293T using FuGENE 6
transfection reagent as previously described (28). Virus containing supernatants were
collected at 48 hours after transfection, filtered to eliminate cells, and target cells
infected in the presence of 8 pg/ml polybrene. For all cell types, 24 hours after infection,
the cells were split into fresh media, selected with 1 pg/ml puromycin. Five days post-
infection, shRNA-expressing cells were analyzed or split again and analyzed 2-3 days
later. All shRNA-expressing cells were analyzed at 50-75% confluence.
Cell Lysis and Immunoprecipitations
All cells were rinsed with ice-cold PBS before lysis. All cells were lysed with Triton-X
100 containing lysis buffer (40 mM HEPES [pH 7.4], 2 mM EDTA, 10 mM sodium
pyrophosphate, 10 mM sodium glycerophosphate, 150 mM NaCI, 50 mM NaF, 1%
Triton-X 100, and one tablet of EDTA-free protease inhibitors [Roche] per 25 ml). The
soluble fractions of cell lysates were isolated by centrifugation at 13,000 rpm for 10 min
in a microcentrifuge. For measurement of the Rho-GTP loading state, Rho Assay
Reagent was used according to the manufacturer's protocol (Millipore). To observe gel
mobility shifting in DEPTOR, 8% Tris Glycine gels (Invitrogen) were used. For all other
applications, 4-12% Bis-Tris gels (Invitrogen) were used.
cDNA Transfection
To examine the effects of ROCK2 overexpression on endogenous S19 MLC2
phosphorylation, 500,000 HEK-293T were plated in 6 cm culture dishes in DMEM/10%
IFS. 24 hours later, cells were transfected with 1 pg of the indicated pRK5-based cDNA
expression plasmids. All cells were lysed at 50-75% confluence 24 hours after
transfection.
Immunofluorescence Assays
25,000-100,000 cells were plated on fibronectin-coated glass coverslips in 12-well
tissue culture plates, rinsed with PBS once and fixed for 15 minutes with 4%
paraformaldehyde in PBS warmed to 370C. The coverslips were rinsed three times with
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PBS and permeabilized with 0.2% Triton X-100 in PBS for 15 minutes. After rinsing
three times with PBS, the coverslips were blocked for one hour in blocking buffer
(0.25% BSA in PBS), incubated with primary antibody in blocking buffer overnight at
40C, rinsed twice with blocking buffer, and incubated with secondary antibodies (diluted
in blocking buffer 1:1000) and/or Phalloidin for one hour at room temperature in the
dark. The coverslips were then rinsed twice more in blocking buffer and twice in PBS,
mounted on glass slides using Vectashield containing DAPI (Vector Laboratories), and
imaged with a 1 Ox or 63X objective using epifluorescence microscopy. Quantification of
the percentage of p-H3 positive cells was performed with CellProfiler
(www.cellprofiler.org) using 1Ox images. After illumination correction, the nuclei were
automatically identified using the DAPI staining. P-H3 positive cells were defined by
threshold intensity. The percentage of p-H3 positive cells was then determined by the
quotient of the total number of nuclei above that threshold intensity divided by total
number of nuclei in the field.
Live Cell Imaging
HeLa cells were plated on glass-bottom dishes (MatTek). Cells were imaged with an
ORCA-ER camera (Hammamatsu) attached to a Nikon TE2000 microscope. All images
were collected, measured, and compiled with the aid of Metamorph imaging software
(Molecular Devices) and Adobe Photoshop. For time-lapse imaging, cells were kept at
370C with the aid of a Solent incubation chamber (Solent Inc.).
Fluorescence Activated Cell Sorting
Exponentially growing cells were treated as indicated, trypsinized, washed once in ice-
cold PBS and fixed overnight in 1 ml 70% ethanol on ice. Cells were washed once in
PBS and incubated in PBS containing 70 pM propidium iodide and 10 mg/ml RNAse A
at 370C for 30 minutes. Flow cytometry analysis was performed using a Becton-
Dickinson FACScan machine and CelIQUEST DNA Acquisition software.
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Chapter 6
Future Directions
Summary
The mTORC1 pathway controls cell growth, survival, and proliferation by spatially
and temporally orchestrating many key aspects of cell metabolism. In the work describe
here, we have investigated the localization of mTORC1-dependent pathways that
control lipid and protein synthesis as well as those that regulate the cell cycle. We
identify that mTORC1 regulates cholesterol and lipid homeostasis by regulating the
cytoplasmic-nuclear localization of the phosphatidic acid phosphatase, lipin 1. In a
growth factor- and nutrient-dependent manner, mTORC1 and GSK3 phosphorylate lipin
1 which promotes its cytoplasmic retention. However, in the absence of mTORC1 and
GSK3 activity, lipin 1 accumulates in the nucleus where it downregulates SREBP target
gene expression by altering the structure of the lamin A-containing nuclear matrix and
sequestering SREBP in it. We also have examined how mTORC1 controls the
cytoskeletal machinery that drives the fission of daughter cells upon completion of the
cell cycle. As part of this effort, we identified a novel mTOR interacting protein,
DEPTOR, which negatively regulates mTORC1 and mTORC2, but paradoxically
activates P13K/mTORC2 signaling when overexpressed. Hyperactivation of mTORC1
caused by DEPTOR depletion hyperactivates Rho-Rho Kinase-dependent, actin-myosin
contractility during cytokinesis and ultimately leads to polyploidy. Lastly, we have shed
light on the long-standing question of how amino acids activate mTORC1 signaling
towards the translational regulator, S6K1. We identify that mTORC1 relocalizes from the
cytosol to a Rab7-containing endomembrane compartment upon amino acid stimulation
of cells where it becomes juxtaposed to the mTORC1 -activating GTPase, Rheb. We
also find that this relocalization, which requires the canonical mTORC1 component,
raptor, and mTORC1 signaling, are both dependent on a novel heterodimer GTPase
complex, Rag A/B/C/D. The following discussion explores some of the new questions
that have emerged from this work.
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Phosphatidic acid: a key signaling lipid for both cholesterol synthesis and
mTORC1 activity?
We find that lipin 1, a phosphatase for the phospholipid, phosphatidic acid (PA),
requires its catalytic activity to regulate SREBP target gene expression (Chapter 2,
Fig.3D). Similarly, the catalytic activity of the lipin 1 S. cerevisiae homolog, Pah1, has
been previously shown to be required for its effects on neutral lipid biosynthesis and
gene expression (1). These results suggest that the levels of the substrate of lipin 1, PA
and as well as its product, diacylgycerol (DAG), are conserved, key regulatory
molecules in sterol- and lipogenesis production. While DAG is readily appreciated as a
rate-limiting substrate in triacylglycerol synthesis (2), the role for PA as a signaling
intermediate in sterol synthesis and SREBP function is less well known. While the
'sensing' of cholesterol abundance in the endoplasmic reticulum (ER) by the SREBP
escort protein, SCAP, has long been known to be a crucial part of the mechanism for
controlling SREBP cleavage (3), more recent work presents a distinct view for how the
SREBP pathway may be thought to be regulated (4). Unlike in mammalian cells, where
most of the pioneering studies on the SREBP pathway were performed, insect cells,
such as the widely utilized drosophila S2 cell line, do not produce sterols and the major
targets of SREBP in these cells are not cholesterol biosynthetic genes, but rather those
that promote saturated fatty acid formation (4). More surprisingly, it was shown it these
cells that phospholipids such as phosphatidylethanolamine (PE), and not cholesterol,
are the major controllers of SREBP cleavage (5). These results suggest that the
cleavage of SREBP, rather than necessarily being tied to the presence or absence of
cholesterol per se, might be controlled by the levels of different components of internal
membranes in different organisms, and that 'membrane integrity' might be a more
general term to describe what is being sensed by this pathway.
Another indication of the potential importance of phospholipids in regulating
cholesterol homeostasis comes from a recent study in yeast on the function of Pahi
phosphorylation. In a gain-of function screen, Han et al. identified the PA-generating,
CTP-dependent, diacylglycerol kinase 1 (DGK1) as a gene whose overexpression
rescues the lethality caused by inositol deprivation of cells harboring a constitutively
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dephosphorylated Pah1 mutation (6, 7). That overexpressing DGK1 restored PA levels
in these Pah1 mutant cells and that this particular phospholipid is required for proper
nuclear membrane proliferation, which is an essential feature of cell division (8),
highlights the importance of PA in eukaryotic cells (7). Though the authors did not
explicitly address the relationship between PA and cholesterol levels in this study, one
hypothesis following from their work for how low levels of nuclear PA might inhibit
cholesterol synthesis could be that the SREBP transcriptional machinery is particularly
sensitive to the physical space provided to it in the nucleus. Our work suggesting that
mTORC1 inhibition or constitutively dephosphorylated lipin 1 promotes the binding of
lamin A with a SREBP response element (Fig. S5C-D) is consistent with this
hypothesis. Furthermore, it has recently been shown that deletion of the Pah1
phosphatase regulatory subunit, spo7, promotes expansion of the nuclear membrane
(9). Considering that this expansion is specifically filled by the nucleolus and that
TORC1 is a key regulator of ribosome biogenesis which is a process that primarily takes
place in the nucleolus (9, 10), it is tempting to consider that sterol biosynthesis might
concurrently be controlled in this same nuclear subcompartment by the PA hydrolyzing
activity of lipin 1.
While we have mainly focused on PA as being a downstream signal of mTORC1
acted on by nuclear lipin 1, PA is also believed to be a key phospholipid for promoting
mTORC1 kinase activity (11). How might these two findings indicate the mutual interest
of mTORC1 and lipin 1 in this particular phospholipid? Consider the following model
based on the evidence we present or reference herein: in the absence of upstream
signals to activate mTORC1 (e.g., amino acids), 1) mTORC1 resides in the cytosol
where it does not contact PA and where it consequently is unable to phosphorylate lipin
1; 2) lipin 1 associates with nuclear membranes (as well as cytoplasmic membranes
depending on how much mTORC1 activity is lost) where it hydrolyzes PA; and thus 3)
mTORCl is not inappropriately activated in the PA-depleted membrane environment
where lipin 1 localizes. On the contrary, in the presence of an mTORC1 -activating
stimuli, 4) mTORC1 becomes associated with PA-containing cytoplasmic membranes;
5) this PA-containing membrane environment promotes the phosphorylation and
redistribution of lipin 1 to the cytosol which; 6) preserves PA levels and mTORC1
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activity in the local membrane environment where mTORC1 resides. Our work
characterizing the localization of mTORC1 is consistent with it being translocated from
the cytosol to cytoplasmic membranes upon activating stimuli such as amino acids
(Chapter 4, Figs.4-5). Recent work by Harris et al. is consistent with lipin 1 translocating
from the cytosol to endomembranes upon decreased mTORC1 activity (12).
Additionally, we show that mTORC1 and lipin 1 can physically interact in cells in a
Torini-manner (Chapter 2, Fig. 2D, S2B), which is consistent with mTORC1 and lipin 1
co-localizing (at least transiently) to a shared compartment in a manner dependent on
mTOR kinase activity. Future work aimed at determining the levels of PA in the
membrane compartments where mTORC1 and lipin 1 jointly reside as well as in more
precisely defining the cytosol/membrane localizations of mTORC1 and lipin 1 upon
changes in mTORC1 activity will be required to further investigate this model.
How does mTORCI regulate SREBP localization?
As previously discussed, SREBP is known to localize in the ER and upon
intracellular cholesterol depletion, to translocate to the golgi and subsequently the
nucleus where it binds sterol response element-containing DNA and transactivates
cholesterol biosynthetic gene expression. We report that in the absence of mTORC1
signaling, SREBP1 relocalizes from presumably the ER and/or golgi to the nuclear
periphery where it colocalizes with lamin A (Chapter 2, Fig. 5H). Our work, while leading
to a preliminary explanation for how mTORC1 inhibition represses SREBP target gene
expression, does not attempt to explain how mTORC1 signaling and cholesterol levels
might be coordinated to determine SREBP localization. However, potentially placing
already synthesized cholesterol upstream of mTORC1, previous work does indirectly
suggest that mTORC1 might regulate the cleaved, mature form of SREBP at the level of
its nuclear import-export.
Rapamycin has previously been shown to regulate the nuclear localization of
multiple nutrient-regulated transcription factors (16). Nuclear transport of cargo is known
to be controlled by the coordinated actions of multiple proteins, notably including the
importins and the Ran GTPase (13). Suggesting a potential role of TORC1 in regulating
nuclear transport through Ran, inactivation of the S. cerevisiae RagA/B homolog, Gtrl,
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or overexpression of the Schizosaccharomyces pombe lipin 1 homolog, Ned1, both
produce phenotypes consistent with mTORC1 inhibition promoting the Ran-GTP state
(14, 15). Regarding the nuclear import of SREBP, it has been shown that reconstitution
of permeabilized cells with co-injection of wild-type importin-@, the active GTP-bound
form of Ran, and mature SREBP-2 promoted the full nuclear accumulation of SREBP-2
(17). On the other hand, co-expression of SREBP-2 and importin alone, promoted
SREBP-2 accumulation at the nuclear rim, which is similar to that we detected with
SREBP-1 after mTORC1 inhibition with Torin1 (Chapter 2, Fig. 5H). Based on the
above results, we find it reasonable to speculate that SREBP localization might be
dependent on mTORC1 regulating importin-p function and/or the Ran-GTP/GDP state.
Furthermore, regarding the function of importins, TOR-dependent
phosphorylation of Gln3, a transcriptional activator of nitrogen catabolite repressible
genes, is known to regulate its interaction with the importin, Srpl p, and thereby control
its localization (18). SREBP is also known to be regulated by phosphorylation which is
controlled by GSK3 (19), a kinase we show both to be regulated by mTORC1 and to
regulate lipin 1 phosphorylation (Chapter 2, Fig.2E-F). Drawing analogy with Gln3, it is
conceivable that mTORC1 controls SREBP localization by controlling the ability of
GSK3 to phosphorylate it. If this were true, how then would lipin 1 participate in the
regulation of SREBP phosphorylation-dependent localization? One way might be
through lipin I controlling PA levels and therefore mTORC1-GSK3 activity. Because
GSK3 phosphorylation of SREBP is known to regulate SREBP degradation, conceivably
this turnover might be accomplished through piecemeal microautophagy of the nucleus,
a process known to be under the control of TORC1 signaling (20). Alternatively,
perhaps PA or DAG initiates a signaling cascade distinct from TORC1 -GSK3 kinase
activity which impinges on the importin-Ran nuclear transport cycle (21). Regardless,
exploration of the understudied subject of nuclear signaling should provide a clearer
picture of how SREBP localization might be controlled by mTORC1.
mTOR: the Target Of DEPTOR
While we learned that DEPTOR negatively regulates the mTOR pathway
(Chapter 3), we still have few insights into its mechanism of action on mTOR. One
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possibility warranting further consideration is whether the ability of DEPTOR to regulate
mTOR depends on its association with a particular membrane environment. Our interest
in this idea comes from a study of another DEP domain containing protein, Dishevelled,
whose interaction with the Frizzled receptor and effects on planar cell polarity signaling
require the interaction of its DEP domain with negatively charged phospholipids (22).
During cytokinesis, it is known that the phosphatidylinositol, PIP3, and the lipid kinase
which generates it, P13K, are present on the leading edge of the daughter cells, while
the PIP3 phosphatase, PTEN, and PIP2 accumulate at the cleavage furrow (23).
Because we detect DEPTOR at the cleavage furrow (Chapter 4, Fig. 4A), one can
reason that DEPTOR might dampen mTOR signaling during cytokinesis by having its
interaction with mTOR being modulated by its concomitant interaction with PIP2.
Experiments to assess whether DEPTOR binds to this lipid or other neutral or
phospholipids in vitro would be a first pass at addressing this question.
Defining the affinity of DEPTOR and mTOR for certain phospholipids might also
enable the development of increasingly physiological mTORC1 and/or mTORC2 in vitro
kinase assays. We found that DEPTOR depletion from mTORC1 and mTORC2
complexes in cells increases their respective in vitro kinase activities (Fig. 3B, D).
However, because we were unable to demonstrate specific binding of DEPTOR to
mTORC1 or mTORC2 in vitro (data not shown), this precluded us from determining
whether DEPTOR alone was sufficient to produce the changes in mTORC1 or mTORC2
kinase activities obtained from DEPTOR deficient cells. Our lab has previously shown
that mTORC1 is activated by the non-ionic detergent, Triton X-100 (24). In future work,
it would be interesting to determine whether certain natural lipids, such as PIP2, might
facilitate a specific interaction of DEPTOR with mTOR in vitro. If this were the case, we
could then test whether the presence of these lipids were required for DEPTOR to
inhibit mTORC1 or mTORC2 in vitro kinase activities.
Lastly, we would like to understand better the importance of mTOR-dependent
phosphorylation of DEPTOR on mTOR activity. Here, it might also prove valuable to
draw analogy to the function of another DEP domain protein, Sst2, which regulates
pheromone signaling in yeast (25). Sst2 docks to the pheromone receptor, Ste2, only
when Ste2 is unphosphorylated, and this allows for the release of Sst2 upon receptor
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densensitization and internalization (25). Similarly, perhaps DEPTOR phosphorylation
by mTOR provides a densensitization mechanism whereby mTOR signaling could be
downregulated once the level of DEPTOR phosphorylation reaches a certain threshold.
Because Sst2 ultimately controls Ste2 localization, one could test this analogy by
determining whether manipulation of DEPTOR function alters the localizations of
mTORC1 and/or mTORC2 (26).
Why is the late endosomellysosome key for mTORC1 pathway activity?
We identify a Rab7-positive compartment to which mTORC1 migrates upon
amino acid stimulation where it comes into proximity with its activator, Rheb (Chapter 4,
Fig.4,5). This result begs the following questions: 'what is unique about the Rab7-
positive compartment?' and 'where is Rab7 in the cell?' Rab7 is a homolog of the yeast
Ypt7, which is a GTPase that localizes to the late endosomes and mediates endosomal
fusion with the vacuole (27). In yeast, it is known that TORC1 localizes to the vacuole
(28, 29) and more recently, our lab has shown that mTORC1 localizes to lysosome,
which is the mammalian vacuole equivalent (30). The vacuole/lysosome is an acidic
organelle with both degradative and storage capabilities (31). Amongst the storage
capabilities, the vacuole is known to accumulate amino acids, and in particular those
that are neutral or possess basic charge (32). Of the basic amino acids, arginine has
received particular notice because the levels of it and its derivatives are substantially
altered in TOR1, TSC1, TSC2, and BHD null cells (33). Pointing to the importance of
the vacuole as a nitrogen reserve, the vacuolar storage of arginine, the amino acid with
the highest nitrogen content involves three separate transport mechanism (32). Key for
TORC1 activation, nitrogen starvation through limitation of glutamine, is one way to
promote the release of vacuolar arginine (34, 35). Importantly, this release is not a
general response to amino acid starvation as it is not elicited by proline deprivation (36).
Interestingly, arsenate, which disrupts ATP production by inhibiting glycolysis (by
blocking 1, 3-biphosphoglycerate synthesis), also leads to arginine mobilization from the
vacuole (37). That respiratory inhibitors or uncouplers similarly block vacuolar arginine
release suggests that, in addition to glutamine, the vacuole might have an energy
requirement for controlling arginine efflux (37).
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How then might arginine occupy a unique role in promoting TOR signaling?
Perhaps the answer lies in polyamine biology. Polyamines are direct products of
arginine catabolism that are known to accumulate in/on endosomal membranes with low
pH (38). Further aligning with a putative role in TORC1 signaling, polyamines, such as
spermidine, are known to be potent inducers of autophagy and have an essential role in
cell growth (39, 40). One hypothesis that could place polyamines upstream of TORC1
activity would be if they were to build-up on vacuolar/lysosomal membranes in the
absence of TORC1 -activating inputs such as glutamine such that they might disrupt the
association of TORC1 with these membranes (i.e., as an result of arginine release from
the vacuole and subsequent polyamine production). Better defining the amino acid flux
and energy requirements that allow for the deposition and/or preservation of TORC1 on
vacuolar/lysosomal membranes will be required to address this hypothesis.
Conclusions
By studying the geography of mTORC1 signaling, namely in the nucleus, on
internal membranes, and of the actin cytoskeleton, we now have a better view of how
mammalian cells control their growth. Rapamycin, a highly selective TOR inhibitor, has
proven itself to be a trusty 'compass' in defining the cellular 'map' of TOR signaling we
know today. Ironically, many of key findings we report here were instead made possible
through use of a distinct class of mTOR inhibitor fronted by Torin1. For example,
because Torin1, unlike rapamycin, inhibits both mTOR in mTORC1 and mTORC2, it
was possible for us to demonstrate that DEPTOR functions as a negative regulator of
both mTOR pathways. Additionally, because Torin1 inhibits mTORC1 more potently
than rapamycin, we could readily detect that mTORC1 controls lipin 1 nuclear-
cytoplasmic shuttling, which was a key initial insight in connecting lipin 1 to the
regulation of the SREBP pathway. Considering the value of Torin1, a next step would
be to put it to use in revisiting TOR signaling in other experimental models which have
relied upon rapamycin until now. It is our expectation that these experiments should
enable the identification of additional players in the TOR signaling as well as shed
further insights on the players these compounds have already helped characterize, such
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as DEPTOR and lipin 1. No doubt, charting the remaining territory of TOR signaling
appears close at hand.
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